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Abstract: Summary Impaired osteogenic differentiation of resident bone marrow stromal cells (BMSCs)
of aged patients with low turnover osteoporosis is considered to be one of the major contributing factors
in the development of structural and mechanical deficiencies associated with osteoporotic bone. As such,
therapies designed to counteract these effects are currently being pursued with an aim to restoring the
stem cell niche and enhancing bone quality. In the current thesis, evidence is provided which supports
the use of autologous adipose-derived stromal cells (ASCs) as a means by which to combat age-related
bone loss. Initial studies were undertaken to compare the differentiation potential of ASCs from os-
teoporotic SAMP6 and non-osteoporotic SAMR1 mice in 2D in vitro culture systems. Their ability to
differentiate towards osteoblast and adipocyte cell lineages was evaluated by histological, biochemical
and molecular techniques. In contrast to BMSCs, the differentiation potential of ASCs was found to be
comparable between both strains. Further in vitro studies were performed to assess the osteogenic poten-
tial of SAMP6-derived ASCs cultured under 3D conditions using long-term silk fibroin scaffold cultures
and short-term scaffold free microtissue spheroid (ASC-MT) cultures. In both cases, ASCs underwent
efficient osteogenesis resulting in mineralized tissue formation. In the final study, ASCs and ASC-MT
were evaluated for their ability to enhance trabecular bone quality following a single intratibial injection
in SAMP6 mice using micro-CT, histological and molecular based analyses. Both ASCs and ASC-MT
could be identified within treated bones after 42 days and moreover, resulted in significant improvements
in several parameters of trabecular bone quality. Furthermore, human ASCs harvested from osteoporotic
patients were also demonstrated as having a positive influence on the osteogenic differentiation potential
of dysfunctional osteoporotic patient-derived BMSCs in vitro. In conclusion, these studies have demon-
strated that adipose tissue may represent a promising autologous cell source for the development of novel
bone regenerative therapeutic strategies for the treatment of age-related bone loss. Zusammenfassung
Als einer der Hauptgründe für die strukturellen und mechanischen Defizite des Knochengewebes von
Patienten mit altersbedingter Osteoporose wird eine beeinträchtigte Differenzierung von adulten Stam-
mzellen aus dem Knochenmark (bone marrow stromal cells, BMSCs) zu knochenbildenden Osteoblasten
angenommen. Dementsprechend werden gegenwärtig Therapieansätze verfolgt, die diese verminderte
Differenzierungskapazität von Stammzellen kompensieren und dadurch die Knochenqualität verbessern
sollen. Im Rahmen dieser Promotion konnte gezeigt werden, dass autologe adulte Stammzellen aus dem
Fettgewebe (adipose-derived stromal cells, ASCs) ein geeignetes Mittel zur Behandlung von altersbe-
dingter Osteoporose darstellen könnten. Zunächst wurde das Differenzierungspotential von ASCs aus
osteoporotischen SAMP6- und nicht osteoporotischen SAMR1-Mäusen zu Osteoblasten und Adipozyten
in vitro in 2D- Zellkulturen mit Hilfe von histologischen, biochemischen und molekularbiologischen Meth-
oden untersucht. Im Gegensatz zu BMSCs konnte dabei kein Unterschied in der Differenzierungsfähigkeit
von ASCs aus osteoporotischen und nicht-osteoporotischen Mäusen festgestellt werden. Daraufhin wurde
das osteogene Potential von ASCs aus osteoporotischen SAMP6-Mäusen in 3D-Zellkulturen untersucht.
Zum einen wurden die Zellen auf einer Seidenfibroin-Matrix kultiviert, zum anderen Mikrogewebe ohne
Matrix (ASC microtissues, ASC-MTs) hergestellt. ASCs zeigten unter beiden Kulturbedingungen eine
effiziente Osteogenese mit einhergehender Mineralisierung. Im abschliessenden Teil wurden ASCs und
ASC-MT einmalig direkt in die Tibia von SAMP6-Mäusen injiziert und anschliessend die trabekuläre
Knochenqualität mittels Mikro- CT sowie histologischen und molekularbiologischen Methoden bestimmt.
Sowohl ASCs als auch ASC-MTs konnten noch 42 Tage nach der Injektion in den behandelten Knochen
nachgewiesen werden, und ihre Applikation resultierte in einer signifikanten Verbesserung verschiedener
Parameter der trabekulären Knochenqualität. Des Weiteren konnte gezeigt werden, dass ASCs osteoporo-
tischer Patienten in vitro einen positiven Einfluss auf die osteogene Differenzierung von dysfunktionellen
BMSCs von Osteoporose-Patienten haben. Zusammenfassend kann gesagt werden, dass das Fettgewebe
eine vielversprechende, autologe Quelle für adulte Stammzellen zur Entwicklung von neuen Therapiean-
sätzen zur Behandlung von altersbedingter Osteoporose darstellen könnte.
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Summary 
Impaired osteogenic differentiation of resident bone marrow stromal cells (BMSCs) of aged 
patients with low turnover osteoporosis is considered to be one of the major contributing 
factors in the development of structural and mechanical deficiencies associated with 
osteoporotic bone. As such, therapies designed to counteract these effects are currently being 
pursued with an aim to restoring the stem cell niche and enhancing bone quality. In the 
current thesis, evidence is provided which supports the use of autologous adipose-derived 
stromal cells (ASCs) as a means by which to combat age-related bone loss. 
Initial studies were undertaken to compare the differentiation potential of ASCs from 
osteoporotic SAMP6 and non-osteoporotic SAMR1 mice in 2D in vitro culture systems. 
Their ability to differentiate towards osteoblast and adipocyte cell lineages was evaluated by 
histological, biochemical and molecular techniques. In contrast to BMSCs, the differentiation 
potential of ASCs was found to be comparable between both strains. Further in vitro studies 
were performed to assess the osteogenic potential of SAMP6-derived ASCs cultured under 
3D conditions using long-term silk fibroin scaffold cultures and short-term scaffold free 
microtissue spheroid (ASC-MT) cultures. In both cases, ASCs underwent efficient 
osteogenesis resulting in mineralized tissue formation. In the final study, ASCs and ASC-MT 
were evaluated for their ability to enhance trabecular bone quality following a single 
intratibial injection in SAMP6 mice using micro-CT, histological and molecular based 
analyses. Both ASCs and ASC-MT could be identified within treated bones after 42 days and 
moreover, resulted in significant improvements in several parameters of trabecular bone 
quality. Furthermore, human ASCs harvested from osteoporotic patients were also 
demonstrated as having a positive influence on the osteogenic differentiation potential of 
dysfunctional osteoporotic patient-derived BMSCs in vitro. 
In conclusion, these studies have demonstrated that adipose tissue may represent a promising 
autologous cell source for the development of novel bone regenerative therapeutic strategies 
for the treatment of age-related bone loss. 
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Zusammenfassung 
Als einer der Hauptgründe für die strukturellen und mechanischen Defizite des 
Knochengewebes von Patienten mit altersbedingter Osteoporose wird eine beeinträchtigte 
Differenzierung von adulten Stammzellen aus dem Knochenmark (bone marrow stromal 
cells, BMSCs) zu knochenbildenden Osteoblasten angenommen. Dementsprechend werden 
gegenwärtig Therapieansätze verfolgt, die diese verminderte Differenzierungskapazität von 
Stammzellen kompensieren und dadurch die Knochenqualität verbessern sollen. 
Im Rahmen dieser Promotion konnte gezeigt werden, dass autologe adulte Stammzellen aus 
dem Fettgewebe (adipose-derived stromal cells, ASCs) ein geeignetes Mittel zur Behandlung 
von altersbedingter Osteoporose darstellen könnten. 
Zunächst wurde das Differenzierungspotential von ASCs aus osteoporotischen SAMP6- und 
nicht osteoporotischen SAMR1-Mäusen zu Osteoblasten und Adipozyten in vitro in 2D-
Zellkulturen mit Hilfe von histologischen, biochemischen und molekularbiologischen 
Methoden untersucht. Im Gegensatz zu BMSCs konnte dabei kein Unterschied in der 
Differenzierungsfähigkeit von ASCs aus osteoporotischen und nicht-osteoporotischen 
Mäusen festgestellt werden. 
Daraufhin wurde das osteogene Potential von ASCs aus osteoporotischen SAMP6-Mäusen in 
3D-Zellkulturen untersucht. Zum einen wurden die Zellen auf einer Seidenfibroin-Matrix 
kultiviert, zum anderen Mikrogewebe ohne Matrix (ASC microtissues, ASC-MTs) 
hergestellt. ASCs zeigten unter beiden Kulturbedingungen eine effiziente Osteogenese mit 
einhergehender Mineralisierung. 
Im abschliessenden Teil wurden ASCs und ASC-MT einmalig direkt in die Tibia von 
SAMP6-Mäusen injiziert und anschliessend die trabekuläre Knochenqualität mittels Mikro-
CT sowie histologischen und molekularbiologischen Methoden bestimmt. Sowohl ASCs als 
auch ASC-MTs konnten noch 42 Tage nach der Injektion in den behandelten Knochen 
nachgewiesen werden, und ihre Applikation resultierte in einer signifikanten Verbesserung 
verschiedener Parameter der trabekulären Knochenqualität. Des Weiteren konnte gezeigt 
werden, dass ASCs osteoporotischer Patienten in vitro einen positiven Einfluss auf die 
osteogene Differenzierung von dysfunktionellen BMSCs von Osteoporose-Patienten haben. 
Zusammenfassend kann gesagt werden, dass das Fettgewebe eine vielversprechende, 
autologe Quelle für adulte Stammzellen zur Entwicklung von neuen Therapieansätzen zur 
Behandlung von altersbedingter Osteoporose darstellen könnte. 
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Abbreviations 
 
MSC    multipotent stromal cell 
BMSC    bone marrow stromal cell 
ASC    adipose-derived stromal cell 
ASC-MT   adipose-derived stromal cell microtissue spheroid 
HSC    hematopoietic stem cell 
SAMP6   senescence accelerated mouse strain prone 6 
SAMR1   senescence-accelerated mouse resistant 1 
ECM     extracellular matrix 
Runx2    Runt-related transcription factor 2 
Sp7     osterix 
BMP     bone morphogenetic protein 
c-fms     colony-stimulating factor 1 receptor 
RANK     receptor activator of nuclear factor-κB  
RANKL   receptor activator of nuclear factor-κB ligand 
M-CSF   macrophage colony-stimulating factor  
OPN    osteopontin 
TRAP     tartrate resistant acid phosphatase 
DMP    dentin matrix acidic phosphoprotein 
MEPE    matrix extracellular phosphoglycoprotein 
OPG     osteoprotegerin 
PTH    parathyroid hormone  
TGFβ    transforming growth factor  
BMD     bone mineral density  
BMU     bone multicellular unit  
C/EBP    enhancer binding protein 
Ppar    peroxisome proliferator-activated receptor 
FGF    fibroblast growth factor 
WAT     white adipose tissue 
BAT    brown adipose tissue 
GVHD    graft-versus-host-disease 
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1 Introduction 
The skeleton, which is composed of bone, soft tissue, and cartilage, is a dynamic organ, and it 
undergoes continuous bone remodeling throughout life. This process involves bone 
resorption coupled with bone formation which allows the skeleton to adapt bone mass and 
strength to external forces, as well as to modify the bone shape during growth and to regulate 
calcium homeostasis [1-3]. An imbalance between bone resorption and formation leads to 
metabolic bone diseases, such as osteoporosis.  
Osteoporosis is the most common metabolic bone disorders affecting 200 million individuals 
worldwide, and due to shifts in the population pyramid towards old age, has since become the 
fourth most common disease [4, 5]. As such, it is a leading cause of mortality and morbidity, 
which is a key factor in the high cost of medical care in aged individuals. Osteoporosis 
constitutes the most common cause of fractures, with more than 1.5 million occurring per 
year in the United States, including over 500’000 cases of hospitalizations, 800’000 
emergency room encounters, as well as visiting two million doctors, and placing of almost 
180’000 individuals into nursing homes [6]. It has been further estimated that osteoporosis 
(especially in the hip) will occur in one out of two Americans over age of 50 by 2020, and 
will eventually result in a higher risk of developing osteoporosis in other skeletal sites [7]. In 
the European Union, it has been estimated that the total costs for medical care for 
osteoporotic patients, including hospitalization and rehabilitation, were over 36 billion Euros 
in 2000 and the corresponding projected costs in 2050 will be over 76 billion Euros [8, 9]. 
Osteoporosis can be classified as either primary or secondary. The main causes of primary 
osteoporosis consist of age and estrogen deficiency arising from the menopause, while 
secondary osteoporosis can occur as a consequence of disorders of energy metabolism such 
as anorexia nervosa, obesity, and diabetes mellitus [6, 10-12]. These individuals experience 
varying degrees of imbalance between bone deposition and bone resorption, resulting in 
progressive loss of bone mineral density (BMD) and increased skeletal fragility. This is 
primarily due to alterations in different factors such as bone microarchitecture, mineralization 
and mechanical properties [13]. This deviations may happen as a consequence of damage in 
the homeostatic control of the bone multicellular unit (BMU) in which the activities of bone 
forming osteoblasts and bone resorbing osteoclasts have become dysregulated [13].  
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The presence of functionally active BMSC-derived mature osteoblasts is crucial for bone 
formation. Studies have shown that BMSCs isolated from aged osteoporotic patients have a 
higher tendency to differentiate towards adipogenesis than osteogenesis, suggesting that the 
structural abnormalities associated with osteoporotic bone maybe as a result of inadequacies 
in bone cell differentiation [14, 15].  
Available treatment options tend to be more supportive than curative and are often associated 
with persistent patient morbidity, further fractures, and eventually mortality [7, 16]. 
Therefore, stem cell-based therapies may represent a viable alternative to conventional 
treatment strategies for the management of bone loss and impaired bone quality in 
osteoporotic patients.  
1.1 Bone tissue 
Bone is an extremely dynamic mineralized tissue characterized by its hardness, resilience, 
growth mechanisms, high degree of vascularity and its capability to remodel itself throughout 
life.  
Bone has several important functions within the body. It provides structural support and 
protection to vital organs in the body, as well as being responsible for maintaining mineral 
homeostasis. It is also the main organ to synthesis blood cells. Bone is also capable of 
maintaining optimal shape and structure, by means of continuous renewal and remodeling, 
through which it is able to respond to changes in the environment with different loading 
demands [17]. Bone also acts as a calcium store for the body and plays an impotent role in 
the regulation of plasma calcium levels [18]. The majority of calcium amount within the body 
is found in the skeleton (99%), and the remaining amount is found in cell membranes and 
extracellular fluid [19]. 
Anatomically, bones can be divided in two major types, including long bones (such as 
humerus, tibia, and femur), and flat bones (like skull, mandible, and sacrum). They are 
derived from either endochondral ossification or intramembranous during development. 
Intramembranous ossification takes place during the development of flat bones and in 
peripheral sites of fracture healing. During intramembranous ossification, BMSCs undergo 
osteogenesis directly resulting in the production of mineralized osteoid tissue.  
Endochondral ossification occurs during the development of short and long bones, growth 
plate, and the natural healing of bone fractures (callus ossification). Upon endochondral 
ossification, BMSCs aggregate and undergo chondrogenesis, forming a transitory hyaline 
cartilage tissue [20]. Chondrocytes within the cartilaginous tissue then undergo hypertrophy 
   Introduction 
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and eventually apoptosis, giving way to osteoblasts and mineralized tissue formation. This is 
followed by formation of blood vessels, which transports the osteoprogenitor cells 
responsible for mineralization and the synthesis of the osteoid. There are two areas where 
ossification occurs during development of long bones, the primary center, which takes place 
within the diaphyseal, and the secondary center located in epiphyseal regions. In between 
these ossification centers, areas of proliferating chondrocytes (epiphyseal or growth plate) 
secure bone formation and growth [21].  
At the histological level, bone may be further classified into two different types of tissue, 
namely cortical bone, and trabecular or cancellous bone. Cortical bone constitutes about 85% 
of the total bone tissue, of which 80 to 90% is calcified, and it is typically found in the long 
bones of the appendicular skeleton. Trabecular bone makes up about 15% of the skeleton and 
only 15 to 25% is calcified, and it is primarily located in the vertebrae as well as other sites of 
the axial skeleton (Figure 1). The relationship between trabecular architecture and bone 
strength serves as an important factor for predicting fracture risk [22]. 
Bone consists of three primary components, including extracellular matrix (ECM), cells, and 
bone marrow. The ECM of the bone is made up of mineralised tissue, which is important for 
providing mechanical strength. Chemically, inorganic minerals, mainly calcium phosphate, 
contribute to two-thirds of the composition of bone tissue and the rest is organic bone 
materials. Calcium together with phosphorus forms hydroxyapatite crystals which is the main 
component of bone tissue (Ca10(PO4)6(OH)2). These lie along the collagen fibrils, mainly 
collagen type I, and are embedded in an amorphous ground substance composed of 
proteoglycans and glycoproteins. Approximately 15% of total bone protein is non-
collagenous endogenous and exogenous protein. Plasma is the main source for the majority of 
exogenous proteins, whereas endogenous proteins, such as osteonectin, osteopontin, 
fibronectin and osteocalcin are synthesized by bone cells [23-27]. These proteins are multi-
functional, and play an important role in regulating bone mineralization and remodeling. 
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Figure 1: Schematic diagram of the bone microstructure [28]. 
 
1.1.1 Bone cells and their functions 
Bone cells are derived from two distinct sources, one of which is BMSCs, which give rise to 
the osteoblastic lineage (osteoblasts, osteocytes and bone lining cells), and the other one is 
hematopoietic stem cells (HSCs) which gives rise to osteoclasts. Bone cells are responsible 
for maintaining the structure of the matrix. 
The osteoblast is a cuboidal mononuclear cell, responsible for bone formation by 
synthesizing the main components of the ECM, including collagen and non-collagenous 
proteins. Osteoblasts are found in clusters along the bone surfaces, lining the layer of bone 
matrix. Morphologically, osteoblasts are characterized by a rounded nucleus, abundant rough 
endoplasmic reticulum, an extensive Golgi apparatus and lysosomes. They become embedded 
in their own synthesized osteoid through the process of bone formation, and have the capacity 
to either undergo apoptosis or differentiate further osteocytes.  
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Runt-related transcription factor 2 (Runx2) and a downstream factor, osterix (Sp7), are 
crucial for osteoblast differentiation [29, 30]. Bone morphogenetic proteins (BMPs) such as 
BMP2 have been observed to trigger the initiation of transcription factors that are crucial for 
the differentiation of osteoblasts [31]. Interaction between BMPs and Wnt proteins is one of 
the possible mechanisms by which BMPs regulate osteoblast differentiation [32]. Wnt protein 
binds to frizzled receptors and the lipoprotein receptor-related protein (LRP)-5 as a co-
receptor on the cell surface. This interaction activates the binding of intracellular Axin 
protein to LRP-5, thereby blocking the degradation of β-catenin leading to activation of 
transcription [33]. Wnt stimulates the expression of BMP2, which increases osteogenesis and 
bone formation through BMP receptors on the cell surface. This pathway is regulated by 
sclerostin, which is an inhibitor of Wnt signaling [34]. Mutations in the sclerostin gene are 
responsible for sclerosteosis, an autosomal recessive disorder characterized by continues 
skeletal overgrowth [35]. 
Osteoclasts are large multinucleated cells responsible for bone resorption, formed by fusion 
of mononuclear progenitors of the monocyte-macrophage lineage. Morphologically, 
osteoclasts contain abundant Golgi complexes, mitochondria and transport vesicles loaded 
with lysosomal enzymes. Prior to bone resorption, osteoclasts polarize due to changes in the 
cytoskeleton and form three distinct plasma membrane domains, including the sealing zone, 
ruffled border, and functional secretory domain. The sealing zone occurs on the apical side 
where the cell membrane adheres tightly to the bone surface. In the cell membrane overlying 
this isolated compartment, numerous thin finger-like extensions form and make up the ruffled 
border, where the actual bone resorption occurs. Simultaneously, a functional secretory 
domain forms on the basolateral side of the cell. The initial attachment of osteoclasts to bone 
surfaces involves binding of integrins to specific amino acid sequences (RGD) within 
proteins such as osteopontin (OPN) at the matrix surface [36-38]. Protons are responsible for 
generating the acidic environment, and are produced by the help of Carbonic anhydrase II in 
the osteoclast cytoplasm. They are then subsequently transported into acidic vesicles via 
activation of a vacuolar type ATPase proton pump located in the membrane of the vesicles 
[39]. These acid-containing vesicles then fuse with the cell membrane to form the ruffled 
border, and the contents of the vesicles are released into the resorptive (Howship’s) lacuna. 
The active secretion of protons acidifies the environment and solubilises the mineral crystals, 
exposing the organic matrix to degrading proteases, whilst providing the optimal pH for their 
activity [40]. The degradation products are endocytosed from the ruffled border, transported 
through the cell, and finally secreted into the extracellular space through the functional 
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secretory domain [41, 42]. Osteoclasts also contain large amounts of tartrate-resistant acid 
phosphatase (TRAP), a metallophosphatase secreted into the resorptive lacunae. When 
activated by proteolytic processing, TRAP exhibits protein phosphatase activity towards 
matrix proteins such as OPN, and regulates osteoclast motility by dephosphorylation of OPN 
in the matrix [43, 44]. 
The majority of the cells embedded within bone matrix are termed osteocytes, and they have 
several cellular extensions from their plasma membrane, which are necessary for interacting 
with other osteocytes and osteoblasts found on the bone surface. Osteocytes are differentiated 
osteoblasts enclosed in separate lacunae throughout the bone. They create a functional 
communicative network enabling cross-talk between the various types of bone cells by 
sending out thin cytoplasmic extensions traversing mineralized bone via thin canals termed 
canaliculi. Osteocytes are involved in the biomechanical regulation of bone mass and 
structure, most likely by sensing bone deformation, pressure, fluid flows and streaming 
potentials. Osteocytes typically express molecules such as dentin matrix protein 1 (DMP1) 
[45] and matrix extracellular phosphoglycoprotein (MEPE) [46]. MEPE is an inhibitor of 
mineralization [47], whereas DMP1 is produced by the osteocyte in a mechanically sensitive 
manner, and influences phosphate homeostasis through control of fibroblast growth factor 
[48]. 
The bone lining cells are flat elongated cells covering quiescent bone surfaces that develop 
from osteoblasts. One of their possible functions is to participate in the regulation of substrate 
exchange between the extracellular fluid of bone marrow and bone fluid compartment. They 
respond to mechanical signals and mediate communication between the osteocyte network 
and the pool of osteoclasts, thus initiating bone resorption [49]. The other functions of these 
cells is to remove the remaining collagen dissolved by osteoclasts in resorptive pits, and 
deposition of a thin layer of collagenous matrix before mature osteoblast begin the process of 
bone formation [50]. 
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1.2 Bone remodeling 
Bone remodeling is the process responsible for maintaining the shape, quality and size of the 
skeleton throughout life. Remodeling is essential for repairing microfractures before they 
accumulate and lead to fatigue fractures under repeated cyclic loading (targeted remodeling), 
as well as providing access to stores of calcium and phosphate and maintaining the mineral 
homeostasis (random remodeling). This process is regulated by different cytokines, hormones 
and mechanical forces [51, 52]. 
Osteoclast precursors initially express colony-stimulating factor 1 receptor (c-Fms) on their 
surface, as well as receptor activator of nuclear factor κB (RANK). Receptor activator of 
nuclear factor κB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF) are 
two hematopoietic cytokines necessary for commitment and differentiation of macrophage 
precursors into mature osteoclasts (Figure 2) [53]. Osteoprotegerin (OPG) is produced by 
osteoblasts and represents a competitive soluble ligand for RANK [54]. The coupling of 
resorption and formation is based upon the RANK-RANKL-OPG axis. RANKL is a protein 
synthesized by osteoblasts, and is present both in a membrane-bound and a soluble form. 
RANKL binds to RANK on osteoclast precursors, thereby promoting osteoclast formation 
[37, 54-56]. Once RANKL binds to RANK, it triggers a signal transduction cascade that 
leads to the expression of a number of genes such as TRAP, cathepsin K, and calcitonin 
receptor [57]. This process is further regulated by OPG, which acts to block activation of 
RANK and thus formation of active osteoclasts. The synthesis of OPG is enhanced by 
estrogen and so the reduction in estrogen levels (e.g. at the onset of menopause) causes less 
synthesis of OPG as well as higher activity of osteoclast [56, 58]. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Bone remodeling process [59]. 
 
Introduction 
  14 
Systemic hormones, such as 1,25-dihydroxyvitamin D3, and parathyroid hormone (PTH) can 
also regulate osteoclasts either directly, or through activation of osteoblasts and stromal cells 
[60, 61]. Following bone resorption, osteoclasts undergo apoptosis and are replaced by bone 
forming osteoblasts through the actions of transforming growth factor beta (TGFβ) [62]. 
Osteoblast activity is also controlled by both systemic hormones and a number of paracrine 
factors, one of which is platelet-derived growth factor BB (PDGF-BB) secreted by 
osteoclasts. PDGF-BB was also shown to induce the production of OPG (negative feedback 
of osteoclastogenesis) [63]. Following their attachment to bone, osteoblasts secrete both 
collagenous and non-collagenous proteins, leading to the production of new matrix. This 
requires about three months until the resorptive cavity is completely refilled, and is followed 
by the secretion of a number of proteins that are essential for regulating bone remodeling 
[64]. 
1.2.1 Pathology of the bone remodeling 
Osteoporosis is a systemic disease affecting the whole skeleton, being characterized by 
reductions in bone mass and deterioration of the microarchitectural structure of bone tissue, 
resulting in loss of mechanical strength and increased risk of fracture [4]. 
An osteoporotic individual is defined by the World Health Organization (WHO) as someone 
who has a bone mineral density (BMD) of 2.5 standard deviations or more below the mean 
peak bone mass (average of healthy young adults) as measured by dual-energy X-ray 
absorptiometry. This is generally referred to as the T-score, which is defined as the measured 
BMD minus young adult mean BMD divided by the young adult standard deviation. 
Established osteoporosis includes T-scores bellow -2.5 and the presence of one or more 
fragility fractures, and can be classified as either primary or secondary [65-67].  
Primary osteoporosis is further divided into type I, which occurs in postmenopausal women, 
appearing usually after the age of 50 years old. Type I osteoporosis mainly affects trabecular 
areas and contributes in particular to vertebral and wrist fractures. It is associated with low 
trabecular bone mass and disturbed trabecular architecture. In addition, cortical bone mass is 
decreased and the diameter of the modularly cavity is expanded due to increased endocortical 
bone resorption overriding periosteal apposition. Type II, also known as senile osteoporosis, 
affects both trabecular and cortical bone in aged men and women, typically from the 7th 
decade of life, and predisposes the hip to fractures.  
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Secondary osteoporosis is related to other conditions such as hypogonadism, endocrine 
disorders, renal failure, rheumatic diseases, gastrointestinal disorders, osteomalacia, rickets 
and Paget’s disease [68]. 
After achieving peak bone mass in the late twenties, both men and women start to lose bone. 
Peak bone mass is mainly determined by genetic factors, but also influenced by 
environmental factors such as diet (e.g. vitamin D, calcium) and physical activity. Therefore, 
those who don’t achieve their genetically optimal bone mass are at a greater risk of 
developing osteoporosis and associated fragility fractures later in life. The development of 
osteoporosis is dependent on several factors such as failure to reach peak bone mass in young 
adulthood, excessive resorption after peak bone mass, or impaired bone formation during 
remodeling [69].  
Postmenopausal osteoporosis is a consequence of withdrawal of the bone-sparing effects of 
estrogen, where resorption overrides bone formation. Age-related bone loss occurs at most 
skeletal sites in adults although its pattern, magnitude and underlying cellular mechanisms 
are remarkably different. In men, trabecular bone volume decreases with age and the 
individual trabeculae become thinner, but remain connected [22]. This is associated with a 
decreased rate of matrix deposition and increased duration of the bone formation phase 
during remodeling. The same trabecular thinning is observed in women until menopause, 
where the rate of bone loss accelerates due to cessation of estrogen production. Lack of 
estrogens coupled with an enhancement of RANKL production by bone marrow osteoblastic, 
T and B cells [70], increases bone turnover rate and the osteoclastic resorption. There is also 
an increase in the activation frequency of basic multicellular units (BMUs), and the enhanced 
osteoclast activity could also leads to deeper Howship’s lacunae. Thus, trabeculae are 
perforated and ultimately removed, resulting in reduced trabecular number and connectivity 
in women [71]. As osteoporosis disease advances, the bone volume reduces as a result of 
expanding marrow volume [72], and more adipose tissue is deposited within the bone marrow 
possibly due to an imbalance between osteogenesis and adipogenesis [73-75]. Therefore, 
osteoporosis has also been referred to as the bone obesity [6]. This concept is further 
supported by reports of osteopenia in a mouse model of accelerated adipogenesis which 
highlights the detrimental effect of imbalances between adipogenesis and osteogenesis on 
bone mass [76]. 
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1.2.2 Effects of age on bone quality 
One of the important elements to characterize bone quality is its resistance to fracture coupled 
with the incorporation of bone density and mechanical strength as well as architecture and 
mineralization [13, 77, 78], and are affected during aging due to alterations in bone turnover 
through the process of bone remodeling. As such, dealing with fracture repair in aged and 
osteoporotic bone is one of the main challenges for orthopaedic surgeons, as a result of 
inferior properties of the cancellous bone [79-81]. It is also further investigated that aging 
play an important role to regulate bone quality and potentially the initiation of osteoporosis 
by using combination knock out of both Werner (Wrn) and telomerase (Terc) genes in 
experimental models of accelerated aging. This mutation leads to reduce trabecular bone 
mass, which is one of the key elements in osteoporotic patients [82]. Another well recognized 
model of accelerated aging is klotho gene-deficient model that develops characteristics of 
age-related osteoporosis such as low-bone turnover osteoporosis with a highly reduction of 
bone formation rates as compared to bone resorption [83, 84]. Furthermore, this is associated 
with alterations in the age, number and spatial distribution of functionally active resident 
bone-forming cells [85]. The senescence accelerated mouse strain prone 6 (SAMP6) model 
has been extensively used for the purpose of investigating the detrimental effects of aging on 
bone quality. The SAMP6 mouse displays bone phenotype such as reduced trabecular bone 
volume, decreased bone strength [86] and reduced areal BMD [87]. An advantage of the 
SAMP6 model, compared with a true aging model, is that bone loss phenotype is clearly 
developed by 3 to 4 months and can be directly compared with the aged matched control, 
senescence-resistant mouse, strain R1 (SAMR1) [87]. Interestingly, as with human 
osteoporotic patients, although bone quality in these mice is severely impaired, the rate of 
fracture union remains unaffected [88]. It is evident therefore that the SAMP6 mouse 
encompasses many of the most salient features associated with the human condition and as 
such, maybe considered a suitable model with which to investigate both disease mechanisms 
and novel therapeutic strategies. Therefore, it is the intention of this thesis to utilize the 
SAMP6 model for the purpose of investigating the role and therapeutic potential of stem cells 
in osteoporosis. It is envisaged that the use of such an appropriate and well-defined 
osteoporotic model will allow us to more effectively translate our experimental results to the 
human condition. 
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1.3 Basic concept of stem cells 
Stem cells represent the building blocks of our bodies and have been defined as the natural 
units of embryonic generation and adult regeneration [89]. Stem cells are distinguished from 
other cell types by two important characteristics. Firstly, they are unspecialized cells capable 
of undergoing self-renewal throughout an organism’s lifetime, sometimes after long periods 
of inactivity. Secondly, they have the ability to become organ-specific cells with distinct 
functions. These two properties make somatic stem cells unique and ideal for tissue 
engineering applications [90].  
Depending on the stage of development, stem cells may be classified as embryonic (derived 
from the totipotent cells of early embryo), fetal (derived from the developing foetus) and 
adult stem cells (derived from mature organs in the adult individual). Recently, pluripotent 
stem cells were artificially derived from somatic cells by specifically inducing the expression 
of genes involved in self-renewal and potency [48, 91, 92]. Stem cells receive various signals 
from their niche, including growth factors and secreted cytokines, as well as signals mediated 
by cell-cell interactions and interactions with ECM to control the process of stem cell 
characteristics [93]. 
 Stem cells are not only necessary for development and organogenesis, but are also important 
for tissue maintenance and repair [94]. Apart from giving the full range of differentiated cells, 
stem cells can proliferate while maintaining their multipotent characteristics. This property of 
stem cells can also occur by so-called asymmetric cell division, suggesting that upon division 
one daughter cell becomes a committed progenitor cell that subsequently undergoes further 
differentiation, while the other daughter cell remains as a stem cell with the same 
characteristics as the mother cell [94, 95]. 
1.3.1 Stem cell niche  
The idea of the stem cell niche was initially proposed over 30 years ago to explain the 
specialized microenvironment where a stem cell resides in vivo [96]. Under normal 
physiological conditions, the stem cell niche consists of a cellular and ECM component, 
which forms a functioning unit of tissue. At a more molecular level, the stem cell niche can 
be considered a dynamic entity in which complex interactions occur between stem cells and 
neighbouring cells, typically involving direct cell-cell interactions and release of diffusible 
soluble factors or cytokines (autocrine or paracrine signalling within the niche), extracellular 
matrix, oxygen tension and pH, amongst many other essential parameters [93, 97, 98]. The 
complex and highly dynamic relationship between stem cells and various components of its 
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surrounding microenvironment play an important role in the regulation of stem cell 
behaviour, with niche-specific signals serving to maintain the stem cell in its quiescent state. 
At selected time points, niche-specific signals can be modified accordingly to induce an 
appropriate response in the stem cell such as proliferation, migration and differentiation [93, 
98].  
1.3.2 Multipotent stromal cells (MSCs) 
MSCs have the potential to undergo differentiation towards various cell lineages, giving rise 
to a variety of mesenchymal tissues, including bone (osteoblast), fat (adipocytes), muscle 
(myocytes), cartilage (chondrocytes) and tendon (tenocytes) [99] (Figure 3). This 
multipotency, together with their capacity for extensive expansion, has led to MSCs being 
considered as a very promising source of cells for regenerative medicine. This is primarily 
due to the ease by which these cells can be isolated and expanded in vitro, whilst still 
retaining their multipotential differentiation capacity under specific conditions [100, 101]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Multi-lineage potential of adult mesenchymal stem cells [102]. 
 
MSCs can be found ubiquitously throughout the body and are routinely isolated from sources 
such as bone marrow, adipose tissue, adult blood, umbilical cord blood, amniotic fluid, 
tendon and ligaments, synovial membranes, deciduous teeth, liver, lung and spleen [103-
112]. 
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MSC differentiation requires the activation of specific regulatory genes and subsequent 
signaling events. The key factors and important mechanisms known to be involved in 
adipogenic and osteogenic differentiation are detailed in the following sections (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Adipogenic and osteogenic differentiation [113]. 
 
1.3.3 Adipogenesis 
The transcriptional regulation of adipogenic differentiation has been studied using several in 
vitro models. In order for MSCs to undergo adipogenesis, a specific medium supplemented 
with 3-isobutyl-1-methylxanthine, insulin, indomethacin, and dexamethasone has frequently 
been used [114-116]. Upon differentiation, the fibroblast-like morphology of MSCs is 
converted into a more rounded shape as a result of changes in the ECM as well as the 
synthesizing of proteins associated with the cytoskeleton [117]. Furthermore, cytoplasmic 
formation of lipid droplets composed of triglycerides and cholesterol esters is enhanced 
during adipogenic differentiation. This is also involved in one or two rounds of clonal 
expansion followed by activation of adipogenic specific genes and achievement of the 
adipogenic phenotype [118]. Up-regulation of gene expression during adipogenic 
differentiation is accomplished by the chronological activation of peroxisome proliferator-
activated receptor γ2 (PPARγ2) and enhancer binding proteins (C/EBPs). Intermediate 
activation of C/EBPβ and C/EBPδ stimulates expression of C/EBPα and PPARγ2 (Fig. 4) 
[117, 119], which then stimulates expression of target genes like fatty acid binding protein 4 
(FABP4), facilitated glucose transporter member 4 (GLUT4), and lipoprotein lipase (LPL) 
[120-122]. Additionally, loss-of-function studies in chimeric mice and overexpression studies 
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in non-adipogenic fibroblasts suggest that PPARγ2 is necessary for induction of adipogenesis 
[123]. 
It has been shown that factors like fatty acids, M-CSF, insulin-like growth factor 1 (IGF1), 
prostaglandins, and glucocorticoids are involved in induction of adipogenic differentiation, 
while Wnt signaling and TGFβ play a more inhibitory role [118]. 
1.3.4 Osteogenesis 
The mechanisms of osteogenesis, which is essential for bone formation, have been studied in 
different in vitro culture systems. One of the important components provided in 
differentiation culture medium is ascorbic acid. This is necessary for accumulation of 
collagen type I in the ECM of differentiating osteoblasts as well as for the expression of bone 
gamma-carboxyglutamate (Gla) protein (osteocalcin) and alkaline phosphatase (ALP). The 
other element is β-glycerophosphate which serves as an exogenous source of organic 
phosphate for matrix mineralization [124, 125].  
At the transcriptional level, osteogenesis is induced by the transcription factors RUNX2 and 
SP7 [126, 127]. RUNX2 requires heterodimerisation with core-binding factor β to achieve its 
transcriptional activity to induce the differentiation of MSCs towards osteoblasts and 
chondroblasts and to inhibit their differentiation into adipocytes and myocytes [128, 129]. 
Furthermore, RUNX2 post-transcriptional regulation can be conducted via phosphorylation 
or protein-protein interactions, and its activity is enhanced by mitogen-activated protein 
kinase (MAPK) signaling as demonstrated in human MSCs stimulated with fibroblast growth 
factor (FGF)-2 [130, 131]. Sp7 is mainly expressed in osteoblasts, and is required for the 
differentiation of pre-osteoblasts into mature osteoblasts after initiation of osteogenesis by 
RUNX2 [30]. Furthermore, it has been shown that Sp7 inhibits expression of transcription 
factor (SOX9), which is necessary for chondrogenic induction.  
Several hormones and signaling pathways also play important roles in the regulation of 
osteogenesis, including BMP and FGF signaling [132]. It has been reported that BMP2 
enhances osteoblast commitment and affect stabilization of RUNX2 by acetylation. This 
process has an inhibitory effect on degradation of the transcription factor by the 
ubiquitination pathway [133]. FGFs together with their corresponding receptors (FGFRs) 
enhance osteogenic differentiation potential of adult MSCs and embryonic bone development 
[131, 134-139].  
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1.3.5 Inverse relationship between adipogenic and osteogenic differentiation 
There is a close relationship between both osteogenic and adipogenic differentiation, as both 
pathways share a common progenitor cell. It has been shown that bone loss is accompanied 
by an increasing accretion of adipose tissue in the bone marrow cavity [72]. As such, an 
appreciation of the pathways that regulate both adipogenesis and osteogenesis may be critical 
to our understanding of how bone loss is controlled. Both RUNX2 and PPARγ are master 
transcriptional regulators and are present in low levels in undifferentiated MSCs, and are 
differentially regulated depending on which cell lineage is chosen [12, 140]. Differentiation 
towards either pathway is regulated by a complex set of paracrine signals, including BMPs, 
Wnts, PPARγ ligands, corticosteroids, and growth factors [74, 140].  Such factors are derived 
from cells in the neighbouring niche environment including osteoblasts, adipocytes, 
hematopoietic stem cells (HSCs), and endothelial cells [74, 141-143]. Additionally, MSC 
differentiation towards either adipogenesis or osteogenesis corresponds to unique 
intracellular redox profiles [144], and each cell type can further modify their extracellular 
redox environment to be more oxidizing (adipocytes) or reducing (osteoblasts), suggesting 
that differentiation into specific phenotypes may also be dependent on redox states [144]. 
Importantly, the pathogenesis of osteoporosis represents a significant imbalance between 
these reciprocally regulated differentiation programs, with excess marrow adipocytes being 
produced at the expense of osteoblasts [5, 6, 10-12, 74, 145-148]. These regulatory 
mechanisms are summarized in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Schematic diagram differentiation number of regulators control MSC fate [148]. 
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1.4 Potential therapeutic applications of MSCs 
MSCs are promising candidates for clinical use in cellular therapies and tissue engineering 
strategies. Cellular therapies are medical processes, which utilize healthy, fully functional 
cells in order to replace dysfunctional cells that have been damaged or even destroyed by 
disease. The principle of tissue engineering is primarily the same, although it additionally 
involves culturing cells on three dimensional structures in vitro, in order to form functional 
units that more closely mimic the in vivo target tissue. A variety of different cell types may be 
used in cellular therapies and tissue engineering, including mature functional cells, 
genetically modified cells or even cells from different species. Optimal cells should be 
readily available and highly expandable in vitro, display consistent differentiation properties 
and be highly biosynthetic, preserve a stable phenotype after specification and not elicit any 
adverse immune response after implantation [149]. Among the cells that fit such a profile, 
MSCs are considered to be most suitable in situations of allogeneic and autologous 
transplantation [150]. 
Allogeneic transplantation can be clinically challenging, since the recipient’s body may 
recognize the allergenic material as foreign, resulting in an immune response and possible 
rejection of the transplanted material. As such, allogeneic transplantation must be 
accompanied by rigorous immune suppression. MSCs are immunologically unique in that 
they express more major histocompatibility complex (MHC) Class I antigens than MHC 
Class II antigens [151]. It has also been reported that both undifferentiated MSCs and their 
differentiated derivatives lack the expression of MHC Class II antigens, strongly suggesting 
that MSCs are non-immunogenic and would not evoke an immune response upon 
transplantation [152]. In agreement with this observation, it has been shown that following 
allogeneic transplantation, MSCs evaded immune recognition and were readily detected in 
recipients after extended time periods [150]. A common complication of allogeneic 
transplantation is graft-versus-host-disease (GVHD), in which functional immune cells 
carried over from the donor in the transplanted material recognize the recipient as foreign and 
trigger an immune response. MSC transplantation has not only been shown to reduce the 
incidence of GVHD, but has also been used as a treatment for this disease [151]. Therefore, 
the potential of MSCs for use in allogeneic transplantation as well as autologous 
transplantation has major clinical significance, since material could be transplanted between 
mismatched individuals. 
   Introduction 
 23 
1.4.1 Use of adult MSCs in promoting new bone formation  
Nowadays, the purpose of using adult MSCs for developing new bone reconstruction 
therapies is prevalent in areas of both experimental and clinical research. Several approaches 
have been utilized in the deployment of these cells to specific locations within dysfunctional 
or damaged bone to assist in restoring normal bone homeostasis. This has been shown by 
using biomaterial carriers seeded with BMSCs, which allow for the implantation of 
osteogenic differentiating cells directly into a defect site [153-155]. In a different approach, 
BMSCs can be introduced into the defect area either by a systemic or local injection. Such an 
approach has already been performed in clinical studies examining the effectiveness of 
BMSC treatment of the degenerative bone condition, osteogenesis imperfecta [156-160]. The 
successful outcome of such bone marrow infusions in children suffering from osteogenesis 
imperfecta was demonstrated by increases in osteoblast numbers and new lamellar bone 
formation [158]. Furthermore, it was also reported that the incidence of fractures among these 
children decreased.  
The genetic alteration of MSCs to optimize both cellular delivery and also performance has 
been validated in several studies investigating the potential of cell-based therapies for the 
treatment of bone loss. It has been demonstrated that systemic transfer of genetically altered 
MSCs overexpressing receptor RANK-Fc and the CXC chemokine receptor-4 (CXCR-4) 
protected against bone loss in an ovariectomized mouse model [161]. Similarly, bone mineral 
density was increased in ovariectomized mice treated with BMSCs overexpressing BMP2 
and α4 integrin [162]. In the case of mouse MSCs overexpressing β-galactosidase- or BMP4, 
cells were directly injected into the bone marrow, rather than intravenously, resulting in a 
much greater proportion of bone engrafted cells and significantly increased trabecular BMD 
[163]. This approach has also been adopted for the transfer of bone marrow cells to senile 
osteoporotic mice. It has been shown that following allogeneic bone marrow transplantation 
from normal mice into irradiated SAMP6 mice, bone mineral density was restored to levels 
comparable to non-osteoporotic mice [164]. However, one major drawback in the use of 
allogeneic bone marrow transplantation is the need for bone marrow ablation in recipients 
due to the presence of immunocompetent cells. One alternative therefore, is to use purified 
stem cell preparations free of contaminating immunoreactive cell types. This concept was 
further evaluated to investigate the effects of immortalized C3H/10T1/2 mouse embryonic 
fibroblasts on bone remodeling. Mouse C3H/10T/2 cells genetically induced to over express 
CXCR4, were shown to restore bone mass and enhance bone formation in glucocorticoid-
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induced osteoporotic mice following either systemic or local intramedullary administration 
[165]. 
The local administration of osteocompetent MSCs directly into bone could therefore offer an 
alternative means by which to enhance bone quality, although the differentiation state of 
these cells and the microenvironment to which they are exposed, may play significant roles in 
determining their fate. In this thesis, adipose tissue will be evaluated as a potential source of 
therapeutic MSCs for the purpose of enhancing of bone quality in a mouse model for senile 
osteoporosis and determine the most appropriate means by which to transplant these cells.  
1.4.2 Biological applications of adipose-derived stromal cells (ASCs) 
In order to use adipose tissue for the purpose of stem cell therapy, one should first be aware 
of the composition of this tissue. Adipose tissue is the specific connective tissue which 
functions as the major storage site for fat in the form of triglycerides. The main portion of 
adipose tissue is composed of lipid-filled cells, maintained in a framework of collagen fibers. 
Adipose tissue contains endothelial cells, fibroblasts, blood cells, pericytes, adipocytes, and 
adipose precursor cells [166]. Fat tissue can be classified as two types; brown adipose tissue 
(BAT) and white adipose tissue (WAT), which is the larger proportion of the body fat. The 
morphology and function of brown adipocytes are distinct from white adipocytes. 
Phenotypically, brown fat cells are rich in mitochondria and accumulate lipids in multiple 
small droplets [167], and their function is to translate energy into heat production [168]. In 
the WAT, mature adipocytes have one large lipid droplet with the nucleus located at the cell 
periphery, and are also referred to as univacuolar adipocytes. WAT serves several functions 
such as heat insulation, mechanical cushion, and most importantly, a source of energy [166, 
169, 170] (Figure 6). Moreover, WAT secretes hormones and signaling factors, which play 
an important role in several physiological and pathophysiological processes [171, 172]. The 
release of adipokines from adipocytes and adipose tissue influences insulin sensitivity, energy 
homeostasis, and vascular homeostasis of the organism [170, 173, 174]. 
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Figure 6: White fat cell and brown fat cell. LV: lipid vacuole; M: mitochondria; N: nucleus. 
[Artwork courtesy of Dr. John Horwitz, U.C. Davis.S.] 
 
ASCs can be isolated from various fat stores throughout the body by minimally invasive 
liposuction or through enzymatic digestion of adipose tissue [175-177]. It has been 
demonstrated that ASC clones derived from lipoaspirates can differentiate towards 
adipogenesis, osteogenesis, and chondrogenesis [178]. These findings together with the fact 
that ASCs can undergo several population doublings while retaining their differentiation 
capabilities support the hypothesis that ASCs are a type of multipotent adult stem cell [178, 
179]. In the case of using adipose tissue, deficiency of autologous donor tissue is very 
unlikely in most individuals. Subcutaneous fat extraction is one of the easiest ways for 
obtaining ASCs for generating different cell lineages [180].  
Regarding osteogenesis, several studies have illustrated that there is a close relationship 
between osteogenic differentiation in bone marrow aspirates and adipose tissue [176, 181, 
182]. It is conceivable therefore, that MSCs isolated from sources other than the bone 
marrow, may also have the potential to enhance the quality level of osteoporotic bone. Recent 
studies utilizing GFP-expressing ASCs have already confirmed that following a single 
intramedullary infusion in mice, not only do the cells become engrafted within the injected 
bones, but they also have many of the characteristic features associated with resident 
osteoblasts, confirming complete osteogenic differentiation of these cells [183]. Moreover, 
pre-exposure of these cells to bone microenvironment enhanced both cell migration and 
survival in the bones of recipient mice following systemic administration. 
It has been shown that ASCs seeded on hydroxyapatite/tricalcium phosphate (HA-TPC) 
matrices are capable of forming bone in vivo, and the majority of the ASCs formed osteoid 
following implantation in mice [182]. Moreover, another study demonstrated that large 
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skeletal defects such as skull fracture, can be healed without genetic manipulation or the 
addition of any exogenous growth factors by using scaffolds seeded with ASCs [184, 185]. 
Information gleaned from such studies may enable us to identify suitably potent stem cell 
sources from which novel autologous stem cell-based therapeutic strategies could be 
developed with an aim to improving bone quality in elderly osteoporotic patients. 
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2 Hypothesis and aims of the thesis 
The fundamental premise of this thesis is that resident BMSCs are centrally involved in the 
development of low turnover osteoporosis and that deficits in bone remodeling may be 
counteracted through manipulation or replacement of these cell populations, thereby resulting 
in improved bone quality. 
Aim 1: Compare the differentiation potential of ASCs from osteoporotic (SAMP6) and non-
osteoporotic (SAMR1) mice. ASCs were isolated from SAMP6 and SAMR1 mice and 
maintained in a 2D in vitro culture system. Their ability to differentiate towards osteoblast 
and adipocyte cell lineages was evaluated using histological, biochemical and molecular 
techniques.  
Aim 2: Establish a 3D in vitro culture system using ASCs in scaffold-free microtissue 
spheroids (ASC-MTs). ASCs were cultured in an ASC-MT format and their osteogenic 
differentiation capacity was evaluated using histological, biochemical and molecular 
techniques.   
Aim 3: Determine whether transplanted ASCs or ASC-MT have the capacity to promote new 
bone formation and enhance trabecular structure in osteoporotic mice. ASCs and ASC-MT 
were injected directly into the bone marrow of SAMP6 mice and their effects on bone quality 
evaluated by radiological and molecular analyses. Transplanted cells were identified through 
the use of CellTracker CM-Dil. The influence of ASCs on BMSC-mediated mineral 
formation was further assessed in in vitro studies utilizing osteoporotic patient-derived 
BMSCs and ASCs. 
It was envisaged that the results gleaned from this study would not only improve our 
understanding of the role of MSCs in osteoporosis but would also allow for the development 
of more effective therapeutic strategies with which to combat bone loss and thus restore bone 
quality. 
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3 Results 
3.1 Overview of published and submitted manuscripts 
3.1.1 Telomere length, telomerase activity and osteogenic differentiation are 
maintained in adipose tissue-derived stromal cells from senile osteoporotic 
SAMP6 mice   
Authors:  Mirsaidi A, Kleinhans KN, Rimann M, Tiaden AN, Stauber M, Rudolph KL, 
Richards PJ. 
Journal:  Tissue Engineering and Regenerative Medicine, 2012; 6:378-90. 
Contribution:  Planning, performing and evaluating all the experiments.  
 
3.1.2 Preparation and osteogenic differentiation of scaffold-Free mouse adipose-
derived stromal cell microtissue spheroids (ASC-MT) 
Authors:  Mirsaidi A, Tiaden AN, Richards PJ. 
Journal:  Current Protocols in Stem Cell Biology, 2013, 27:2B.5.1–2B.5.12. 
Contribution:  Planning, performing and evaluating all the experiments. 
 
3.1.3 Therapeutic potential of adipose-derived stromal cells in age-related osteoporosis 
Authors:  Mirsaidi A, Genelin K, Vetsch J, Stanger S, Lindtner RA, Blauth M, Müller 
R, Kuhn GA, Hofmann S, Ebner HL, Richards PJ. 
Journal:  Biomaterials, 2014, 35:7326-35. 
Contribution:  Planning, performing and evaluating all the in vitro and in vivo experiments. 
 
3.1.4 ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-
fat diet and impairs adipocyte function and differentiation. 
Authors:  Erener S., Mirsaidi A., Hesse M., Tiaden A.N., Ellingsgaard H., Kostadinova 
R., Donath M.Y., Richards P.J., and Hottiger M.O. 
Journal:  FASEB Journal, 2012, 26(6):2631-8. 
Contribution:  Planning and performing cell culture, including isolation and differentiation of 
ASCs as well as evaluation of differentiation by qRT-PCR and Oil red/ 
Alizarin red staining (Fig. 5, 6, S3). 
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3.1.5 Human serine protease HTRA1 positively regulates osteogenesis of human bone 
marrow-derived mesenchymal stem cells and mineralization of differentiating 
bone-forming cells through the modulation of extracellular matrix protein. 
Authors:  Tiaden AN, Breiden M, Mirsaidi A, Weber FA, Bahrenberg G, Glanz S, 
Cinelli P, Ehrmann M, Richards PJ.   
Journal:  Stem Cells, 2012, 30:2271-2282. 
Contribution:  Planning, performing cell culture, including isolation and differentiation of 
ASCs as well as evaluation of differentiation by qRT-PCR, alizarin red and 
immunofluorescence staining in 3D cell culture system (Fig. 2, 5c, S4). 
 
3.1.6 Detrimental role for human high temperature requirement serine protease A1 
(HTRA1) in the pathogenesis of intervertebral disc (IVD) degeneration. 
Authors:  Tiaden AN, Klawitter M, Lux V, Mirsaidi A, Bahrenberg G, Glanz S, Quero 
L, Liebscher T, Wuertz K, Ehrmann M, Richards PJ.   
Journal:  Journal of Biological Chemistry, 2012, 15; 287(25):21335-45. 
Contribution:  Preparing frozen tissue sections for histological analysis. RNA and protein 
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Abstract
Adipose tissue provides for a rich and easily accessible source of multipotent stromal cells and thus
offers the potential for autologous cell-based therapy for a number of degenerative diseases. Senile
osteoporosis is characterized by a reduction in bone quality, which is associated with inadequacies
in bone marrow stromal cell (BMSC) differentiation. In the present study, we have characterized
adipose-derived stromal cells (ASCs) isolated from aged osteoporotic mice and evaluated their
suitability as a source of osteogenic precursor cells. Significant reductions in both tibia bone quality
and telomere length in liver tissue were observed in the senescence-acceleratedmouse prone 6 strain
(SAMP6), as compared to the control age-matched senescence-accelerated mouse resistant 1 strain
(SAMR1), thus confirming osteoporosis and accelerated ageing traits in this model. ASCs isolated
from inguinal fat expressed mesenchymal surface markers and were capable of differentiating along
the osteoblast, adipocyte and chondrocyte lineages. Telomere length was not compromised in ASCs
from SAMP6 mice but was actually found to be significantly increased as compared to control
SAMR1 mice. Furthermore, ASCs from both strains were comparable in terms of telomerase activity,
p21 mRNA expression, SA–β-gal activity and proliferative capacity. The overall osteogenic and
adipogenic potential of ASCs was comparable between SAMP6 and SAMR1 strains, as determined
by quantitative molecular, biochemical and histological analyses. In conclusion, adipose tissue
may represent a promising autologous cell source for the development of novel bone regenerative
therapeutic strategies in the treatment of age-related osteoporosis. Copyright  2011 John Wiley &
Sons, Ltd.
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1. Introduction
Bone quality is regarded as being the resistance of bone to
fracture and reflects the incorporation of bone density
and mechanical strength as well as architecture and
mineralization (Lane, 2006; Seeman and Delmas, 2006;
Recker and Barger-Lux, 2004). These elements of bone
quality are severely affected in aged osteoporotic patients
Copyright  2011 John Wiley & Sons, Ltd.
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by alterations in bone turnover through the process of
bone remodelling. Such deviations may arise from a loss
in the homeostatic control of the bone multicellular unit,
where the activities of bone-forming osteoblasts and bone-
resorbing osteoclasts are no longer balanced (Seeman
and Delmas, 2006). Bone formation is reliant on the
presence of functionally active mature osteoblasts derived
from progenitor cells within the bone marrow, termed
bone marrow stromal cells (BMSCs), through a process
of osteogenic differentiation (Bruder et al., 1994). The
observation that BMSCs isolated from aged osteoporotic
patients have a reduced osteogenic capacity implies that
the structural abnormalities associated with osteoporotic
bone may be as a consequence of inadequacies in bone
cell differentiation (Rodr ı´guez et al., 1999, 2000). This
is further supported by studies using the senescence-
accelerated mouse prone 6 strain (SAMP6).
The SAMP6 strain was originally described by Mat-
sushita et al. (1986), originating from crossbreeding
between AKR/J mice and mice from an unknown strain.
In addition to the SAMP6 strain, numerous other strains
were also developed, including the resistant strain, termed
SAMR1, which displayed no pathological phenotype.
Unlike chronologically aged mouse models, osteoporosis-
like traits, including reduced trabecular bone volume
(Matsushita et al., 1986), decreased bone strength (Silva
et al., 2002) and reduced areal bone mineral density
(BMD) (Takeda, 1999) are clearly developed in the
SAMP6 strain as early as 3–4 months of age, as compared
to their age-matched SAMR1 strain counterparts. It is now
well established that the osteoporotic phenotype observed
in SAMP6mice is associated with defects in the osteogenic
differentiation capacity of resident BMSCs (Jilka et al.,
1996; Silva et al., 2005). Additionally, data from our own
studies have revealed that, in contrast to their reduced
osteogenic potential, BMSCs from SAMP6 mice actually
demonstrate an enhanced capacity for adipogenesis, thus
lending some insight into the mechanisms responsible
for reduced bone quality in these mice (Egermann et al.,
2010).
The role of ageing in determining the quality of
bone and potential onset of osteoporosis has also been
highlighted through studies utilizing other experimental
models of accelerated ageing. Compound knockout mice
bearing mutations in both the Werner and telomerase
genes result in mice with a significant decrease in
trabecular bone mass and is directly related to an
impairment in BMSC osteogenesis (Choi et al., 2008;
Chang et al., 2004). Osteoporotic features are also
apparent in klotho gene-deficient mice, a well-recognized
model of accelerated ageing, and are associated with
alterations in the age, number and spatial distribution
of functionally active resident bone-forming cells (Kuro-
o et al., 1997; Kawaguchi et al., 1999; Suzuki et al.,
2005). It is essential, therefore, that therapeutic strategies
employed to treat osteoporosis in elderly patients are
effective not only in preventing further bone loss but also
in stimulating the formation of high-quality bone through
manipulation of the BMSC niche.
The use of stem cells from adipose tissue, termed
adipose-derived stromal cells (ASCs), for the purpose of
developing new bone reconstruction therapies is now
prevalent in areas of both experimental and clinical
research. This is primarily due to the ease by which
these cells can be isolated and expanded in culture and
their characteristic multipotency under specific conditions
(Pittenger et al., 1999). ASCs have the capacity for
osteogenic differentiation and may be easily accessed
from subcutaneous fat stores through minimally invasive
procedures (Halvorsen et al., 2000, 2001; Zuk et al., 2001;
Scha¨ffler and Bu¨chler, 2007). Moreover, the proliferative
capacity (Schipper et al., 2008; Zhu et al., 2009; Khan
et al., 2009) and osteogenic potential (Shi et al., 2005;
Weinzierl et al., 2006; Zhu et al., 2009; Khan et al., 2009)
of ASCs appear not to be adversely affected by donor age.
However, the application of ASCs as a cell-based therapy
for the purpose of enhancing orthopaedic tissue repair and
regeneration is at an early stage of research (Tapp et al.,
2009) and, as such, no studies have yet been carried out to
evaluate the possible therapeutic potential of autologous
ASCs for the treatment of osteoporotic bone disease.
In the present study, we characterize ASCs isolated
from aged osteoporotic mice and evaluate their potential
as autologous bone regenerative stem cells for the
treatment of senile osteoporosis. Initial quantitative
analyses employing fluorescence in situ hybridization
and µCT confirmed SAMP6 as a model for accelerated
ageing and osteoporosis, respectively. ASCs isolated and
expanded from both SAMP6 and SAMR1 mice displayed
many of the key features associated with mesenchymal
stem cells, such as specific surface marker expression
and multipotent differentiation capabilities. There was
no evidence of telomere shortening or increased cellular
senescence in cultured ASCs isolated from SAMP6 mice
as compared to SAMR1 mice. In fact, telomeric DNA
levels were actually found to be significantly greater
in ASCs from SAMP6 mice. Furthermore, in contrast to
our previous studies, in which BMSCs from SAMP6 mice
were shown to be defective in terms of their osteogenic
capability (Egermann et al., 2010), ASCs from these mice
demonstrated no such impairment in either the early or
late phases of osteogenic differentiation. Similarly, ASC
adipogenesis was comparable between the two mouse
strains. These findings therefore highlight the potential
for adipose tissue as a source of functional osteogenic
precursor cells for the purpose of autologous cell-based
therapy in aged bone disease.
2. Materials and methods
2.1. Animals
Experiments were performed using 20 week-old male
SAMR1 and SAMP6 mice (Harlan Laboratories, Horst,
The Netherlands). All animal research procedures were
approved by the Animal Experimentation Committee of
the Veterinary Office of the Canton of Zu¨rich, Switzerland,
Copyright  2011 John Wiley & Sons, Ltd. J Tissue Eng Regen Med (2011).
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and followed the guidelines of the Swiss Federal Veteri-
nary Office for the use and care of laboratory animals.
2.2. Microcomputed tomography (µCT)
Tibia were scanned by microcomputed tomography(µCT
40; Scanco Medical AG, Bru¨ttisellen, Switzerland) and
the measured data filtered using a three-dimensional
(3D) constrained Gaussian filter with finite filter support
(1 voxel) and filter width (s = 0.8). The system was
operated in cone beam mode at 70 kVp, 114 µA and a
focal spot size of 8 µm. The images were then binarized
to separate the object from background, using a global
thresholding procedure. A component-labelling algorithm
was subsequently applied to remove all unconnected
parts, which typically arise from image noise. A fully
automated algorithm was used to identify three volumes
of interest, the full bone (FULL), the metaphyseal
trabecular bone (TRAB) and a cortical ring in the
diaphysis (CORT). The FULL compartment identifies
the outline of the whole organ. This compartment was
used to estimate the total amount of bone in the tibia.
The TRAB compartment identifies the trabecular bone
in the proximal metaphysis. It is proximally limited
by the growth plate and distally by 20% of the tibia
length. The CORT compartment identifies a cortical ring
of 1.0 mm height. This ring was placed at 50% of
tibia length as measured from the proximal end of the
tibia. The three compartments were then analysed with
standard morphometric algorithms (Hildebrand et al.,
1999; Odgaard, 1997).
2.3. Isolation and culture of mouse ASCs
Subcutaneous inguinal fat pads were removed, washed
extensively in phosphate-buffered saline (PBS) and
digested in Hepes buffer (with calcium and magne-
sium) containing 0.1% collagenase A (Roche Diagnostics,
Rotkreuz, Switzerland) and 0.2% bovine serum albumin
(BSA) for 40 min at 37 ◦C. Stromal cells were collected
by centrifugation, filtered through a 40 µm sieve (Becton-
Dickinson) and cultured in complete medium consisting
of Dulbecco’s modified Eagle’s medium (DMEM-low glu-
cose, with Glutamax; Invitrogen AG, Basel, Switzerland),
supplemented with 10% fetal bovine serum (FBS; Invit-
rogen AG) and antibiotics. The supernatant was replaced
after 1 day with fresh complete medium and cells were
used between passage 1 and 4 unless otherwise stated.
2.4. Flow cytometry analysis of surface antigens
Cells were directly stained with phycoerythrin-labelled
antibodies (Lucerna-Chem, Switzerland) specific for
CD29, CD105, Sca1, CD34 and CD45. Specificity was
confirmed through the use of appropriate phycoerythrin-
labelled istotype control antibodies. Flow cytometry was
carried out on a CyAn ADP flow cytometer, using Dako
Summit software, v 4.3.
2.5. Telomere analysis
2.5.1. Telomere restriction fragment (TRF) length
analysis
Genomic DNA was extracted and isolated from liver
tissue by phenol–chloroform extraction, using standard
protocols, and TRF analysis performed using pulsed-
field gel electrophoresis (PFGE) as previously described
(Wiemann et al., 2002). Briefly, 6 µg DNA was digested
overnight at 37 ◦C, using HinfI and Rsa1. Samples were
run on a 1% agarose gel with a low-range PFG marker
as a size standard, using a Gene Navigator System (GE
Healthcare) at 11 V/cm with a 3 s pulse time. The gel
was dried for 1 h in a vacuum drier, followed by 30 min
denaturation and 30 min neutralization. After 1 h pre-
hybridization, the gel was incubated in hybridization
buffer with the (TTAGGG)3 oligonucleotide radioactively
labelled telomere probe overnight at 37 ◦C. The gel was
washed three times with 0.25% SSC and 0.1%SDS and
then exposed on a PhosphorImager-screen for 3 days.
Telomere signals were calculated with PCbas 2.0 and
Excel (Microsoft) computer programs.
2.5.2. Quantitative fluorescence in situ
hybridization (Q-FISH)
Q-FISH was performed on interphase nuclei, as described
previously with some modifications (Satyanarayana
et al., 2003). In brief, paraformaldehyde-fixed paraffin-
embedded tissue sections (7 µm) were dewaxed in
xylene and rehydrated in a descending ethanol series.
After washing in PBS, samples were boiled in citrate
buffer for 15 min in a microwave. For ASCs grown on
glass slides, cells were first fixed in methanol:acetic
acid (3:1, v/v) and allowed to air-dry overnight. The
hybridization mix containing the Cy3-telomere probe
(Applied Biosystems) was applied to the samples and
denatured at 80 ◦C for 3 min, followed by a 2 h incubation
at room temperature in a humid chamber. Samples
were mounted in DAPI containing mounting solution
and images (×200 magnification) captured, using the
Leica DMI6000B automated inverted research microscope
system (Leica Microsystems), and telomere fluorescence
intensity (TFI) was quantified using the TFL-TELO V1.0
telomere analysis program developed by P. Landsdrop.
2.6. Induction and quantification
of differentiation
2.6.1. Osteogenesis
ASCs were plated at 5000 cells/cm2 and incubated
in α-minimum essential medium (α-MEM; Invitrogen
AG), supplemented with 10% FBS, 50 µM L-ascorbic
acid 2-phosphate sesquimagnesium salt hydrate (Sigma-
Aldrich, Buchs, Switzerland), 10 mM β-glycerophosphate
(Sigma-Aldrich) and 5 µM retinoic acid (Sigma-Aldrich)
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for up to 14 days, with regular changes of medium.
Alkaline phosphatase (ALP) activity was determined in
cell lysates, using p-nitrophenylphosphate (pNPP) liquid
substrate (Sigma-Aldrich). Optical densities measured at
405 nm were converted to molar units using a standard
curve of known concentrations of p-nitrophenol (pNP;
Sigma-Aldrich) and normalized to total protein content
and reaction time. Mineralization in cell colonies was
identified using alizarin red S (Sigma-Aldrich) and was
quantified by colorimetric analysis at 570 nm, following
extraction using 10% cetylpyridinium chloride (Sigma-
Aldrich). Values were converted to molar units using a
standard curve of known concentrations of alizarin red S
and normalized to total DNA content. All differentiation
studies were carried out using ASCs at passage 3–4.
2.6.2. Adipogenesis
ASCs were plated at 10 000 cells/cm2 and incubated in
adipogenic medium consisting of DMEM supplemented
with 10% FBS, 1 µM dexamethasone (Sigma-Aldrich),
10 µg/ml insulin (Sigma-Aldrich), 0.1 mM indomethacin
(Sigma-Aldrich) and 0.5 mM isobutylmethylxanthine
(IBMX; Sigma-Aldrich) for 2 days. The cells were then
maintained in adipogenic medium without IBMX for up
to 14 days. Triglyceride content in differentiated cells was
identified using 0.3% oil red O (Sigma-Aldrich), and the
number of adipocytes was counted per 30 fields of view
by fluorescence microscopy and normalized to total cell
number, following counterstaining with Hoechst 33 342
(Sigma-Aldrich). All differentiation studies were carried
out using ASCs at passage 3–4.
2.6.3. Chondrogenesis
For chondrogenic differentiation, 2× 105 cells were
grown in pellet cultures and incubated in DMEM-high
glucose (Invitrogen AG) supplemented with 1% FBS,
50 µM L-ascorbic acid 2-phosphate sesquimagnesium salt
hydrate, 0.5 µg/ml insulin and 10 ng/ml human TGFβ1
(Peprotech, UK) for 28 days. Paraffin wax sections (5 µm)
of fixed pellet cultures were stained with toluidine blue
(Sigma-Aldrich) in order to visualize proteoglycans. All
differentiation studies were carried out using ASCs at
passage 3–4.
2.7. Quantitative reverse-transcription–
polymerase chain reaction (qRT–PCR)
Total RNA was isolated and purified using TRIzol
reagent (Invitrogen AG) according to the manufacturer’s
instructions. RNA (0.5 µg) was reverse-transcribed to
cDNA, using superscript II (Invitrogen AG) and ran-
dom hexanucleotide primers (Promega AG, Du¨bendorf,
Switzerland). Quantification of mRNA expression was
performed with TaqMan Gene Expression Assays (Applied
Biosystems) specific for p21 (Mm00432448 m1), Alpl
(Mm01187117 m1), Spp1 (Mm01611440 mH), Pparγ2
(Mm00440940 m1) and Fabp4 (Mm00445878 m1),
using the StepOnePlus Real-Time PCR System (Applied
Biosystems), and values normalized to the 18S ribosomal
RNA (Hs03003631 g1). Each 10 µl reaction consisted of
1× TaqMan Fast Universal PCR Master Mix (Applied
Biosystems), 1× TaqMan Gene Expression Assay and
10 ng cDNA. All reactions were performed in fast optical
96-well reaction plates (Applied Biosystems) at 95 ◦C for
20 s, 40 cycles of 95 ◦C for 1 s and 60 ◦C for 20 s. ASCs
were used at passage 3–4 and all assays were performed
in triplicate.
2.8. Analysis of senescence
2.8.1. Telomerase assay
Telomerase activity in cell lysates was determined
using the TeloTAGGG Telomerase PCR ELISA (Roche
Diagnostics, Rotkreuz, Switzerland) according to the
manufacturer’s instructions. A total of 1× 104 cells were
used per measurement and optical densities measured
at 450 nm were normalized to a standard cell lysate
supplied with the kit. The mean absorbance readings
from negative control cell extracts heated at 85 ◦C for
10 min were subtracted from all measurements.
2.8.2. Senescence-associated β-galactosidase
(SA-β-gal) assay
SA–β-gal activity was determined in ASCs using the
Senescence Cells Histochemical Staining Kit (Sigma-
Aldrich), according to the manufacturer’s instructions,
and counterstained with Hoechst 33 342. The percentage
of SA–β-gal-positive cells was determined from at least
20 fields of view, using the Leica DMI6000B automated
inverted research microscope system. ASCs were used at
passage 3 and the assay performed in triplicate.
2.8.3. WST-1 proliferation assay
ASC proliferation was tested at various time points over a
14 day incubation period, using the WST-1 assay (Roche,
Switzerland) according to themanufacturer’s instructions.
ASCs were plated at 3× 103 cells/cm2, incubated with
WST-1 for 2 h at selected time points and absorbance
measured at 450 nm. ASCs were used at passage 3–4 and
the assays were performed in triplicate.
2.9. Statistical analysis
All statistical analyses were carried out using SPSS17.0
(SPSS Inc., Chicago, IL, USA). Parametric analysis of
Normally distributed data was performed using the
two-tailed unpaired Student’s t-test for comparison of
two groups or one-way analysis of variance (ANOVA)
for multiple group comparisons. The non-parametric
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Table 1. Quantitative µCT analysis of SAM tibia
Index SAMP6 (n = 8) SAMR1 (n = 8) pa
AVD (%) 62.73 (±0.512) 70.79 (±0.52) <0.001
BV/TV (%) 4.723 (±0.33) 8.437 (±0.52) <0.001
BS/TV (1/ mm) 2.012 (±0.14) 3.219 (±0.18) <0.001
Tb.Th (mm) 0.0685 (±0.002) 0.0736 (±0.001) =0.064
Tb.Sp (mm) 0.682 (±0.02) 0.480 (±0.01) <0.001
Tb.N (1/ mm) 1.38 (±0.05) 1.90 (±0.06) <0.001
Conn.D (1/ mm3) 13.77 (±1.59) 19.68 (±2.4) =0.059
BV (%) 70.49 (±0.87) 76.08 (±0.5) <0.001
Ct.Th (mm) 0.27 (±0.005) 0.28 (±0.003) =0.092
J (mm4) 0.1585 (±0.007) 0.119 (±0.004) <0.001
Imax (mm4) 0.09 (±0.004) 0.07 (±0.002) <0.001
Imin (mm4) 0.07 (±0.003) 0.049 (±0.0008) <0.001
AVD, apparent volume density; BV/TV, trabecular bone volume density; BS/TV, trabecular bone surface density; Tb.Th, trabecular
thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number; Conn.D, trabecular connectivity density; BV, cortical bone volume
density; Ct.Th, cortical thickness; J, polar moment of inertia; Imax and Imin, second moment of inertia.
ap values determined using one-way ANOVA. All results are expressed as mean ± S.E.M.
Mann–Whitney U-test was used to determine differences
between frequencies observed in Q-FISH analysis of
telomere length and in the assessment of oil red O
staining. In all cases, p < 0.05 was considered statistically
significant, and all data were expressed as mean ±
standard error of the mean (SEM).
3. Results
3.1. Analysis of bone loss and ageing in SAMP6
mice
Initial studies were carried out to confirm that the
SAMP6 strain used in the current study displayed
osteoporotic traits similar to those reported for the human
condition. Bone volume and structure were initially
compared in tibias from SAMP6 and SAMR1 strains by
the use of quantitative µCT analysis (Table 1). SAMR1
mice displayed significant increases (p < 0.001) in bone
volume density in both the full compartment (AVD) and
the trabecular compartment (BV/TV) as compared to
their SAMP6 counterparts. Such differences in BV/TV
levels were reflected by the increased trabecular number
(Tb.N; p < 0.001) and decreased spacing between the
trabeculae (Tb.Sp; p < 0.001). Similarly, bone surface
density (BS/TV; p < 0.001)was also significantly elevated
in SAMR1mice. In the cortical compartment, bone volume
density (BV) was significantly increased (p < 0.001) in
SAMR1 mice. Furthermore, reduced values for the second
moment of inertia (Imin and Imax; p < 0.001) and the
polar moment of inertia (J; p < 0.001) in SAMR1 mice
indicated an increase in bending stiffness and a higher
torsion strength, respectively.
Telomere shortening is now regarded as being a key
determinant of an organism’s life expectancy and overall
health and, as such, has significant pathological impli-
cations in numerous degenerative disorders (Sahin and
Depinho, 2010). In addition to its osteoporotic phenotype,
the SAMP6 strain has also been proposed as a model
of accelerated ageing, due primarily to its shortened
life span as compared to the longer-lived SAMR1 con-
trol strain (Takeda, 1999). However, no studies have
yet sought to determine whether telomere length is also
compromised in these animals. We therefore conducted
a series of studies to examine and quantify telomere
length in native tissue, using paraffin wax-embedded liver
sections. Quantitative analysis of interphase nuclei by flu-
orescence in situ hybridization (Q-FISH) demonstrated a
significant reduction in fluorescence intensity measure-
ments in SAMP6 (91.68± 1.4; p < 0.001; Figure 1A)
as compared to SAMR1 (111.8± 1.9; Figure 1B). Defi-
ciencies in telomere length were also confirmed in
SAMP6 mice, using quantitative southern blot analysis
of genomic DNA. TRF length was significantly reduced in
SAMP6 (36.34± 0.22; p < 0.001) as compared to SAMR1
(44.23± 0.85) (Figure 1C). A significant increase in the
ratio of loaded genomic DNA to telomere signal was also
observed in SAMP6 (1.6± 0.2; p < 0.01) as compared
to SAMR1 (0.6± 0.13) (Figure 1D), thus signifying an
overall loss of telomeric DNA in SAMP6 samples. These
data therefore reinforce the notion of SAMP6 as a model
for age-related bone disease and introduce the concept
of telomere deficiencies as being a potential contributory
factor to premature ageing in these mice.
3.2. Characterization of ASCs from SAM strains
ASCs offer an appealing source of cells for tissue-
engineering strategies, due to their ease of isolation,
expansion and ability to differentiate into several types of
mesenchymal tissue. In the present study, we investigated
whether ASCs isolated from the SAM strains also
possessed such attributes by examining surface marker
expression and multipotent capabilities. Subcutaneous
adipose tissue was harvested and ASCs isolated and
expanded. ASC populations from SAMP6 and SAMR1
mice expressed high levels of several markers considered
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Figure 1. Telomere length in liver tissue from SAMP6 mice is significantly reduced as compared to SAMR1 controls. (A, B)
Frequency distributions of telomere fluorescence intensity in SAMP6 (n = 6 animals) (A) and SAMR1 (n = 4 animals) (B) mice
following Q-FISH analyses on paraffin wax-embedded liver sections. Average telomere fluorescence intensity (indicated by dashed
line) was calculated from measuring a total of 771 and 513 nuclei from SAMP6 and SAMR1 mice, respectively. (C, D) The mean
TRF length in DNA samples from SAMP6 (n = 6 animals) and SAMR1 (n = 6 animals) was analysed using a specific radiolabelled
telomeric probe and pulsed-field gel electrophoresis (C), and the ratio of loaded DNA to telomere signal determined (D). All data
are expressed as mean ± SEM. ∗p < 0.01; ∗∗p < 0.001
to be representative of mesenchymal stem cells, including
CD29, CD105 and Sca1, but were almost completely
negative for the well-known haematopoietic markers
CD34 and CD45 (Figure 2A). Cell morphology was
comparable in freshly isolated undifferentiated ASCs
from SAMP6 and SAMR1 mice and multipotency was
demonstrated through their ability to differentiate into
adipocytes, osteoblasts and chondrocytes (Figure 2B).
Therefore, the stromal vascular fraction of adipose tissue
derived from both SAMP6 and SAMR1 mice contains
mesenchymal stem cells with multipotent capabilities.
3.3. Analysis of ageing and senescence in ASCs
from SAM strains
The effect of ageing on BMSC and ASC function has
already been extensively studied in both rodent and
human cell systems. BMSCs isolated from aged donors
are generally considered to have a lower proliferative
capacity than those from young donors, and this has
been associated with telomere shortening and increased
levels of senescence markers (Stenderup et al., 2003;
Baxter et al., 2004; Stolzing et al., 2008). By contrast,
the proliferation capacity of ASCs does not appear to
be significantly affected by donor age, with only a
moderate decrease being reported in cells from aged
donors (Schipper et al., 2008; Zhu et al., 2009; Khan et al.,
2009). We therefore set out to examine and compare
various parameters of ageing in ASCs isolated from
SAMP6 and SAMR1 mice. Q-FISH analysis was initially
carried out to compare telomere length in cultured
undifferentiated ASCs isolated from SAMP6 (Figure 3A)
and SAMR1 mice (Figure 3B). Unexpectedly, ASCs
isolated from SAMP6 mice actually demonstrated a small,
but significant, increase in themean telomere fluorescence
intensity as compared to cells from SAMR1 mice (p <
0.001). Despite these differences in telomere length,
ASCs from both strains maintained equivalent levels of
telomerase activity (Figure 4A), expressed comparable
levels of mRNA specific for the senescence marker
p21 (Figure 4B) and demonstrated similar proliferative
capacities (Figure 4C). The actual level of senescence
in ASCs from both strains was deemed to be very
low, as demonstrated by an almost complete absence
of any positive staining for senescence-associated-β-
galactosidase (SA–β-Gal) activity (Figure 4D). Therefore,
short-term cultures of ASCs isolated from SAMP6 mice do
not appear to show any signs of accelerated ageing, as
compared to ASCs from control SAMR1 mice when grown
under standard conditions.
3.4. Osteogenic potential of ASCs from aged
osteoporotic SAMP6 mice
There is now a growing body of evidence to suggest that
ASCs have the potential to retain their differentiation
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Figure 2. ASCs isolated from SAM strains express mesenchymal surface markers and are multipotent. (A) FACS analysis was used
to determine the proportion of ASCs expressing mesenchymal (CD29, CD105, Sca-1) or haematopoietic (CD34, CD45) cell surface
antigen markers. (B) Freshly isolated undifferentiated ASCs at passage 0 (P0) showed similar cell morphologies between SAMP6 and
SAMR1 strains (scale bar = 100 µm). Multipotent differentiation was induced under specific culture conditions for adipogenesis,
osteogenesis and chondrogenesis and visualized using oil red O (scale bar = 100 µm), alizarin red S (scale bar = 5 mm) and
toluidine blue (scale bar = 200 µm), respectively. In all cases, experiments were carried out in triplicate
capacity with ageing. Studies using ASCs isolated
from adult mice demonstrated that osteogenic potential
was maintained when cells were grown in osteogenic
medium supplemented with retinoic acid and BMP-2
(Shi et al., 2005). Similarly, studies investigating the
osteogenic potential of human ASCs have found no
direct correlation between differentiation capacity and
donor age (Weinzierl et al., 2006; Zhu et al., 2009; Khan
et al., 2009) We therefore sought to identify whether
osteogenesis in ASCs isolated from SAMP6 mice was also
maintained, thus offering a potentially abundant source
of bone regenerative autologous stem cells in osteoporotic
individuals.
Quantitative PCR analysis was initially performed in
order to examine the relative expression levels of various
early- and mid-phase markers of osteogenic differentia-
tion, including genes encoding for liver/bone/kidney-type
alkaline phosphatase (Alpl) (Figure 5A) and osteopon-
tin (Spp1) (Figure 5B). Increases in Alpl expression were
observed in both strains during the early stages of osteoge-
nesis and, at day 3, were significantly elevated in SAMP6
as compared to SAMR1 (p < 0.001). Expression levels of
Alpl in SAMP6 gradually decreased and had returned to
baseline by day 14. In contrast, Alpl expression remained
upregulated in SAMR1 and was significantly increased
as compared to SAMP6 at day 14 (p < 0.001). A grad-
ual increase in Spp1 expression was also observed over
the course of the experiment in both strains. Expres-
sion levels were significantly greatest in SAMR1 during
the first half of induction, reaching a maximum at day
7 (p < 0.01). However, by day 14, Spp1 mRNA expres-
sion in SAMR1 was significantly reduced as compared to
SAMP6 (p < 0.05).
Alkaline phosphatase (ALP) activity was also shown to
increase during the early phase of osteogenic induction
reaching a maximum by day 7 in both strains (Figure 5C).
As with Alpl mRNA expression, ALP protein activity was
significantly enhanced in SAMP6 during the early phase of
osteogenesis at day 3 as compared to SAMR1 (p < 0.05).
ASCs incubated in osteogenic medium for up to 14 days
also showed extensive mineralization, as visualized by
alizarin red S staining (Figure 5D). The development of
a mineralized matrix appeared to parallel the pattern
of osteopontin expression in these cultures, whereby a
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Figure 3. Telomere length is maintained in ASCs isolated from
SAMP6 mice. Frequency distributions of telomere fluorescence
intensity in interphase ASCs from SAMP6 (n = 4 animals)
(A) and SAMR1 (n = 4 animals) (B) mice, as determined
by Q-FISH analyses. Average telomere fluorescence intensity
(indicated by dashed line) was calculated by measuring a total of
516 and 448 nuclei from SAMP6 and SAMR1 mice, respectively.
∗p < 0.001
marked reduction in alizarin red S-positive staining was
observed in ASCs from SAMP6 as compared to SAMR1
mice up until the late phase of differentiation at day 14. At
this time point, quantitative measurement of the alizarin
red S bound to cellular matrix revealed comparable
levels between both SAM strains (Figure 5E). Therefore,
although some variations are observed between SAMP6
and SAMR1 during both the early and mid-phases of
osteogenic induction, it would appear that osteogenesis
as a whole is maintained in ASCs isolated from aged
osteoporotic SAMP6 mice.
3.5. Adipogenic potential of ASCs from aged
osteoporotic SAMP6 mice
We have previously shown that BMSCs isolated from
the SAMP6 strain differentiate towards adipocytes to a
much greater degree than those isolated from SAMR1
mice (Egermann et al., 2010), and as such may represent
a significant contributory factor to the osteoporotic
phenotype observed in SAMP6 mice. Therefore, we
investigated whether this alteration in adipogenesis
was also apparent in ASCs isolated from SAMP6
mice. The expression of adipogenic markers peroxisome
proliferator-activated receptor γ2 (Pparγ2) (Figure 6A)
and fatty acid binding protein 4 (Fabp4) (Figure 6B)
were highly upregulated in ASCs following adipogenesis
induction. Expression levels of both markers were
generally found to be comparable between the two strains,
with a small significant increase (p < 0.05) in Fabp4
mRNA being observed in ASCs from SAMP6 mice at
day 5 only (Figure 6B). Further analysis using oil red O
staining revealed no significant differences in the number
of adipocytes in SAMP6 and SAMR1 ASC cultures at day
10 (Figure 6C, D). Therefore, as with ASC osteogenesis,
although some variations were observed between ASCs
from SAMP6 and SAMR1 mice during adipogenesis,
their overall potential to form mature adipocytes was
comparable.
4. Discussion
Bone marrow stromal cells (BMSCs) are regarded as
being key components of the bone multicellular unit,
due to their potential for osteogenic differentiation, and
thus play a central role in the overall maintenance of
bone quality. However, their general fitness appears
to decline with donor age and passage number, as
evidenced by increases in cellular ageing markers and an
inability to maintain osteogenic potential under normal
conditions and following exposure to stress (Roura et al.,
1999; D’Ippolito et al., 2006; Stolzing et al., 2008).
Such observations have therefore led to speculation
that deficiencies in resident BMSC differentiation may
play a significant role in the development of age-related
osteoporotic phenotypes.
The concept of defective bone marrow cells as an
underlying cause of aged osteoporosis was originally
introduced by Meunier et al. (1971) and has since been
corroborated by a series of studies examining bone
quality, using various experimental models, where BMSC
performance is impaired. Bonyadi et al. (2003) have
reported that BMSCs isolated from Sca-1−/− mice had a
reduced tendency towards osteogenic differentiation and
that these mice displayed many of the features associated
with senile osteoporosis. Similarly, a low turnover
osteoporosis is evident in the klotho mouse strain, where
bone marrow osteogenesis is also significantly reduced
(Kuro-o et al., 1997). Perhaps more striking are the
results from investigations utilizing the senile osteoporotic
SAMP6 model, where the osteogenic differentiation
potential of resident BMSCs has consistently been shown
to be defective in comparison to BMSCs isolated from
the age-matched SAMR1 control strain (Jilka et al.,
1996; Silva et al., 2005; Egermann et al., 2010). These
observations therefore highlight the fact that age-related
inadequacies in cellular differentiation must be taken
into account when considering the potential impact of
therapeutic strategies aimed at restoring bone quality in
osteoporotic patients.
Adipose-derived stromal cells (ASCs) represent a
readily available population of cells, with the ability
to differentiate into osteoblasts both in vitro and in vivo
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Figure 4. Senescence state of ASCs from SAMP6 and SAMR1 mice. (A) Telomerase activity was measured in ASCs (1× 104) from
SAMP6 (n = 3–4 animals) and SAMR1 (n = 3–4 animals) at passage 1 (P1) and passage 4 (P4), using the TeloTAGGG telomerase
PCR ELISA. All measurements are expressed as arbitrary units and were normalized to a positive standard following the subtraction
of basal values. (B) The expression level of the senescence marker p21 was determined in ASCs (n = 3 animals) by qRT–PCR. The
expression value of p21 was normalized to the amount of 18S ribosomal RNA in order to calculate the relative amount of mRNA.
(C) ASC proliferation was compared between SAMP6 (n = 3–5 animals) and SAMR1 (n = 3–5 animals) over 14 days, using the
WST-1 proliferation assay and values expressed as optical densities (OD). (D) SA–β-gal staining of ASCs from SAMP6 (n = 3) and
SAMR1 (n = 3) mice (scale bar = 50 µm). In all cases, data are expressed as mean ± SEM
Figure 5. ASCs from SAMP6 maintain their osteogenic potential in vitro. The mRNA expression levels of Alpl (A) and Spp1 (B) were
determined in ASCs from both SAMP6 (n = 4 animals) and SAMR1 (n = 3 animals) by qRT–PCR, following osteogenic induction.
The expression value of each gene was normalized to the amount of 18S ribosomal RNA in order to calculate relative amounts of
mRNA. (C) ALP activity was quantified in protein lysates from ASCs over the course of osteogenic differentiation and normalized
to total protein content (n = 3–4). (D) Alizarin red S staining was used to visualize mineralization over the course of osteogenic
differentiation. Representative images are shown from two separate experiments. Scale bar = 5 mm. (E) Quantitative analysis of
alizarin red S staining in ASC cultures at day 14 after osteogenic induction (n = 4–5 animals). All tests were carried out in triplicate
and data expressed as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
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Figure 6. ASCs from SAMP6 and SAMR1 mice demonstrate comparable adipogenic potential in vitro. The mRNA expression levels
of Pparγ2 (A) and Fabp4 (B) were determined in ASCs from both SAMP6 (n = 4 animals) and SAMR1 (n = 4 animals) mice by
qRT–PCR, following adipogenic induction. The expression value of each gene was normalized to the amount of 18S ribosomal RNA
in order to calculate relative amounts of mRNA. (C) Representative fluorescent images of ASCs stained with oil red O (red) and
Hoechst 33342 nuclear stain (blue). (D) The percentage of cells demonstrating triglyceride accumulation was quantified in ASCs at
day 10 (n = 3). Scale bar = 75 µm. All tests were carried out in triplicate and data expressed as mean ± SEM. ∗p < 0.05
(Justesen et al., 2004; Hicok et al., 2004), and fulfil all
criteria deemed necessary for regenerative applications
involving stem cells (Gimble, 2003). As such, there is
now a growing clinical interest in the use of ASCs as
a novel therapeutic approach in bone tissue engineering
(Helder et al., 2007). Indeed, the in vivo application of
ASCs to treat a variety of bone defects has already shown
promising results (Dudas et al., 2006; Li et al., 2007;
Yoon et al., 2007; Mesimaki et al., 2009). However, the
use of ASCs as a potential stem cell-based therapeutic
strategy for the treatment of age-related osteoporotic bone
loss has not yet been addressed. In the present study,
we isolated and characterized ASCs from SAMP6 and
SAMR1mice and assessed their osteogenic and adipogenic
differentiation capabilities. Initial studies confirmed that
the SAMP6 mice used in the current study displayed
both osteoporosis- and accelerated ageing-related traits
as compared to the age-matched control SAMR1 strain.
ASCs isolated from both SAMP6 and SAMR1 strains
were easily accessed from subcutaneous inguinal fat
pads and could be expanded in culture over several
passages. They consistently expressed the characteristic
surface markers associated with mesenchymal stem cells
and readily differentiated into adipocytes, osteoblasts
and chondrocytes, thus confirming their multipotency.
Due to the premature ageing-like features associated
with the SAMP6 model, we also analysed ASCs for
various biological markers of advanced ageing. ASCs
isolated from both SAMP6 and SAMR1 strains expressed
similar levels of p21 mRNA and displayed an almost
complete absence of staining for SA–β-gal activity,
both of which are intrinsically linked to cellular
senescence. Interestingly, ASCs from SAMP6mice actually
demonstrated a significant increase in telomeric DNA
as compared to SAMR1 mice. It is unclear as to why
ASCs isolated from what are considered to be biologically
younger SAMR1 mice should display signs of telomere
shortening in culture. It is generally accepted that
telomere length is maintained in part through the actions
of the telomerase reverse transcriptase (Tert) (Chan and
Blackburn, 2002) and that the differentiation potential of
both BMSCs and ASCs is dependent on telomerase activity
(Simonsen et al., 2002; Lu et al., 2004; Kang et al., 2004).
In the present study, no significant differences were
observed in ASC telomerase activity between SAMP6
and SAMR1 mice when tested at various passages. As
such, alterations in telomere length cannot be attributed
to differences in telomerase activity in these cells. This
is supported by findings from studies using human and
non-human primate ASCs, where telomere length was
maintained for as long as 30 passages despite significant
reductions in telomerase activity (Izadpanah et al., 2006).
The multipotent and proliferative capacity of ASCs from
SAMR1 mice also appeared not to be adversely affected
by the reduced telomeric DNA levels. Therefore, it seems
more likely that mechanisms acting independently of
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telomerase are responsible for the differences observed in
telomere length between ASCs from SAMP6 and SAMR1
mice, the specific determination of which awaits further
investigation.
Maintenance of ASC functionality with increasing
chronological age has already been alluded to in sev-
eral studies comparing ASCs isolated from animal and
human subjects (Shi et al., 2005; Weinzierl et al., 2006;
Schipper et al., 2008; Zhu et al., 2009; Khan et al., 2009;
Yu et al., 2011). However, the effects of genuine biological
ageing on the functional properties of ASCs have not yet
been fully addressed. The fact that SAMP6 mice show sev-
eral defining features associated with advancing age, as
compared to their chronologically age-matched SAMR1
counterparts, implies that the age-related phenotypes
observed in this mouse strain are related to biological
ageing. We therefore compared ASCs from chronolog-
ically age-matched SAMP6 and SAMR1 mice in terms
of their potential to differentiate along the osteoblast
lineage and ability to generate mineralized matrix. We
demonstrated that, unlike BMSCs, ASCs isolated from
aged osteoporotic SAMP6 mice had the capacity to retain
their overall osteogenic differentiation potential when
compared to age-matched SAMR1 control mice. How-
ever, differences between strains were observed during
both the early and mid-phases of osteogenesis, as deter-
mined by quantitative analysis of molecular markers of
osteogenic differentiation as well as through measure-
ments of ALP activity and mineral deposition. Levels of
ALP expression and activity were actually found to be
greatest in ASCs from SAMP6 mice during the first week
of osteogenesis and reduced to a level equal to or below
that of SAMR1mice by day 14. Conversely, levels of osteo-
pontin expression were highest in ASCs from SAMR1mice
for the first 7 days but were superseded by SAMP6 cul-
tures at day 14. Similarly, SAMR1 cultures mineralized
at a faster rate as compared to ASCs from SAMP6 mice,
although by day 14, the level of alizarin red S staining
was comparable between strains. It is unclear why miner-
alization was delayed in SAMP6 cultures as compared to
SAMR1 mice. It is possible that the increased osteopon-
tin expression levels observed in SAMR1 cultures may be
partly responsible for the early appearance of mineralized
matrix. This is supported by the fact that only at the
later stage of differentiation, where osteopontin expres-
sion levels become significantly increased, do SAMP6
cultures demonstrate matrix deposition. The importance
of osteopontin as an instigator of matrix mineralization in
differentiating osteoblasts has previously been reported
in studies using both mouse and rat osteoblast precursor
cells (Beck et al., 1998; Kojima et al., 2004). Furthermore,
a mineralizing phenotype was evident in differentiating
MC3T3-E1 cell lines expressing high levels of osteopontin,
even in the absence of ALP activity (Beck et al., 1998).
Therefore, although equivalent levels of mineralization
are observed in SAM cultures during the final stages of
differentiation, a delay in mineral deposition is neverthe-
less apparent in SAMP6 cultures and would seem to be
independent of ALP activity.
In addition to their osteogenic potential, ASC adipo-
genesis must also be taken into account when consider-
ing their use in the regeneration of osteoporotic bone.
We have previously shown that BMSCs from SAMP6
mice have an increased tendency towards adipogenesis
rather than osteogenesis when compared to SAMR1 mice
(Egermann et al., 2010) and, as such, give rise to higher
levels of fat marrow. We therefore compared adipogenesis
in ASCs from both strains in order to ascertain whether
such abnormalities in adipogenic differentiation were also
evident in these cells. Despite there being some variations
between the two strains in terms of the expression levels
of the early adipogenic markers Pparγ2 and Fabp4, the
actual number of mature adipocytes present at completion
of the experiment was not significantly different.
In summary, our findings demonstrate that ASCs iso-
lated from a recognized murine model for aged osteo-
porosis maintain telomere length, show no signs of
premature cellular senescence, retain a high capacity
for osteogenic differentiation and show no alterations in
expected adipogenic differentiation potential. Such obser-
vations therefore support the notion of adipose tissue
being a valuable source of osteoprogenitor cells, and that
the ability of such cells to proliferate and differentiate
does not appear to be adversely affected by the biological
age or osteoporotic status of the donor from which they
were isolated. Further analysis of ASC function in chrono-
logically aged mice from different genetic backgrounds,
as well as from human subjects, is needed in order to
confirm these observations and thus validate the use of
autologous stem cell-based therapeutic strategies for the
treatment of bone loss in aged patients.
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UNIT 2B.5Preparation and Osteogenic
Differentiation of Scaffold-Free Mouse
Adipose-Derived Stromal Cell Microtissue
Spheroids (ASC-MT)
Ali Mirsaidi,1 Andre´ N. Tiaden,1 and Peter J. Richards1
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ABSTRACT
In this unit, previously described methods are expanded upon, where procedures relat-
ing to the preparation, culturing, and osteogenic differentiation of scaffold-free mouse
adipose-derived stromal cell microtissue spheroids (ASC-MT) are outlined. Not only is a
detailed methodology of how to engineer such spheroids are presented, but a full account
of how to induce and analyze osteogenesis in these ASC-MT constructs is given along
with relevant figures to help better illustrate the methods described. Curr. Protoc. Stem
Cell Biol. 27:2B.5.1-2B.5.12. C© 2013 by John Wiley & Sons, Inc.
Keywords: adipose-derived stromal cells ! osteogenesis ! 3D-culture
INTRODUCTION
The use of adipose-derived stromal cells (ASCs) in tissue engineering and regenerative
medicine is becoming increasingly popular due to the ease by which these cells can be
isolated from donor fat tissue and their capacity for multipotent differentiation (Tapp
et al., 2009). Microtissue spheroids (MTs) represent an alternative cell culture technique
with which to investigate tissue-specific processes in vitro, and are believed to represent a
more physiologically relevant environment for cells than the traditional two-dimensional
(2-D) culture system (Friedrich et al., 2009; Kelm and Fussenegger, 2010). Here, the
methodology of how to engineer and analyze scaffold-free mouse ASC-MTs undergoing
osteogenic differentiation is described. The first protocol section delivers an extended
guideline for the preparation and expansion of ASCs isolated from murine subcutaneous
inguinal fat pads followed by an extensive description of how to successfully establish,
culture, and harvest mouse ASC-MTs using the hanging drop technology. Furthermore,
the outlined protocols for generating 2-D ASC monolayers and ASC-MT hanging drop
cultures include detailed instructions on how to differentiate mouse ASCs towards the os-
teogenic lineage. Support protocols are also provided to describe analysis of mouse ASC
osteogenic differentiation in both experimental settings using Alizarin Red S staining to
visualize mineralized matrix formation.
NOTE: Aseptic technique is required for the handling of all solutions and equipment in
contact with living cells.
NOTE: All animal research procedures were approved by the Animal Experimentation
Committee of the Veterinary Office of the Canton of Zu¨rich, Switzerland, and followed
the guidelines of the Swiss Federal Veterinary Office for the use and care of laboratory
animals.
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BASIC
PROTOCOL 1
ASC ISOLATION AND EXPANSION
The procedures described here allow for the standardization of methodologies employed
for the isolation of multipotent mouse stromal cells derived from adipose tissue and will
ensure a high level of consistency between individual experiments and investigators.
Materials
Male mice (8- to 12-weeks old)
70% ethanol
Betadine (Mundipharma Medical Company)
Growth medium I (see recipe)
Dulbecco’s phosphate-buffered saline (D-PBS, Life Technologies, cat. no.
14190-094)
Digestion solution (see recipe)
0.25% trypsin-EDTA (Life Technologies, cat. no. 25200-056)
Sterile surgical instruments (forceps, tweezers, clamps, micro-scissors, scalpels)
15- and 50-ml tubes (Falcon)
Sterile petri dishes
Stereomicroscope
Shaker, 37°C
Centrifuge
40-µm cell strainer (BD Falcon, cat. no. 352340)
25- and 75-cm2 culture flasks (Nunclon, cat. nos. 734-2064 and 734-2066)
37oC, 5% CO2 humidified incubator
5- and 10-ml serological pipets, sterile
Prepare mice and dissect inguinal fat pad
1. Prepare 8- to 12-week-old male mice prior to dissection by shaving lower ventral
surface and cleaning skin area with 70% ethanol and Betadine.
In female rodents, the mammary glands, which also reside within the inguinal fat pad may
represent a source of contaminating cells and should be avoided. For this reason, male
rodents are the better choice for ASC isolation.
2. Lay mouse dorsal side down (face up), and make incision into skin with scissors
along ventral surface from femoral part of hind limb upwards.
It is important to perform this step carefully and to not puncture the peritoneal cavity.
3. Retract skin on one side and hold in place with needles to expose inguinal fat pad as
made evident by the presence of the inguinal lymph node (Fig. 2B.5.1).
4. Remove portion of inguinal pad from upper leg all the way through the abdominal
cavity (from lateral to medial) while avoiding removal of lymph node if present.
5. Place fat tissue into a 50-ml tube containing 25 ml growth medium while extracting
the contralateral fat pad.
Fat tissue floats.
Process fat tissues
6. Transfer fat tissues to a sterile petri dish, cut into pieces using micro-scissors, and
then transfer back into a 50-ml tube containing 25 ml growth medium.
Performing this step under a stereomicroscope to visualize and remove major blood
vessels and connective tissue, which may act as a source of contaminating cells, is
recommended.
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Figure 2B.5.1 Mouse inguinal fat pad including lymph node (dashed circle).
7. Wash the minced tissue quickly by transferring floating tissue with forceps into a
fresh 50-ml tube containing 25 ml D-PBS.
8. Transfer the washed floating minced tissue pieces into a 15-ml tube with sterile
tweezers and add 5 ml digestion solution to release the stem cells embedded within
the fat tissue matrix.
9. Incubate tissues 30 min on a 37°C shaker to allow full exposure of minced tissue to
the digestion solution (low speed rotary shaker at 80 rpm).
For an efficient digestion of the tissue, periodically remove tubes from rotary shaker and
mix vigorously.
10. Add 5 ml of D-PBS to bring the total volume up to 10 ml and centrifuge 5 min
400 × g, room temperature, to separate the population of mature adipocytes from
the pelleted stromal vascular fraction. Repeat this step two additional times for a
total of three times.
Mature adipocytes float due to intracellular accumulation of lipid vesicles.
Process adipose stromal fraction
11. Remove supernatant and resuspend pellets in 5 ml growth medium to inactivate
collagenase activities.
12. Pass the medium through a 40-µm cell strainer to remove undigested particles, then
wash the filter with an additional 5 ml growth medium, and centrifuge 5 min at
400 × g, room temperature.
13. Remove supernatant and resuspend the adipose stromal fraction in 5 ml of growth
medium.
14. Transfer cell suspension to 25-cm2 culture flask and incubate in a 37°C, 5% CO2
humidified incubator to allow the adipose stromal cells to adhere to plastic.
15. After 24 hr, change the growth medium to remove non-adherent cells from culture.
16. Grow ASCs to 60% confluency in a 25-cm2 culture flask, rinse with D-PBS, and
detach ASCs with trypsin-EDTA (0.25%) for 2 min in a 37°C, 5% CO2 incubator.
Incubate until cells are released from the surface (!2 min). Verify that cells are detached
under a light microscope.
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17. Inactivate the trypsin by adding growth medium (with 1:10 dilution factor), then
mix gently with a pipet and directly transfer to a 75-cm2 culture flask. When ASCs
are 60% confluent, split further at a ratio of 1:3.
Growth medium is used to quench the proteolytic activity of trypsin.
SUPPORT
PROTOCOL 1
INDUCTION OF OSTEOGENIC DIFFERENTIATION IN ASC
2-D CULTURES
The protocol described here will allow for standardization of methodologies employed
for the induction of osteogenic differentiation in ASCs and will ensure a high level of
consistency between individual experiments and investigators.
Materials
ASCs (see Basic Protocol 1)
Growth medium II (see recipe)
Osteogenic induction medium (see recipe)
Dulbecco’s phosphate-buffered saline (D-PBS, Life Technologies, cat. no.
14190-169)
10% (v/v) formaldehyde solution (Sigma, cat. no. F1635) in D-PBS
Alizarin Red S working solution (see recipe)
5- and 10-ml serological pipets, sterile
37°C, 5% CO2 humidified incubator
Rocking platform
Light microscope
1. For osteogenic differentiation, plate ASCs in growth medium II at 5000 cells/cm2 in
sterile tissue culture plates and incubate in a 37°C, 5% CO2 humidified incubator to
allow ASCs to adhere to tissue culture plastic.
2. After 24 hr, change the growth medium II to osteogenic induction medium and replace
half of the osteogenic medium every 3 days thereafter.
3. After 14 days, remove the osteogenic induction medium and wash ASCs three times
with D-PBS.
4. Fix ASCs with 10% (v/v) formaldehyde solution for 60 min at room temperature.
5. Remove fixative and wash ASCs three times with distilled water.
6. Add Alizarin Red S working solution (0.5 ml/cm2) to ASCs, and incubate 10 min at
room temperature with gentle rocking.
It is important to ensure that the Alizarin Red S working solution is at pH 4.2.
7. Remove the stain and wash thoroughly with distilled water. Repeat for a total of three
washes.
8. Visualize Alizarin Red S staining under a light microscope (Fig. 2B.5.2).
BASIC
PROTOCOL 2
GENERATION OF OSTEOGENIC ASC-MTs
ASC-MTs are produced using the hanging drop technique. The procedures described
here will allow for standardization of methodologies employed for culturing ASCs in
hanging drops and will ensure a high level of consistency between individual experiments
and investigators.
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Figure 2B.5.2 Osteogenic differentiation. ASCs were grown in control medium (A) or osteogenic
induction medium (B) and stained with Alizarin Red S after 14 days. Scale bar = 2.5 mm.
Materials
ASCs (see Support Protocol 1)
Dulbecco’s phosphate-buffered saline (D-PBS, Life Technologies, cat. no.
14190-169)
0.25% trypsin-EDTA (Life Technologies, cat. no. 25200-056)
Growth medium I or II (see recipe)
Osteogenic induction medium (see recipe)
Trypan blue solution (Sigma, cat. no. T8154)
Light microscope
5- and 10-ml serological pipets, sterile
15-ml tubes (Falcon)
Centrifuge
Hemacytometer
Terasaki plates (Nunc, cat. no. 734-2079)
Reagent reservoir (Thermo Scientific, cat. no. 8093-11)
Multichannel electronic pipettor (Thermo Scientific, cat. no. 2034)
1250-µl tips (Thermo Scientific, cat. no. 8041)
37°C, 5% CO2 humidified incubator
1. Plate ASCs at 5000 cells/cm2 and induce toward osteogenesis under sterile conditions
in a 37°C, 5% CO2 humidified incubator (see Support Protocol 1).
2. On day 3, rinse ASCs with D-PBS and detach with 0.25% trypsin-EDTA. Incubate
until cells are released from the surface (!2 min). Verify that cells are detached under
a light microscope.
3. Inactivate the trypsin by adding growth medium I using a 1:10 dilution ratio, mix
gently, and transfer into a clean 15-ml tube.
Growth medium is used to quench the proteolytic activity of trypsin.
4. Centrifuge ASCs 5 min at 300 × g, room temperature, to obtain a cell pellet.
5. Aspirate the supernatant and gently resuspend the ASCs in an appropriate volume of
osteogenic induction medium to allow for accurate cell counting.
6. Determine cell number from a 50-µl aliquot of the cell suspension using a hema-
cytometer and determine viability through dye exclusion with Trypan blue solution.
Adjust cell concentration to allow for 5000 cells per ASC-MT.
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7. Dilute ASCs in osteogenic induction medium to 2 × 105 cells/ml, and then transfer
a maximum of 25 ml cell suspension into a reagent reservoir for plating ASCs into
Terasaki plates using a multichannel pipettor.
In cases where higher volumes (e.g., several plates) are required, refill the reservoir with
the remaining cell suspension for the next pipetting run.
8. Adjust pipet tip distances in a way that each tip fits perfectly into every second well
of the Terasaki plate.
9. For pipetting, use the maximum possible pipetting speed. Aspirate cell suspension
into each pipet tip, release the first round of droplets into the reservoir to remove air
bubbles and then pipet 25 µl of suspension into each well.
The droplet size range is very limited and should lie between 23 to 27 µl. The force
generated by larger volumes makes the droplets heavier and therefore more likely to merge
together, while smaller volumes do not provide either enough space for cell assembly or
sufficient nutrients.
10. Begin pipetting while approaching the well from the side, then move to straight
above the well, deposit droplet, and pull out towards the top very gently, since fast
movement can also destroy the droplet. Refill tips prior to becoming empty.
Avoid using the last remnants of the medium in the tips, as the accuracy of the volume,
and thus cell number, in the last droplets cannot be guaranteed.
11. When a Terasaki plate is completely filled, replace the lid and, while holding one
edge to the surface of the working area, carefully turn the plate upside down with-
out destroying the droplets (this will enable gravity-enforced ASC-MT spheroid
formation).
Careful consideration of the working space is essential as it is important to avoid excessive
vibrations.
12. Transfer plates to a 37°C, 5% CO2 incubator for an incubation period up to 6 days.
Over the course of culture time, the ASC-MTs will become more spherical and more
defined, but also the droplets will shrink in size due to evaporation.
BASIC
PROTOCOL 3
HARVESTING AND PROCESSING OF ASC-MT FOR HISTOLOGICAL
ANALYSIS OF OSTEOGENIC DIFFERENTIATION
The procedures described here will allow for standardization of methodologies employed
for the harvesting and tissue processing of osteogenic ASC-MTs from hanging drop cul-
ture and will ensure a high level of consistency between individual experiments and
investigators. As detailed assessment of tissue morphology is required for characteri-
zation of ASC-MT differentiation, development of an efficient protocol for histological
analysis of ASC-MTs is essential.
Materials
Dulbecco’s phosphate-buffered saline (D-PBS, Life Technologies, cat. no.
14190-169)
Terasaki plates containing osteogenic ASC-MTs (see Basic Protocol 2)
10% (v/v) formaldehyde solution (Sigma, cat. no. F1635) in D-PBS
Low-melting-point agarose (Sigma, cat. no. A9414)
Hematoxylin blue
Paraffin wax (Paraplast, Sigma, cat. no. P3558)
Sterile petri dishes (12-cm diameter)
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Figure 2B.5.3 Harvesting ASC-MTs from Terasaki plates. (A) The ASC-MT-harvesting device
was prepared in-house using a polished stainless-steel plate, which was angled to allow for ease
of placement during harvesting. Once in contact with the harvesting device, the droplets readily
detach from the Terasaki plates thus allowing for optimized transfer to the appropriate collection
vessel. (B) Visualization of ASC-MTs under phase-contrast microscope. Scale bar = 100 µm.
Sterile, non-adhesive, stainless-steel ASC-MT harvesting device
Light microscope
Sterile 0.2- and 1.5-ml microcentrifuge tubes (Eppendorf)
Tweezers
Microcentrifuge
Disposable needles
Tissue processing/embedding cassettes with lid (Sigma, cat. no. Z672122)
Tissue processor (Leica Histoprocessor, cat. no. ASP200S)
Paraffin embedding station (Leica, cat. no. EG1150H)
Embedding moulds (VWR Scientific)
1. Add sterile D-PBS to a sterile petri dish until it is half full.
2. Carefully remove the Terasaki plate lid while keeping plate in the same orientation
as incubated (upside down).
3. Approach the hanging drops from below with the sterile harvesting device, and allow
the droplets to come into contact with the harvesting device (Fig. 2B.5.3A).
4. Immerse the ASC-MT-laden surface of the harvesting device into the D-PBS-filled
petri dish. Repeat this step two to three times until every ASC-MT is extracted out of
the Terasaki plate. Repeat for all Terasaki plates.
5. Gently swirl petri dishes for up to 10 sec until the ASC-MTs start accumulating in
the center of the plate (see Fig. 2B.5.3B).
For an efficient harvest of all ASC-MTs from the petri dish, perform the swirling motion
under a light microscope to gain better visibility of the floating ASC-MTs.
6. Carefully pipet the ASC-MTs located in the center of the petri dish into a 1.5-ml
microcentrifuge tube. Allow the ASC-MTs to sediment for up to 5 sec inside the
microcentrifuge tube for further processing.
7. Remove any excess D-PBS and fix ASC-MTs with 0.5 ml 10% formaldehyde solution
in D-PBS for 60 min at room temperature.
8. Prepare 1% agarose solution in double deionized water, boil, and allow it to cool
down while monitoring the temperature.
It is important to cool down the agarose solution to a temperature between 40° and 45°C
to protect ASC-MTs.
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Table 2B.5.1 Processing Program using the Leica Histoprocessor
Reagent Duration (min)a Temperature (°C)
Ethanol (70%) 00:10 37
Ethanol (90%) 00:10 37
Ethanol (absolute) 00:10 37
Ethanol (absolute) 00:10 37
Ethanol (absolute) 00:10 37
Ethanol (absolute) 00:20 37
Xylene 00:10 37
Xylene 00:10 37
Xylene 00:15 37
Histowax 00:10 62
Histowax 00:10 62
Histowax 00:20 62
aTotal duration = 3:21 hr.
9. Remove fixative and wash ASC-MTs three times with 1 ml D-PBS. Resuspend ASC-
MTs with 100 µl of D-PBS and transfer them into a 0.2-ml microcentrifuge tube and
pulse spin for 5 sec in a microcentrifuge.
10. Remove the supernatant, and resuspend ASC-MTs quickly in 50 µl of 1% agarose
solution using a 200-µl tip enlarged by removing the tip with scissors.
11. Pulse spin the ASC-MTs for 5 sec in a microcentrifuge, and place tube on ice for 20
min to allow for the agarose to solidify.
12. Remove the agarose plug from the 0.2-ml microcentrifuge tube with disposable
needles. Dip the tip of the agarose plug into a dye solution (e.g., hematoxylin blue)
to facilitate localization of the ASC-MTs during tissue sectioning.
13. Transfer the agarose plugs into a conventional paraffin-embedding cassette, and
place them into automated tissue processor (Leica Histoprocessor) for processing
using the program detailed in Table 2B.5.1.
14. Embed tissue in molten paraffin wax and store at room temperature.
SUPPORT
PROTOCOL 2
ANALYSIS OF OSTEOGENESIS IN ASC-MT PARAFFIN WAX SECTIONS
Materials
Alizarin Red S working solution (see recipe)
DPX mountant (Sigma, cat. no. 44581)
Microtome (Leica, cat. no. RM2235)
Superfrost Plus slide (Thermo Scientific, cat. no. J1800AMNZ)
37°C incubator
60°C heating block
Light microscope
Additional reagents and equipment for hanging drop generation of ASC-MTs (see
Basic Protocol 2) and ASC-MTs in paraffin wax (see Basic Protocol 3)
1. Generate ASC-MTs in osteogenic medium for up to 6 days in hanging drop format
using four Terasaki plates (see Basic Protocol 2).
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Figure 2B.5.4 Alizarin Red S staining of paraffin wax sections of ASC-MTs. Scale bar = 50 µm.
2. After 4 to 6 days, harvest ASC-MTs and process for tissue sectioning (see Basic
Protocol 3).
3. Trim paraffin blocks as necessary and cut 3- to 5-µm sections using a microtome and
transfer onto a Superfrost Plus slide. Allow slides to dry overnight at 37°C and store
them at room temperature until use.
4. Before staining slides for Alizarin Red S, place 1 hr at 60°C.
5. Remove paraffin wax from tissue sections on slides by incubating in 300 ml of xylene
for 5 min. Repeat step for a total of two times.
6. Rehydrate in two steps by dipping slides for 5 min in 100% ethanol, and then for 5
min in 90% ethanol.
Water may remove calcium prior to Alizarin Red S staining.
7. Allow sections to dry for 20 min at room temperature.
8. Add slides to 2% Alizarin Red S working solution for 5 min.
9. Rinse sections quickly in distilled water.
10. Dry sections for 20 min at room temperature and mount them with DPX mountant.
11. Visualize Alizarin Red S under a light microscope (Fig. 2B.5.4).
Red staining is a positive indicator of mineral deposition within the tissue sections.
REAGENTS AND SOLUTIONS
For culture recipes and steps, use sterile tissue culture–grade water. For other purposes,
use deionized, distilled water or equivalent in recipes and protocol steps. For suppliers,
see SUPPLIERS APPENDIX.
Alizarin Red S working solution
Prepare 2% (w/v) Alizarin Red S (Sigma, cat. no. A5533) in double deionized water;
adjust pH to 4.2 with 10% (v/v) ammonium hydroxide (Sigma, cat. no. 221228).
Store up to 1 month at room temperature in the dark.
Digestion solution
Hank’s balanced salt solution (HBSS, Life Technologies, cat. no. 14025-050)
continued
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0.1% (w/v) collagenase A (Roche, cat. no. 10103586001)
0.2% (w/v) bovine serum albumin (Roche, cat. no. 10735086001)
Fixative solution
Prepare 10% (v/v) formaldehyde solution (Sigma, cat. no. F1635) in D-PBS
Store up to 6 months at room temperature
Growth medium I
Dulbecco’s modified Eagles medium (DMEM, Life Technologies, cat. no.
21885-025)
10% (v/v) fetal bovine serum (Biowest, cat. no. S05081S1830)
1% (v/v) penicillin/streptomycin (Sigma, cat. no. P4333151140)
Store up to 3 months at 4°C
Growth medium II
Minimum essential medium alpha (α-MEM, Life Technologies, cat. no. 22561-021)
10% (v/v) fetal bovine serum (Biowest, cat. no. S05081S1830)
1% (v/v) penicillin/streptomycin (Sigma, cat. no. P4333151140)
Store up to 3 months at 4°C
Osteogenic induction medium
Growth medium II (see recipe) supplemented with:
1 M β-glycerol phosphate (Sigma, cat. no. G9422) in DMEM (Life Technologies;
cat. no. 21885-025)
50 mM L-ascorbic acid 2-phosphate (Sigma, cat. no. A8960) in double deionized
water
10 mM retinoic acid (Sigma, cat. no. R2625) in DMSO (Sigma, cat. no. D2650)
Filter sterilize using a 0.2-µm filter
Store up to 12 months at −80°C
COMMENTARY
Background Information
Multipotent mesenchymal stem cells, in-
cluding adipose-derived stromal cells (ASCs),
represent a promising source of bone-forming
cells for the treatment of various mus-
culoskeletal disorders, including age-related
bone loss (Tapp et al., 2009; Mirsaidi et al.,
2012). Cell culture-based studies investigating
the osteogenic differentiation of mesenchy-
mal stem cells are routinely performed in 2-D
cell culture systems. However, microtissue
spheroids (MTs) may represent an alternative
means by which to investigate cellular behav-
ior in a more tissue-specific context (Kelm and
Fussenegger, 2010; Tiaden et al., 2012). They
can be produced from a variety of different
cell types, including cell lines (Kelm et al.,
2003; Friedrich et al., 2009) as well as pri-
mary stem cells (Keller, 1995; Tiaden et al.,
2012). In contrast to cells grown in a standard
2-D monolayer system, cells cultured in MTs
are maintained in a three-dimensional (3-D)
configuration. This 3-D arrangement is con-
sidered to be potentially more representative
of the native cellular environment, where the
surrounding cellular milieu and extracellular
matrix (ECM) can significantly influence cell
shape (Goldmann, 2002), polarity (Boudreau,
2003), tension (Tarone et al., 2000), and differ-
entiation (Bokel and Brown, 2002). Moreover,
ECM is essential to organize the communi-
cation between single cells and drives devel-
opmental as well as differentiation processes
(Schenk and Quaranta, 2003). Furthermore,
the 3-D configuration is believed to support os-
teoblast formation and matrix mineralization
through the process of cellular condensation
(Dunlop and Hall, 1995). As such, MTs offer
an alternative means by which to investigate
osteogenic differentiation and bone formation
in vitro, and in the case of ASC-MTs, could
represent a novel therapeutic strategy for the
treatment of bone disorders such as age-related
osteoporosis.
Critical Parameters and
Troubleshooting
Using ASCs to generate osteogenic micro-
tissues is primarily dependent on the purity
of the cell population isolated from mouse
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Table 2B.5.2 Troubleshooting Guide for Common Problems Encountered During Preparation,
Culturing, and Osteogenic Differentiation of ASC-MTs
Problem Possible cause Solution
Heterogeneous cell culture
after ASC isolation from
inguinal fat pad
Female mice used Use male mice
Contamination of culture
with immune cells, epithelial
cells, and fibroblasts
Remove lymph nodes, blood
vessels, and connective
tissues prior to tissue
digestion
Low cell recovery after tissue
digestion
Amount of initial fat tissue
used too low
Increase amount of fat tissue
extracted from mouse
Insufficient collagenase
digestion
Prepare fresh digestion
solution just prior to usage
and include manual shaking
step to increase cell
dissociation from fat tissue
No Alizarin Red S staining in
ASC 2-D culture or
osteogenic ASC-MTs
Induction medium too old Prepare fresh osteogenic
induction medium before
each induction experiment
Using Alizarin Red S
working solution with wrong
pH
Ensure Alizarin Red S
working solution is pH 4.2
Droplets merge together
during generation of
osteogenic ASC-MTs
Force generated by larger
volumes makes the droplets
heavier and mixes them
together
Only use volumes from 23 µl
to 27 µl per well of Terasaki
plate
Low numbers of ASC-MTs
harvested for histology
Not all of the ASC-MTs have
accumulated in center of Petri
dish
Perform swirling motion of
Petri dish and view under a
light microscope to gain
better visibility of the floating
ASC-MTs
Inconsistent morphology of
ASC-MT upon histological
analysis
Temperature of agarose mold
too high
Cool agarose solution to 45°C
before adding to ASC-MTs
inguinal fat pads. Procedures relating to the
preparation and culturing of ASCs to yield
a homogeneous cell culture with the desired
number of cells while retaining a low pas-
sage number are described. After extracting
fat pads, it is recommended to remove ma-
jor blood vessels and connective tissue, which
may act as a source of contaminating cell
types. Therefore, the visualization of tissue us-
ing a stereomicroscope and removal of non-fat
tissue is recommended. As ASC isolation from
one mouse is limited to two fat pads only, it is
important to manually shake harvested tissues
during digestion to increase the efficiency of
ASC isolation and thus maximize cell num-
bers. In addition, it is advisable to allow ASCs
to reach at least 60% confluency prior to fur-
ther passaging, thus ensuring a better prolif-
eration rate in further passages. For induction
of ASC osteogenesis, it is advisable to prepare
fresh medium, which can be stored at 4°C for
the duration of the study (usually 2 weeks).
To perform Alizarin Red S staining, adjust-
ing the Alizarin Red S working solution pH
to 4.2 is critical to ensure specific staining of
the mineralized matrix. The other important
parameter in this assay is the use of high-
purity distilled water in each of the washing
steps, as alkaline buffers (such as PBS) can
remove the Alizarin Red S stain. In the case of
ASC-MT generation, it is essential to pipet the
correct volume and to avoid any unnecessary
vibrations or movement, which may disturb
the hanging drop. Once osteogenic ASC-MTs Somatic StemCells
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are harvested, preparation of an agarose mold
at 45°C is an important requirement for the
preservation of ASC-MTs for further process-
ing. To analyze osteogenic differentiation in
ASC-MT paraffin wax sections, it is necessary
to rehydrate the sections in up to 90% ethanol
only, as water may remove calcium prior to
Alizarin Red S staining. Common problems
and solutions encountered during the prepara-
tion, culturing, and osteogenic differentiation
of ASC-MTs are described in Table 2B.5.2.
Anticipated Results
The protocol for ASC isolation from in-
guinal fat pads from both the left and right
side of one male mouse is expected to gener-
ate!0.9± 0.2× 106 cells per 75-cm2 culture
flask at passage one with!60% to 80% conflu-
ency after 5 days expansion. Performing 3 days
of osteogenic induction of ASCs in monolayer
culture, followed by generation of osteogenic
ASC-MTs using the hanging drop technique
with an initial seeding density of 5000 cells,
gives spherical tissues in the range of 100 µm
and 250 µm in diameter. These ASC-MTs can
be harvested and further processed for various
histochemical analyses such as Alizarin Red
S staining in which osteogenic differentiation
can be determined by visualizing calcium de-
position after 4 to 6 days.
Time Considerations
The amount of time needed to complete the
isolation of ASCs from inguinal fat pads varies
greatly with user experience and the number
of mice needed per experiment. Preparation
of all necessary surgical instruments and solu-
tions should be done 1 hr prior to dissection of
mice. The minimum time required to isolate
ASCs from 4 to 6 mice is !4 hr. Once the
ASCs have been seeded into monolayer cul-
ture and induced towards osteogenesis, it usu-
ally takes at least 10 to 14 days to observe ma-
trix mineralization as determined by Alizarin
Red S staining. Once osteogenic ASC-MTs
have been harvested, an additional 2 hr should
be necessary for embedding in agarose solu-
tion and a further 4 hr for tissue processing and
embedding in paraffin wax.
Literature Cited
Bokel, C. and Brown, N.H. 2002. Integrins in
development: Moving on, responding to, and
sticking to the extracellular matrix. Dev. Cell
3:311-321.
Boudreau, N.J. 2003. Organized living: From cell
surfaces to basement membranes. Sci STKE
2003:pe34.
Dunlop, L.L. and Hall, B.K. 1995. Relationships be-
tween cellular condensation, preosteoblast for-
mation and epithelial-mesenchymal interactions
in initiation of osteogenesis. Int. J. Dev. Biol.
39:357-371.
Friedrich, J., Seidel, C., Ebner, R., and Kunz-
Schughart, L.A. 2009. Spheroid-based drug
screen: Considerations and practical approach.
Nat. Protoc. 4:309-324.
Goldmann, W.H. 2002. Mechanical aspects of cell
shape regulation and signaling. Cell Biol. Int.
26:313-317.
Keller, G.M. 1995. In vitro differentiation of em-
bryonic stem cells. Curr. Opin. Cell Biol. 7:862-
869.
Kelm, J.M. and Fussenegger, M. 2010. Scaffold-
free cell delivery for use in regenerative
medicine. Adv. Drug Deliv. Rev. 62:753-764.
Kelm, J.M., Timmins, N.E., Brown, C.J., Fusseneg-
ger, M., and Nielsen, L.K. 2003. Method
for generation of homogeneous multicellular
tumor spheroids applicable to a wide vari-
ety of cell types. Biotechnol. Bioeng. 83:173-
180.
Mirsaidi, A., Kleinhans, K.N., Rimann, M., Tiaden,
A.N., Stauber, M., Rudolph, K.L., and Richards,
P.J. 2012. Telomere length, telomerase activity
and osteogenic differentiation are maintained in
adipose-derived stromal cells from senile os-
teoporotic SAMP6 mice. J. Tissue Eng. Regen.
Med. 6:378-390.
Schenk, S. and Quaranta, V. 2003. Tales from the
crypt[ic] sites of the extracellular matrix. Trends
Cell Biol. 13:366-375.
Tapp, H., Hanley, E.N. Jr., Patt, J.C., and Gruber,
H.E. 2009. Adipose-derived stem cells: Charac-
terization and current application in orthopaedic
tissue repair. Exp. Biol. Med. 234:1-9.
Tarone, G., Hirsch, E., Brancaccio, M., De Acetis,
M., Barberis, L., Balzac, F., Retta, S.F., Botta,
C., Altruda, F., and Silengo, L. 2000. Integrin
function and regulation in development. Int. J.
Dev. Biol. 44:725-731.
Tiaden, A.N., Breiden, M., Mirsaidi, A., Weber,
F.A., Bahrenberg, G., Glanz, S., Cinelli, P.,
Ehrmann, M., and Richards, P.J. 2012. Hu-
man serine protease HTRA1 positively regulates
osteogenesis of human bone marrow-derived
mesenchymal stem cells and mineralization of
differentiating bone-forming cells through the
modulation of extracellular matrix protein. Stem
Cells 30:2271-2282.
Scaffold-Free
Mouse
Adipose-Derived
Stromal Cell
(mASC) Spheroids
2B.5.12
Supplement 27 Current Protocols in Stem Cell Biology
Results 
 57 
 
 
 
 
 
Therapeutic potential of adipose-derived stromal cells in age-related
osteoporosis
Ali Mirsaidi a, b, 1, Konstantin Genelin c, 1, Jolanda R. Vetsch d, Scott Stanger d, Felix Theiss e,
Richard A. Lindtner c, Brigitte von Rechenberg e, Michael Blauth c, Ralph Müller d,
Gisela A. Kuhn d, Sandra Hofmann Boss d, f, g, Hannes L. Ebner c, Peter J. Richards a, b, *
a Bone and Stem Cell Research Group, CABMM, University of Zurich, 8057 Zurich, Switzerland
b Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland
c Department of Trauma Surgery and Sports Medicine, Innsbruck Medical University, A-6020 Innsbruck, Austria
d Institute for Biomechanics, ETH Zurich, 8093 Zurich, Switzerland
e Musculoskeletal Research Unit, CABMM, University of Zurich, 8057 Zurich, Switzerland
f Department of Biomedical Engineering, Eindhoven University of Technology, P.O. Box 513, 5600 MB Eindhoven, The Netherlands
g Institute for Complex Molecular Systems, Eindhoven University of Technology, P.O. Box 513, Eindhoven 5600 MB, The Netherlands
a r t i c l e i n f o
Article history:
Received 24 April 2014
Accepted 5 May 2014
Available online 2 June 2014
Keywords:
Osteoporosis
Osteogenesis
Stem cell
Bone regeneration
Transplantation
a b s t r a c t
Adipose-derived stromal cells (ASCs) are increasingly being used for orthopedic-based tissue engineering
approaches due to their ability to readily undergo osteogenic differentiation. In the present study, we
used in vitro and in vivo approaches to evaluate the use of ASCs as a treatment strategy for age-related
osteoporosis. Molecular, histological and micro-computed tomography (micro-CT) based approaches
conﬁrmed that ASCs isolated from 18-week-old osteoporotic senescence-accelerated mice (SAMP6) were
capable of undergoing osteogenesis when cultured in either silk ﬁbroin (SF) scaffolds or scaffold-free
microtissues (ASC-MT). A single intratibial injection of CM-Dil-labeled isogeneic ASCs or ASC-MT into
SAMP6 recipients signiﬁcantly improved trabecular bone quality after 6 weeks in comparison to un-
treated contralateral bones, as determined by micro-CT. Injected ASCs could be observed in parafﬁn wax
bone sections at 24 h and 6 weeks post treatment and induced a signiﬁcant increase in several molecular
markers of bone turnover. Furthermore, a signiﬁcant improvement in the osteogenic potential of oste-
oporotic patient-derived human bone marrow stromal cells (BMSCs) was observed when differentiated
in conditioned culture media harvested from osteoporotic patient-derived human ASCs. These ﬁndings
therefore support the use of ASCs as an autologous cell-based approach for the treatment of osteoporosis.
© 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Osteoporosis is characterized by signiﬁcant deﬁcits in both bone
mass and bone quality, resulting in low bone strength and a
reduced resistance to fractures [1]. There is nowamounting body of
scientiﬁc evidence to suggest that impaired osteogenic differenti-
ation of resident bone marrow stromal cells (BMSCs) may play a
decisive role in mediating osteoporotic bone loss. Deﬁciencies in
osteogenesis have previously been reported in BMSCs isolated from
osteoporotic patients, where signiﬁcant decreases in osteoblast-
mediated mineral deposition were observed [2e4]. Inadequacies
in the osteogenic capacity of BMSCs have also been linked to
osteoporotic bone phenotypes associated with various animal
models of aging [5e9]. Furthermore, the diminished osteogenic
differentiation potential of BMSCs from osteoporotic patients ap-
pears to be in direct contrast to their ability to form adipocytes,
thereby introducing the concept of fat marrow accretion as a po-
tential confounding factor in the regulation of bone quality
[7,9e11]. Nevertheless, despite these observations, the most widely
prescribed treatments for osteoporosis are focused on inhibiting
bone resorption [12]. The fact that BMSCs represent a critical
component of the homeostatic machinery controlling bone turn-
over [13], alternative therapeutic strategies designed at targeting
the BMSC niche in osteoporotic bone marrow may therefore war-
rant further consideration.
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The use of adipose-derived stromal cells (ASCs) for the purpose
of enhancing orthopedic tissue repair and regeneration is now
widespread in areas of both experimental and clinical research
[14,15]. ASCs have several advantages over other multipotent stem
cell sources in that they are easily accessed non-invasively and have
been shown to maintain both their proliferative [16e18] and
osteogenic [17e19] potential with age. Moreover, we and others
have recently reported that unlike their BMSC counterparts, the
osteogenic differentiation capabilities of ASCs isolated from oste-
oporotic humans and mice remain intact [4,20], thereby high-
lighting their potential as an autologous cell-based therapy for
treating age-related bone loss. Indeed, encouraging results have
already been obtained from several studies investigating the ther-
apeutic effects of systemically and locally administered ASCs on
experimental osteoporosis [21e23]. However, to date, all studies
investigating the therapeutic potential of ASCs in osteoporosis have
focused on the prevention of bone loss in ovariectomized (OVX)
mouse models, and have utilized cells obtained from non-
osteoporotic animals.
In the present study, we hypothesize that ASCs isolated from
osteoporotic SAMP6 mice have the capacity to generate mineral-
ized matrix when induced to undergo osteogenesis in three-
dimensional (3-D) culture systems, and can signiﬁcantly enhance
various parameters of bone quality in vivo following a single low
dose intratibial injection. We use molecular, biochemical, histo-
logical and micro-CT analyses to evaluate the osteogenic potential
of osteoporotic SAMP6-derived ASCs in 3-D scaffold-based and
scaffold-free systems, and to validate their use as a therapeutic
intervention for treating age-related bone loss in amousemodel for
senile osteoporosis. Furthermore, we assess the capacity of ASCs to
inﬂuence the osteogenic differentiation of BMSCs isolated from
aged osteoporotic patients.
2. Materials & methods
2.1. Animals
Experiments were performed using 18-week-old male and female senescence
accelerated mouse prone 6 (SAMP6) mice (Institute for Laboratory Animal Science,
University of Zurich, Switzerland). All animal research procedures were approved by
the Animal Experimentation Committee of the Veterinary Ofﬁce of the Canton of
Zurich, Switzerland and followed the guidelines of the Swiss Federal Veterinary
Ofﬁce for the use and care of laboratory animals.
2.2. Human patients
Human ASCs and BMSCs were harvested from a total of n ¼ 6 non-osteoporotic
and n¼ 9 osteoporotic female donors (>65 years of age) undergoing routine surgery.
Osteoporosis was conﬁrmed by dual energy X-ray absorptiometry (DXA; Hologic
QDR 4500) according to WHO guidelines. All procedures were carried out in
accordance with the ethics commission guidelines for InnsbruckMedical University.
2.3. Cell isolation and culture
ASCs isolated from inguinal fat pads of 18-week-old male SAMP6 mice were
puriﬁed and characterized according to previously published protocols established in
our laboratory [20,24]. Human BMSCs or ASCs were harvested from the femoral
medullary cavity or subcutaneous adipose tissue respectively, as previously described
[20,24,25]. In all cases, cells weremaintained in normal growthmedium consisting of
Dulbecco's modiﬁed eagle medium (DMEM-low glucose, with Glutamax; Life Tech-
nologies, Zug, Switzerland), supplemented with 10% fetal bovine serum (FBS; Life
Technologies) and penicillin (50 units/ml) and streptomycin (50 mg/ml) (Life Tech-
nologies). Cells were used between passage 2 and 4 unless otherwise stated.
2.4. Osteogenesis of SAMP6-derived ASCs in 3-D culture systems
The osteogenic induction of mouse ASCs was performed using protocols pre-
viously established in our laboratory [20,24]. ASC-seeded SF scaffolds were prepared
as previously described [26,27]. Brieﬂy, silk cocoons from Bombyx Mori L. were
cooked twice in sodium carbonate for 1 h to extract sericins. Dried silk was dissolved
in 9M lithium bromide and dialyzed against ultrapure water for 36 h. Frozen, dia-
lyzed silk solution was lyophilized for four days and dissolved in hexa-
ﬂuoroisopropanol (HFIP) at 17% (w/v). Silk solution (1 ml) was pipetted onto 2.5 g
sodium chloride granules of 300e400 mm diameter and left for 3 days until the HFIP
had completely evaporated. Sodium chloride was leached out for 24 h in water and
scaffolds cut into discs of 5 mm in diameter and 2 mm in height. For cell cultivation
on SF scaffolds, 3 " 106 ASCs per scaffold were seeded by pipetting a droplet of 50 ml
of cell suspension on top of each scaffold. Constructs were placed in an incubator at
37 #C, 5% CO2, 100% humidity for 90 min and a drop of culture mediumwas applied
every 20 min to prevent scaffolds from drying out. Five cell seeded constructs were
ﬁxed on the bottom of a bioreactor applicable for micro-CT monitoring. Each
bioreactor was ﬁlled with 5ml of osteogenic inductionmedium consisting of normal
growth medium supplemented with 50 mM L-ascorbic acid 2-phosphate sesqui-
magnesium salt hydrate (SigmaeAldrich, Buchs, Switzerland), 10 mM b-glycer-
ophosphate (SigmaeAldrich) and 5 mM retinoic acid (SigmaeAldrich). Medium was
exchanged three times per week for up to 6 weeks. ASC-MT cultures were prepared
as previously described [24,28]. Brieﬂy, 2.5 " 103 ASCs were cultured in 25 ml
hanging drops of osteogenic medium in Terasaki plates (VWR, Switzerland) for up to
6 days. In all cases, osteogenic differentiation was evaluated by Alizarin red (Sig-
maeAldrich) staining of parafﬁn wax tissue sections and by the analysis of osteo-
genic gene expression using quantitative reverse-transcription polymerase chain
reaction (qRT-PCR). Fully formed ASC-MTwere also cultured in sterile plastic culture
plates under normal growth conditions or in osteogenic medium for up to 14 days,
and the ability of ASCs to migrate out from the microtissues and also induce
mineralization determined by microscopic analysis.
2.5. Osteogenesis of human BMSCs from osteoporotic patients
Age-matched BMSCs harvested from osteoporotic (OP; n ¼ 9) or non-
osteoporotic (non-OP; n ¼ 6) patients were cultured for up to 21 days in osteo-
genic medium (OM) consisting of 50 mM L-ascorbic acid 2-phosphate sesqui-
magnesium salt hydrate, 10 mM b-glycerophosphate and 10 nM dexamethasone
(SigmaeAldrich), and osteogenesis compared at selected time points using the
alkaline phosphatase (ALP) activity assay or by Alizarin red staining as previously
described [25]. For studies investigating the inﬂuence of osteoporotic patient-
derived ASCs on the osteogenic potential of osteoporotic patient-derived BMSCs,
cultures of human BMSCs (n ¼ 4) or ASCs (n ¼ 4) isolated from age-matched oste-
oporotic patients were initially used to generate conditioned medium. Supernatants
from cells cultured in normal growth medium (GM) were harvested at 48 h to
generate conditioned medium (CM) designated ASC-CM or BMSC-CM. For osteo-
genic differentiation, human osteoporotic patient-derived BMSCs (n ¼ 4) were
Fig. 1. (A) Digital radiograph illustrating an intratibial injection into the left proximal tibia of a SAMP6 mouse. (B) Representative hematoxylin & eosin stained parafﬁn wax section
of decalciﬁed tibia 1 day after injection. Scale bar ¼ 500 mm. (C) Micro-CT analysis of tibial plateau from non-injected (upper panel) and injected (lower panel) bones at 24 h post
treatment.
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cultured for up to 14 days in OM supplemented with 100% of either ASC-CM or
BMSC-CM in triplicates, and osteoblast formation determined by Alizarin red
staining as previously described [25].
2.6. Intratibial injection
SAMP6 mice were anaesthetized with an i.p. injection of Fentanyl (0.05 mg/kg),
Midazolam (5 mg/kg) and Medetomidin (0.5 mg/kg) in 0.9% NaCl, and the left tibia
injected with either undifferentiated ASCs (n¼ 9), ASCs pre-differentiated for 3 days
in osteogenic medium either as a monolayer (n ¼ 13) or as ASC-MT (n ¼ 13), or PBS/
EDTA (vehicle; n ¼ 9). Prior to implantation, cells were labeled with CM-Dil (Life
Technologies) according to the manufacturer's recommendations. A pre-drilled hole
was created in the left proximal tibia of 18-week-old female SAMP6mice using a 26-
gauge needle. Following brief ﬂushing of the cavity with heparin (10 IE/ml), 10 ml of
cells (15 " 104) or vehicle were injected directly into the medullary canal using a
Hamilton syringe (Fig. 1AeC). The contralateral tibia remained untreated and served
as the control. Tracking of injected CM-Dil-labeled ASCs was performed in dewaxed
DAPI-stained parafﬁn sections of tibia taken at 24 h and 42 days following injection
and analyzed using the Leica DMI6000B automated inverted research microscope
system (Leica Microsystems, Heerbrugg, Switzerland).
2.7. Micro-CT monitoring of SF scaffolds
Bioreactors containing cell seeded scaffolds (n ¼ 5 per bioreactor) were scanned
weekly for up to 6 weeks on a micro-CT40 (Scanco Medical AG, Brüttisellen,
Switzerland). Scans were operated at 45kVp energy level, 177 mA intensity, 200 ms
integration time, 2-fold frame-averaging at high resolution mode leading to an
isotropic resolution of 18 mm. The bioreactors were removed from the incubator for
1 h during the measurement. Greyscale images were ﬁltered by applying a 3-D
Gaussian ﬁlter (sigma 1.2, support 1) and a global threshold of 12.8% of the
maximal grey values (corresponding to a density value of 127.59 mg HA/cm3). Un-
connected objects smaller than 50 voxels were not analyzed. Samples were evalu-
ated morphometrically for mineralized tissue volume density (BV/TV).
2.8. Micro-CT analysis of mouse tibia
Tibia were excised and stored in 70% ethanol. Micro-CT40 (Scanco Medical AG,
Brüttisellen, Switzerland) scans were performed with the X-ray tube operating at an
energy of 55 kVp and an intensity of 145 mA. Three-dimensional images with an
isotropic voxel size of 15 mmwere reconstructed from 1000 projection images taken
over 180# and an integration time of 300 ms. A 3-D Gaussian ﬁlter (sigma 0.8,
support 1) was then applied to all images, and a global threshold corresponding to
22.4% of the maximum grey values was used to separate bone from marrow and
surrounding soft tissues. Three compartments were selected for the evaluation. Full
bone and cortical bone (5% of bone length located at 50% of length) were determined
by an automated algorithm [29]. A trabecular compartment of 150 slices located
distal of the growth plate was selected by manual contouring. Bone morphometric
parameters were calculated within each compartment as described previously
[30,31].
2.9. qRT-PCR analysis
Total RNA was puriﬁed from either mouse ASCs or mouse bone tissue using
TRIzol reagent and treated with TURBO DNase (Life Technologies) as previously
described [20,28]. RNA (0.5 mg) was reverse transcribed to cDNA using superscript II
(Life Technologies) and random hexanucleotide primers (Promega AG, Dübendorf,
Switzerland), and quantiﬁcation of mRNA expression performed using TaqMan Gene
Expression Assays (Life Technologies) (Table 1). For all in vitro studies, values were
normalized to Mrps12 mRNA levels and presented as fold change according to the
2$DDCT method unless otherwise stated. For the measurement of gene expression
levels in bone tissue, total RNA was harvested from the diaphysis of 5e6 bone
samples and values normalized to GapdhmRNA levels and presented as 2$DCT. Each
10 ml reaction consisted of 1x TaqMan Fast Universal PCR Master Mix (Life Tech-
nologies), 1x TaqMan Gene Expression Assay and 10 ng cDNA (based upon initial
RNA concentrations). All reactions were performed in triplicate in fast optical 96-
well reaction plates (Life Technologies) at 95 #C for 20 s and 40 cycles of 95 #C for
1 s and 60 #C for 20 s.
Table 1
List of TaqMan Gene Expression Assays used in RT-PCR analysis.
Gene symbol Protein product Assay IDa
Alpl Alkaline phosphatase Mm01187117_m1
Col1a2 Collagen type 1A 2 Mm00483888_m1
Ctsk Cathepsin K Mm00484039_m1
Gapdh Glyceraldehyde-3-phosphate dehydrogenase Mm99999915_g1
HtrA1 High temperature requirement protease A1 Mm00479887_m1
Ibsp Integrin binding sialoprotein Mm00492555_m1
Mrps12 Mitochondrial ribosomal protein S12 Mm00488728_m1
Opn Osteopontin Mm01611440_m1
Tnfa Tumor necrosis factor alpha Mm00443258_m1
a TaqMan Expression Assay identity code according to supplier (Life Technologies,
Zug, Switzerland).
Fig. 2. (A) Representative micro-CT images of SF scaffolds seeded with ASCs (1 " 106) at selected time points following incubation in osteogenic induction medium. Top panel,
transverse cross section; bottom panel, longitudinal cross section. (B) Micro-CT analysis of mineralized tissue volume density (BV/TV) in ASC-seeded SF scaffolds (Treated) (n ¼ 5) as
compared to SF scaffolds alone (Control) (n ¼ 5). *p < 0.05, **p < 0.01 as determined by the Student's t-test (mean ± S.D.). (C) Representative image of an Alizarin red and DAPI
stained parafﬁn wax section of ASC-seeded SF scaffold 42 days after osteogenic induction. Scale bar ¼ 25 mm. Red, mineral deposition; blue, cell nuclei. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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2.10. Histology
Parafﬁn wax sections of ASC microtissue spheroids were incubated with poly-
clonal rabbit anti-HTRA1 (1:50) or rabbit anti-osteocalcin (1:1000) using the con-
ditions previously described [27]. Samples were then washed and incubated with
goat anti-rabbit-Cy3 (1:400) for 1 h and mounted in DAPI containing Mowiol so-
lution and images captured using the Leica DMI6000B system.
2.11. Statistical analysis
All statistical analyses were carried out using SPSS19.0 (SPSS Inc., Chicago, IL).
Parametric analysis of normally distributed data was performed using either the
two-tailed unpaired or paired Student's t-test for comparison of two groups or one-
way analysis of variance (ANOVA) with Tukey's post hoc test for multiple group
comparisons. In all cases, a p-value of <0.05 was considered statistically signiﬁcant,
and all data were expressed as mean ± standard deviation (S.D).
3. Results
3.1. Osteogenic differentiation of ASCs in 3-D culture systems
The ability of ASCs to grow and differentiate under 3-D culture
conditions was initially evaluated using SF scaffolds. Micro-CT
analysis revealed signiﬁcant increases in mineralized tissue for-
mation in SF scaffolds seeded with ASCs after 21 days (p < 0.05),
and this continued to increase up until completion of the study at
day 42 (p < 0.01) (Fig. 2A and B). Alizarin red staining of parafﬁn
sections at day 42 conﬁrmed localization of seeded ASCs in areas
of mineralized matrix (Fig. 2C). Further analysis of ASC osteo-
genesis was also performed using ASC-MT. ASCs readily formed
spheroid microtissues when cultured in hanging drops (Fig. 3A
and B). Under osteogenic conditions, ASC-MT produced mineral-
ized matrix within 6 days (Fig. 3C and D) and stained positive for
known markers of osteogenic differentiation including HTRA1
(Fig. 3E and F) and osteocalcin (Fig. 3G and H). Furthermore,
several genetic markers of osteogenesis including alkaline phos-
phatase (Alpl) (p < 0.01), osteopontin (Opn) (p < 0.01), and high
temperature requirement serine protease A1 (HtrA1) (p < 0.01)
were signiﬁcantly upregulated in comparison to undifferentiated
ASC-MT after 3 days in culture (Fig. 3I). Additional studies
revealed that ASCs initially grown as ASC-MT retained both their
proliferative capacity as well as their potential to undergo osteo-
genesis when transferred to tissue culture plates (Fig. 4). Cells
were observed to migrate out from the microtissues and could
induce mineral formation within the 2-D culture system already
after 7 days.
3.2. Tracking of injected ASCs
CM-Dil positive ASCs were easily identiﬁed within the bone
marrowof mice 24 h following a single intratibial injection of either
undifferentiated ASCs (Fig. 5A) or pre-differentiated ASC-MT
Fig. 3. (A) Undifferentiated ASC-MT after 6 days in hanging drops visualized in situ. Scale bar ¼ 100 mm. (B) Hematoxylin & eosin stained parafﬁn wax section of undifferentiated
ASC-MT after 6 days in hanging drops. Scale bar ¼ 100 mm. (CeD) Representative images of Alizarin red stained parafﬁn wax sections of ASC-MT cultured for 6 days in growth
medium (C) or osteogenic induction medium (D). Scale bar ¼ 100 mm. (EeH) Representative immunoﬂuorescence images of parafﬁn wax sections of ASC-MT cultured for 6 days in
growth medium (E, G) or osteogenic induction medium (F, H) and stained with anti-HTRA1 (E, F) or anti-osteocalcin (G, H). Positive staining was detected using an anti-rabbit Cy3
antibody (red). Nuclei were stained with DAPI (blue). Scale bar ¼ 25 mm. (I) qRT-PCR analysis of alkaline phosphatase (Alpl), osteopontin (Opn) and high temperature requirement
protease A1 (HtrA1) in ASC-MT cultured for 3 days in growth medium (Control) or osteogenic induction medium (Ost). Values were normalized to Mrps12 and the fold change as
compared to undifferentiated controls determined using the 2"DDCT method (mean ± S.D.). *p < 0.01 as determined by the Student's t-test.
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(Fig. 5B). At 42 days post injection, CM-Dil positive cells were still
evident within all of the treated bones, although to a much lesser
extent than bone sections at 24 h post injection (Fig. 5C and D).
Untreated contralateral bones remained absent of CM-Dil-labeled
cells at all time points.
3.3. Inﬂuence of ASCs on bone quality in SAMP6 mice
In order to determine the effects of ASCs on bone quality, micro-
CT was performed on bone samples taken at day 42 following
treatment. Animals injected with undifferentiated ASCs, pre-
differentiated ASC-MT or PBS/EDTA showed no adverse reactions
and treatments were generally well tolerated. However, intratibial
injections of ASCs that had been pre-differentiated as monolayers
for 3 days prior to implantation resulted in >50% mortality, with
death occurring immediately after the administration of these cells.
As such, we were unable to accurately assess the inﬂuence of these
cells on bone quality in SAMP6 mice. Histological analysis revealed
that themost likely cause of death was due to pulmonary embolism
as evidenced by both cartilaginous and ﬁbrous deposits within lung
vacuoles taken from mice that died shortly after receiving an
intratibial injection of pre-differentiatedmouse ASCs (Suppl. Fig. 1).
Fig. 4. Analysis of ASC outgrowth from ASC-MT. Undifferentiated ASCs were cultured in ASC-MT for 4 days, and then transferred to culture plates and incubated for 7 days (A, C, E)
or 14 days (B, D, F) in normal growth medium (A, B) or osteogenic induction medium (CeF). Cells were stained with Alizarin red (AeD) or left unstained and visualized by phase
contrast light microscopy (EeF). AeD, scale bar ¼ 2 mm; EeF, scale bar ¼ 500 mm.
Fig. 5. Representative ﬂuorescence images of parafﬁn wax sections of tibia injected with undifferentiated ASCs (A, C) or ASC-MT (B, D) at 24 h (A, B) and 42 days (C, D) post
treatment. Scale bar ¼ 50 mm. Inset and arrowhead, high magniﬁcation images of CM-Dil labeled cells. Scale bar ¼ 25 mm. Red, CM-Dil; blue, DAPI.
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When compared to untreated contralateral tibia, undifferenti-
ated ASC-treated and pre-differentiated ASC-MT-treated tibia
demonstrated signiﬁcant increases in trabecular bone volume
density (BV/TV) (ASC, p ¼ 0.01; ASC-MT, p ¼ 0.002) and trabecular
number (Tb.N) (ASC, p ¼ 0.01; ASC-MT, p ¼ 0.01), although
trabecular thickness (Tb.Th) (ASC, p¼ 0.3; ASC-MT, p¼ 0.1), was not
signiﬁcantly affected (Fig. 6A and B). Furthermore, the distance
between trabeculae (Tb.Sp) was signiﬁcantly reduced in both
treatment groups (ASC, p ¼ 0.01; ASC-MT, p¼ 0.02). By contrast, no
signiﬁcant changes in BV/TV (p ¼ 0.07), Tb.N (p ¼ 0.89), Tb.Sp
(p ¼ 0.77) or Tb.Th (p ¼ 0.30), were observed in tibia treated with
PBS/EDTAwhen compared to the respective untreated contralateral
tibia. Additionally, no signiﬁcant changes in cortical bone param-
eters were observed in any of the treatment groups tested (data not
shown).
3.4. Effect of ASCs on gene expression in vivo
RNAwas harvested from the tibia of mice after 14 days following
treatment with either PBS/EDTA or ASCs, and analyzed for various
genetic markers using qRT-PCR. The expression levels of all genetic
markers analyzed were found to be signiﬁcantly upregulated in
ASC-treated bones as compare to untreated contralateral controls
(Fig. 7). Similarly, with the exception of Tnfa, PBS/EDTA treatment
also induced signiﬁcant increases in the expression levels of all
gene markers. However, in comparison to PBS/EDTA-treated bones,
ASC-treated bones showed signiﬁcant increases in genetic markers
associated with osteogenesis, including, Opn (p < 0.01), Ibsp
(p < 0.05), Col1a2 (p < 0.01), HtrA1 (p < 0.01), as well as resorption-
associated markers, Tnfa (p < 0.01) and Ctsk (p < 0.01). No
signiﬁcant differences in the expression proﬁles of any of the genes
tested were observed between the untreated contralateral control
bones of PBS/EDTA- and ASC-treated mice.
3.5. Osteogenic differentiation of human osteoporotic BMSCs
The osteogenic potential of human BMSCs isolated from aged
osteoporotic patients was conﬁrmed as being impaired as
demonstrated by marked reductions in both ALP activity (Fig. 8A)
and Alizarin red staining (Fig. 8B) in comparison to BMSCs from
non-osteoporotic patients. Supplementation of osteogenic medium
(OM) with conditioned medium harvested from osteoporotic
patient-derived ASCs (ASC-CM) cultured under normal growth
conditions, signiﬁcantly enhanced mineral formation of osteopo-
rotic patient-derived BMSCs after 14 days as compared to cells
cultured in OM alone, or OM supplemented with conditioned
medium from osteoporotic patient-derived BMSCs (BMSC-CM)
(Fig. 8C).
4. Discussion
ASCs represent an easily accessible population of multipotent
stromal cells, and unlike their BMSC counterparts, have the po-
tential to readily undergo osteogenic differentiation independently
of donor age and status of bone quality [18e20]. As such, the use of
ASCs in bone tissue engineering is becoming more commonplace
[32e37] and investigators have now started to recognize their
potential as a therapeutic strategy for the treatment of osteoporosis
[21e23]. Indeed, previous ﬁndings from our own studies have
demonstrated that ASCs isolated from osteoporotic SAMP6 mice
Fig. 6. (A) Micro-CT analysis of treated and untreated tibia from SAMP6 mice 42 days after surgical intervention. Tibia were treated (Treated) with either PBS/EDTA (PBS/EDTA)
(n ¼ 9), undifferentiated ASCs (ASC) (n ¼ 9), or pre-differentiated osteogenic ASC-MT (n ¼ 13). In all cases, treatments were compared to the contralateral control tibia (untreated).
BV/TV, trabecular bone volume density; Tb.N, trabecular number; Tb.Sp, trabecular spacing; Tb.Th, trabecular thickness. All results are expressed as mean ± S.D. *p < 0.05, **p < 0.01
as determined by the paired Student's t-test. (B) Representative 3-D micro-CT images of control tibia (untreated), PBS/EDTA-treated tibia (PBS/EDTA), ASC-treated tibia (ASC) and
ASC-MT-treated tibia (ASC-MT).
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were able to retain their osteogenic potential under 2-D culture
conditions when compared to ASCs from non-osteoporotic SAMR1
control mice [20]. However, no studies have yet sought to evaluate
the therapeutic potential of isogeneic ASCs on bone quality in this
mouse model for senile osteoporosis.
In the present report, in vitro 3-D culture systems were initially
used to evaluate the osteogenic potential of SAMP6-derived ASCs in
order to simulate a more accurate natural physiological environ-
ment. Preliminary investigations were carried out using a scaffold-
based approach, whereby micro-CT was used to monitor the min-
eral formation in long-term cultures of SAMP6-derived ASCs
seeded on SF scaffolds. A gradual increase in mineralized tissue
formation was observed in ASC-seeded scaffolds over the 42 day
culture period. Additional histological analysis using Alizarin red
and DAPI staining conﬁrmed that cells could still be identiﬁed
within the scaffolds after 42 days, being localized to areas of min-
eral deposition. Short-term osteogenic differentiation of ASCs
grown in scaffold-free microtissue spheroids was observed after
only 3 days in osteogenic induction medium as evidenced by sig-
niﬁcant increases in osteogenic markers Alpl, Opn and HtrA1. By day
6, mineral depositionwas apparent in the majority of tissues, along
with the expression of osteogenic proteins HTRA1 and osteocalcin.
Furthermore, cells cultured within spheroid microtissues were
conﬁrmed as being able to retain their proliferative capacity as well
as their osteogenic potential following outgrowth onto a plastic
surface. These preliminary ﬁndings therefore conﬁrmed that
SAMP6-derived ASCs were capable of maintaining their functional
capacity for osteogenesis when cultured in 3-D environments and
thus encouraged us to further investigate their capacity to inﬂuence
bone formation in vivo.
The underlying premise for using ASCs to treat osteoporotic
bone, stems from the concept that resident BMSCs are defective in
terms of their ability to maintain a normal osteogenic potential and
thus have a reduced tendency to generate bone-forming osteo-
blasts [2,3,7e9]. Supplementation of osteoporotic bone with
competent osteoprogenitor cells may therefore represent a viable
means by which to re-establish normal bone homeostasis and
enhance bone quality. Indeed, this concept has already been tested
by several independent research groups and has been shown to
have signiﬁcant beneﬁts in terms of preventing bone loss in various
experimental OVX mouse models. Human ASCs demonstrated a
protective effect on OVX-induced bone loss in nude mice when
intravenously injected at the time of surgical intervention [21].
These effects were hypothesized as being mediatedmainly through
paracrine effects of the transplanted ASCs based on the fact that no
cells could be visualized within bone after 48 h post injection.
Similarly, the systemic administration of genetically modiﬁed
mouse ASCs restored normal bone parameters in immunocompe-
tent mice after 28 days, although no data was presented to indicate
whether ASCs could be detected within the bones of treated ani-
mals [22]. More recently, it was demonstrated that a single intra-
tibial injection of ASCs into the femur of OVX SAMP8mice, an aging
animal model primarily used in studies of learning and memory,
resulted in signiﬁcant increases in bone mineral density as
Fig. 7. qRT-PCR analysis was performed on mRNA isolated from tibia treated (Treated) with either PBS/EDTA or ASC and the corresponding contralateral control tibia (Untreated) of
SAMP6 mice 14 days after surgical intervention. Values were normalized to Gapdh and presented as 2!DCT (RNA of 5e6 mice pooled, technical triplicates, mean ± S.D.). *p < 0.05,
**p < 0.01, as determined by one-way ANOVA. Opn, osteopontin; Ibsp, Integrin binding sialoprotein; Col1a2, Collagen type 1A2; HtrA1, high temperature requirement protease A1;
Tnfa, tumor necrosis factor alpha; Ctsk, Cathepsin k.
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compared to control groups, which was evident at 4 months
following the initial treatment [23]. However, these effects
appeared to require the in vitro osteogenic differentiation of ASCs
prior to implantation. In the present study, we observed a signiﬁ-
cant improvement in the trabecular bone quality of SAMP6 mice 42
days following a single intratibial injection of either undifferenti-
ated SAMP6-derived ASCs or pre-differentiated osteogenic ASC-MT
as compared to untreated contralateral bones. Furthermore, CM-Dil
labeled cells could still be detected within the bone marrow of
treated tibia even at this late time point. Attempts were also made
to assess the effects of a single intratibial injection of a cell sus-
pension of pre-differentiated osteogenic ASCs, but unexpectedly,
this resulted in high mortality rates associated with pulmonary
embolism. It remains unclear as to why such adverse events should
have occurred following the use of these cells, especially as other
studies using pre-differentiated mouse ASCs reported no untoward
effects [23]. However, one possible explanation may relate to the
size of cells that were injected into the bone cavity. A recent study
evaluating the therapeutic potential of human placenta-derived
mesenchymal stem cells (hMSCs) in ischemic stroke, demon-
strated high incidences of embolism and neurological abnormal-
ities following the intra-carotid injection of hMSCs previously
cultured as monolayers [38]. By contrast, the injection of hMSC
suspensions derived from 3-D microtissue spheroids, led to a
subsequent improvement in neurological function with no reports
of vascular obstruction. These opposing effects were attributed to
differences in the size of hMSCs produced, with microtissue-
derived hMSCs showing a noticeable decrease in diameter as
compared to hMSCs grown as monolayers. Such alterations in cell
dimension may therefore go someway to explaining why osteo-
genic ASCs cultured as monolayers, but not as ASC-MT, resulted in
embolism. Certainly, this could represent an important point of
concern when considering such an approach in humans and may
therefore warrant further investigation. It would appear therefore
that incorporation of ASCs into microtissue spheroids may repre-
sent one possible means by which to overcome this potentially
detrimental effect of pre-differentiated osteogenic ASCs when
injected directly into the bone marrow cavity.
In addition to improvements being made in trabecular bone, we
also observed signiﬁcant increases in the gene expression of bone
turnover markers in the tibia of ASC-treated mice as compared to
PBS/EDTA-treated mice. This is in line with previous investigations
in which the beneﬁcial effects of locally administered ASCs on
mouse bone quality have been associated with alterations in ge-
netic markers of osteogenesis [23]. However, it should be
mentioned that in the current study, the majority of genes tested
Fig. 8. (AeB) Osteogenic differentiation of human BMSCs isolated from osteoporotic (OP) (n ¼ 5e9) or non-osteoporotic (non-OP) (n ¼ 5e6) patients was compared using the ALP
activity assay (A) and Alizarin red staining (B). *p < 0.05 as determined by Student's t-test. (C) The osteogenic potential of osteoporotic patient-derived BMSCs (n ¼ 4) cultured in
osteogenic medium (OM) or OM supplemented with either conditioned medium from osteoporotic patient-derived ASCs (ASC-CM) or BMSCs (BMSC-CM) was determined by
Alizarin red staining at day 14 after osteogenic induction. Undifferentiated cells cultured in growth medium (GM) served as negative controls. *p < 0.01 as determined by one-way
ANOVA. All experiments were performed in triplicate and results expressed as mean ± S.D.
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were signiﬁcantly upregulated in both ASC- and PBS/EDTA-treated
mice when compared to untreated contralateral bones, thus indi-
cating that the mere act of injecting into the tibia alone was sufﬁ-
cient to upregulate gene expression.
It is interesting to note, that the capacity of pre-differentiated
osteogenic ASC-MT to enhance trabecular bone quality was com-
parable to undifferentiated ASCs, despite them having already been
induced along the osteogenic lineage. This would therefore imply
that the transplanted ASCs may have mediated their effects
through the stimulation of resident cells, rather than instigating
new bone formation directly. This concept was further tested
in vitro utilizing ASCs and BMSCs isolated from human osteoporotic
patients. Initial observations conﬁrmed that the osteogenic po-
tential of osteoporotic patient-derived BMSCs was signiﬁcantly
impaired as compared to normal, age-matched non-osteoporotic
control samples. Furthermore, we could demonstrate that condi-
tioned media harvested from osteoporotic patient-derived ASCs
was able to better support osteoporotic patient-derived BMSC
osteogenesis. Although similar ﬁndings were reported in studies
utilizing human ASCs with either human BMSCs or mouse osteo-
blastic cell lines [21,39], as far as we are aware, this is the ﬁrst direct
evidence that human osteoporotic ASCs have the capacity to impart
a pro-osteogenic paracrine effect on human osteoporotic patient-
derived BMSCs in vitro. It is possible therefore, that the increases
in SAMP6 trabecular bone quality following ASC treatment were
due, in part, to the paracrine actions of injected ASCs on resident
BMSC populations.
5. Conclusion
We have demonstrated that ASCs isolated from osteoporotic
SAMP6 mice have the capacity to undergo osteogenic differentia-
tion and induce mineralized tissue formation in short- and long-
term 3-D cultures, and that a single intratibial injection of undif-
ferentiated ASCs or pre-differentiated ASC-MT, signiﬁcantly
enhanced parameters of bone quality in SAMP6 mice. Furthermore,
in vitro data utilizing human osteoporotic patient-derived BMSCs
and ASCs is provided, which supports the concept of transplanted
ASCs inﬂuencing bone formation in a paracrine manner. Our data
therefore highlights the potential beneﬁts of using ASCs as an
autologous cell-based therapeutic strategy to treat osteoporosis.
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Supplementary Fig. 1. Hematoxylin and eosin stained paraffin wax sections of lung tissue taken from a mouse 
shortly after death due to a single intratibial injection of pre-differentiated osteogenic ASCs. (A) Large numbers 
of eosinophils were often observed in fibrillar masses within blood vacuoles throughout the lung tissue (*). (B) 
In some cases, vacuoles were observed containing large emboli consisting of cartilage and mineralized tissue 
(*). Scale bar = 50 µm 
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ABSTRACT ADP-ribosyltransferase Diphtheria toxin-
like 1 [ARTD1; formerly called poly-ADP-ribose poly-
merase 1 (PARP1)] is a chromatin-associated enzyme
involved in regulating metabolic homeostasis. The liver
is at the core of glucose and lipid metabolism and is
significantly affected by obesity and the metabolic
syndrome. Here, we show that when fed a high-fat diet
(HFD), mice lacking ARTD1 developed exacerbated
hepatic steatosis. ARTD1!/! mice had a 19% higher
liver weight than wild-type (WT) animals and exhibited
a significantly increased serum concentration of choles-
terol (38%) and impaired glucose tolerance. In addi-
tion, adipocyte function and size were significantly
reduced in ARTD1!/! mice fed an HFD (7794 "m2 for
WT and 5579 "m2 for ARTD1!/! mice). The signifi-
cantly reduced adipogenic differentiation of adipose-
derived stromal cells (ASCs) isolated from ARTD1!/!
mice (28 vs. 11% Oil red O-positive cells in WT and
ARTD1!/! ASCs, respectively) suggested that impaired
adipogenesis as the underlying cause for this adipose
tissue malfunction. This function of ARTD1 was spe-
cific for adipogenesis, since osteogenic differentiation
was not affected by the ARTD1 deletion. In summary,
we show that ARTD1!/! mice fed an HFD display
impaired adipogenesis and show exacerbated hepatic
steatosis, which can have important implications for
nonalcoholic fatty liver disease.—Erener, S., Mirsaidi,
A., Hesse, M., Tiaden, A. N., Ellingsgaard, H., Kostadi-
nova, R., Donath, M. Y., Richards, P. J., Hottiger,
M. O. ARTD1 deletion causes increased hepatic lipid
accumulation in mice fed a high-fat diet and impairs
adipocyte function and differentiation. FASEB J. 26,
2631–2638 (2012). www.fasebj.org
Key Words: adipogenesis # ADP-ribosylation # liver # PARP-1
Obesity is a complex metabolic disorder character-
ized by an excess of body fat that is closely associated
with other serious health conditions, such as heart
disease and diabetes (1). White adipose tissue (WAT) is
the predominant storage site for excess energy in the
form of fat in adult humans, but also functions as an
important endocrine organ (2, 3). However, it appears
that low-grade chronic inflammation (metaflamma-
tion) in metabolic tissues is the underlying mechanism
leading to the disruption of nutrient and energy me-
tabolism (4, 5).
ADP-ribosyltransferase Diphtheria toxin-like 1 [ARTD1;
formerly called poly-ADP-ribose polymerase 1 (PARP1);
ref. 6] is a chromatin-associated enzyme that modifies
itself and target proteins by transferring the ADP-ribose
moieties from nicotinamide adenine dinucleotide
(NAD!) to specific acceptor residues on target pro-
teins (7). ARTD1 is thus able to regulate protein
function, chromatin compaction, and gene expression
(7, 8) and is subsequently involved in numerous bio-
logical phenomena, such as stress response, inflamma-
tion, and differentiation or cell cycle regulation, as well
as in infectious diseases and cancer (9). Mice lacking
ARTD1 also exhibit metabolic phenotypes, such as
1 Correspondence: Institute of Veterinary Biochemistry and
Molecular Biology, University of Zürich, Winterthurerstrasse
190, Zürich 8057, Switzerland. E-mail: hottiger@vetbio.uzh.ch
doi: 10.1096/fj.11-200212
This article includes supplemental data. Please visit http://
www.fasebj.org to obtain this information.
Abbreviations: aP2, adipocyte protein 2; ARTD, ADP-ri-
bosltransferase Diphtheria toxin-like; ASC, adipocyte-derived
stromal cell; ATGL, adipose triglyceride lipase; CD36, cluster
of differentiation 36; DMEM, Dulbecco’s modified eagle
medium; FBS, fetal bovine serum; FFA, free fatty acid; Glut4,
glucose transporter type 4; GTT, glucose tolerance test; H&E,
hematoxylin and eosin; HFD, high-fat diet; HSL, hormone
sensitive lipase; ITT, insulin tolerance test; NAD!, nicotin-
amide adenine dinucleotide; NAFLD, nonalcoholic fatty liver
disease; ND, normal diet; PAR, poly-ADP-ribose; PPAR",
peroxisome proliferator-activated receptor "; PARP, poly-
ADP-ribose polymerase; PBS, phosphate-buffered saline;
WAT, white adipose tissue; WT, wild type
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alterations in body weight, WAT formation, and the
development of high-fat diet (HFD)-induced obesity,
although these vary depending on the strain back-
ground (10–12). The deletion of ARTD1, a major
NAD!-consuming enzyme, can lead to increased cellu-
lar NAD! levels (10). Consequently, ARTD1 deletion
can activate NAD!-dependent enzymes, such as sir-
tuins, and thereby indirectly induce phenotypes, such
as increased mitochondrial biosynthesis and altered
energy metabolism (10, 13). Furthermore, the enzy-
matic activity of ARTD1 also directly partakes in the
sustained expression of the key regulator of adipocyte
function, peroxisome proliferator-activated receptor "
(PPAR"; ref. 14). In cell culture, ARTD1 modulates
PPAR"-dependent gene expression [such as cluster of
differentiation 36 (CD36) or adipocyte protein 2 (aP2)]
and adipocyte function (14) and may thus also be
involved in adipogenesis in vivo.
To identify and characterize such direct in vivo
functions of ARTD1 in metabolism, we analyzed
ARTD1#/# and wild-type (WT) mice of the C57BL/6
background fed an HFD. Here, we report that deletion
of ARTD1 caused increased hepatic fat accumulation
and dyslipidemia in mice exposed to HFD. These
effects correlated with increased PPAR"2 target gene
expression in liver samples from ARTD1#/#mice fed an
HFD as well as with elevated serum levels of cholesterol,
smaller adipocyte size, and impaired adipocyte differ-
entiation. These results define a novel function for
ARTD1 in the development of hepatic steatosis, as well
as in the modulation of adipocyte differentiation and in
adipose tissue function in vivo. These findings may thus
provide novel insights into the molecular pathways that
govern the onset, development, and progression of
prevalent human diseases such as nonalcoholic fatty
liver disease (NAFLD).
MATERIALS AND METHODS
Animals and animal care
In the ARTD1#/# male C57BL/6 mice used in this study and
obtained from Zhao-Qi Wang (Leibniz Institute for Age
Research–Fritz Lipmann Institute, Jena, Germany), part of
the second exon and second intron of the ARTD1 gene is
replaced with the neomycin resistance gene (15). ARTD1#/#
and WT mice were fed an HFD consisting of 60% of calories
from fat (S3282; Bio-Serv, Frenchtown, NJ, USA) starting at
6–8 wk of age for 14 wk. Control mice were fed a normal diet
(ND) consisting of 4.5% fat. Animals were housed in a
specific pathogen-free facility with a 12-h light-dark cycle and
given free access to food and water. Animal experiments were
performed according to the regulations of the Cantonal
Veterinary Office (Zurich, Switzerland).
Culture and analysis of mouse adipocyte-derived stromal
cells (ASCs)
ASCs were isolated, cultured, and analyzed as described
previously (16). In short, fat pads were removed from male
mice and digested with 0.1% collagenase A (Roche Diagnos-
tics, Rotkreuz, Switzerland). Stromal cells were collected by
centrifugation and cultured in supplemented Dulbecco’s
modified eagle medium (DMEM; low glucose with Glutamax;
Invitrogen AG, Basel, Switzerland), 10% fetal bovine serum
(FBS; Invitrogen), and antibiotics. Supernatant was replaced
after 1 d with fresh complete medium and cells were used
between passage 3 and 4. Total RNA was isolated and puri-
fied using TRIzol reagent (Invitrogen) and reverse tran-
scribed using superscript II (Invitrogen) and random
hexanucleotide primers (Promega AG, Dübendorf, Switzer-
land). mRNA expression analysis was performed with
primers specific for ARTD1 (Mm01321084_m1), PPAR"2
(Mm00440940_m1), aP2 (Mm00445878_m1), and glucose
transporter type 4 (GLUT4; Mm00436615_m1) and by using
the StepOnePlus Real-Time PCR System (Applied Biosys-
tems/Life Technologies, Zug, Switzerland). All values were
normalized to the RPS12 ribosomal RNA (Mm00488728_m1).
Adipogenesis
To assess adipogenesis, ASCs were plated at 10,000 cells/cm2
and incubated in adipogenic medium (DMEM supplemented
with 10% FBS and 1 $M dexamethasone; Sigma-Aldrich,
Buchs, Switzerland), 10 $g/ml insulin (Sigma-Aldrich), 0.1
mM indomethacin (Sigma-Aldrich), and 0.5 mM isobutyl
methylxanthine (IBMX; Sigma-Aldrich). After 2 d, cells were
switched to adipogenic medium without IBMX for up to 14 d.
Triglyceride content was determined using 0.3% Oil Red O
(Sigma-Aldrich), and adipocytes were counted in 30 fields of
view by fluorescence microscopy.
Osteogenesis
ASCs were plated at 5000 cells/cm2 and incubated in %-min-
imum essential medium (%-MEM; Invitrogen), supplemented
with 10% FBS, 50 $M l-ascorbic acid 2-phosphate sesquimag-
nesium salt hydrate (Sigma-Aldrich), 10 mM &-glycerophos-
phate (Sigma-Aldrich), and 5 $M retinoic acid (Sigma-Al-
drich) for up to 14 d with regular changes of medium.
Mineralization in cell colonies was identified using Alizarin
Red S (Sigma-Aldrich).
RNA extraction and real-time PCR analysis from WAT
Mouse tissues were isolated, rinsed in phosphate-buffered
saline (PBS), frozen in liquid nitrogen and stored at #80°C
until extraction. Total RNA was extracted from WAT using
the RNeasy Lipid Tissue Kit (Qiagen, Hombrechtikon, Swit-
zerland) according to the manufacturer’s instructions, with
the inclusion of a DNase digestion step. Total RNA from liver
and also from 3T3-L1 cells was extracted using the Total RNA
isolation mini kit (Macherey Nagel, Oensingen, Switzerland)
with a DNase step. Equal amounts of RNA from 5–8 mice
were pooled and reverse-transcribed using the high-capacity
cDNA reverse transcription kit (Applied Biosystems/Life
Technologies, Zug, Switzerland). Real-time PCR was per-
formed using the Rotor-Gene 3000 (Corbett Life Science,
now Qiagen) and SYBR Green using the primers listed in
Supplemental Table S1. Cyclophilin was chosen as the internal
control for normalization and for the relative quantification
of gene expression.
Whole-cell extraction
Tissues were lysed in RIPA buffer (50 mM Tris, pH 8; 400 mM
NaCl; 0.5% Triton Nonidet P-40; 1% DOC; 0.1% SDS; 1
$g/ml pepstatin; 1 $g/ml bestatin; 2 $g/ml leupeptin; 2 mM
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PMSF; 10 mM !-glycerophosphate; 1 mM NaF; and 1 mM
DTT), homogenized with a needle and syringe, and rotated
for 20 min at 4°C. Lysate was centrifuged for 20 min at 4°C at
14,000 rpm. Total proteins were loaded on 7.5% SDS gels and
blotted with anti-PAR and anti-tubulin antibodies.
Serum measurements
Serum insulin concentrations were measured with the insulin
ELISA kit (Mercodia Inc., Uppsala, Sweden). Blood glucose
was determined by using the FreeStyle Lite glucometer (Ab-
bott, Baar, Switzerland).
Glucose tolerance tests (GTTs) and insulin tolerance tests
(ITTs)
For the GTT, mice were unfed overnight (14 h); for the ITT,
mice were unfed for 3 h. Glucose (1.2 g/kg body weight) or
human recombinant insulin (HFD: 1.4 U/kg; ND: 0.75 U/kg)
was injected intraperitoneally. Blood glucose concentrations
were determined from tail using the FreeStyle Lite glucom-
eter (Abbott).
Histology and cell-size measurement
Freshly isolated epididymal WAT and liver tissue from mice
fed HFD was fixed in 4% formalin and embedded in paraffin.
Sections were stained with hematoxylin and eosin (H&E) or
Oil Red O. Adipocytes were photographed with a Leica DMR
microscope (Leica Microsystems, Glattbrugg, Switzerland)
and cell morphology and size were analyzed using the Leica
IM 1000 software. Liver photographs were recorded using an
Olympus AH-2 microscope (Olympus, Tokyo, Japan)
equipped with an Axiocam camera (Carl Zeiss, Oberkochen,
Germany).
RESULTS
ARTD1!/! mice fed HFD have increased liver weight
and hepatic lipid deposition
To determine the role of ARTD1 in metabolic disor-
ders, we analyzed 6–8 wk old WT and ARTD1"/" mice
in the C57BL/6J background that were fed ND or HFD.
WT and ARTD1"/" mice fed ND had identical body
weights (Supplemental Fig. S1A). Both WT and
ARTD1"/" mice fed HFD gained significantly more
body weight as compared to those fed ND (identified as
week 0; Fig. 1A). Furthermore, in comparison to
ARTD1"/"mice fed HFD,WTmice were heavier, which
was not attributable to differences in food intake (Sup-
plemental Fig. S1B). A pathological analysis revealed
that the most apparent phenotype of the ARTD1"/"
mice fed HFD was the significantly increased liver
weight (Fig. 1B). Histological examination (H&E and
Oil Red O staining) of liver sections revealed markedly
increased hepatic lipid deposition in ARTD1"/" mice
fed HFD, as compared to the WT controls (Fig. 1C),
while no apparent difference was observed in mice fed
ND (data not shown). H&E staining of skeletal muscle
tissue of WT and ARTD1"/" mice did not reveal any
difference (Fig. 1C).
ARTD1!/! mice fed HFD exhibit altered PPAR"2
target gene expression and dyslipidemia
Hepatic lipid accumulation is often associated with an
ectopic induction of PPAR#2 and PPAR#2-dependent
gene expression in the liver and muscle (17). We
therefore tested whether the increased lipid deposition
in livers of ARTD1"/" mice correlated with alterations
in PPAR#2 target gene expression in the liver. The
expression of PPAR#2 in ARTD1"/" livers was increased
but not significantly different as compared to WT
samples (Fig. 2A). However, the PPAR#2 target genes
aP2 (fatty acid binding protein) and LPL (lipoprotein
lipase) were significantly up-regulated in ARTD1"/"
livers of mice fed HFD. Significantly increased compen-
satory expression was also observed for PPAR$, a key
regulator involved in fatty acid catabolism. Lipin, an-
other highly inducible enzyme that is involved in tri-
glyceride metabolism, was unaffected between the two
genotypes, indicating that not all factors involved in
lipid metabolism were changed in the livers of
ARTD1"/" mice. These results, and in particular the
strongly elevated expression of aP2, revealed that livers
of ARTD1"/" mice fed HFD show gene expression
Figure 1. ARTD1"/" mice fed HFD display decreased weight gain and have reduced adipocyte size. A) Body weight of WT and
ARTD1"/" mice that were fed HFD. HFD feeding started when mice were 6–8 wk old (time point 0; n%8–9 mice/group).
*P & 0.05. B) Liver weight was measured and normalized with body weight (n%8–9 mice/group, means'se). *P & 0.05, 14 wk
after HFD. C) Representative images of Oil Red O-stained (top panels) or H&E-stained (bottom panels) sections of
paraffin-embedded liver tissue from WT or ARTD1"/" mice fed HFD (n%4). H&E-stained skeletal muscle sections are shown as
a control and for comparison (right panel).
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patterns typically associated with adipocytes and adipo-
genesis (17).
The hepatic lipid accumulation observed in ARTD1!/!
mice suggested that the metabolic analytes might be
altered in these animals. We therefore measured the
plasma levels of free fatty acids (FFAs), triglycerides, and
cholesterol. Indeed, ARTD1!/! mice displayed a mar-
ginal elevation in FFA and triglyceride levels as well as
significantly increased cholesterol amounts, which also
hinted at a disturbed lipid homeostasis in ARTD1!/!mice
(Fig. 2B). However, lipolysis was likely not the cause for
these alterations in lipid levels, since neither adipose
triglyceride lipase (ATGL) nor hormone sensitive lipase
(HSL) mRNA levels were significantly affected by the
ARTD1 deletion (Fig. 2C).
ARTD1!/! mice fed HFD exhibit defective glucose
homeostasis
The increased FFA blood concentration and hepatic
lipid accumulation can generate metabolic signals that
impair the metabolization of glucose (18). To deter-
mine whether the hepatic lipid accumulation and dys-
lipidemia in ARTD1!/! mice is accompanied by abnor-
malities in glucose homeostasis, we performed GTTs in
WT and ARTD1!/! mice fed HFD. Mice were injected
with 1.2 g glucose/kg body weight, and glucose levels
were quantified over a period of 2 h. Overall,
ARTD1!/!mice had an 18% increased glucose content
(area under curve) and required more time to clear the
injected glucose, although the basal glucose levels were
not significantly altered (Fig. 3A, B). Since this analysis
was performed with mice that experienced 14 h of food
withdrawal, the differences betweenWT and ARTD1!/!
mice may be underestimated (19). To explore the
potential mechanism causing impaired glucose toler-
ance in ARTD1!/! mice, we examined aspects of insu-
lin secretion in mice with and without ARTD1. A
significant increase in plasma insulin was observed in
ARTD1!/! mice as compared to WT mice following an
i.p. glucose injection (Fig. 3C), thus indicating that
"-cell function is unlikely to be impaired in
ARTD1!/! mice. This insulin burst, which was not
observed in WT mice, may hide elevated glucose
levels in the ARTD1!/! mice at earlier time points.
We next asked whether insulin sensitivity contributes
to this phenotype. To assess whole-body insulin sen-
sitivity, ITTs were performed in mice after 12 wk of
exposure to HFD. Mice were injected with 1.4 U
insulin/kg body weight, and glucose levels were
determined during 90 min. Serum glucose levels of
ARTD1!/! mice were 20% higher as compared to the
WT control (area under curve), which is suggestive of
a tendency toward insulin resistance, but this effect
was not significant (Fig. 3D).
Comparable analysis with animals fed the ND re-
vealed that glucose levels and response to GTTs and
ITTs did not significantly change between the two
genotypes (Supplemental Fig. S1C–E). Furthermore,
insulin-stimulated AKT phosphorylation in muscle and
WAT tissue from WT and ARTD1!/! mice fed ND was
Figure 2. ARTD1!/! mice fed HFD exhibit altered PPAR#2 target gene expression and dyslipidemia. A) Real-time RT-PCR
analysis of PPAR#2 and PPAR#2 target genes in liver tissue obtained from WT and ARTD1!/! mice that were fed HFD (RNA
of 7 mice pooled, means$sd of technical duplicates, 14 wk after HFD). B) Serum free fatty acid (FFA), triglyceride, and
cholesterol levels were measured from independent samples of 5 WT and 4 ARTD1!/! mice. C) Real-time RT-PCR analysis of
ATGL and HSL expression in WAT of WT and ARTD1!/! mice (RNA of 5–6 mice pooled, technical replicates, means$sd).
Figure 3. ARTD1!/! mice exhibit deteriorated glucose homeostasis. A) Serum glucose levels were measured from WT and
ARTD1!/! mice. B) GTT: mice were injected with glucose (1.2 g/kg body weight), and glucose levels were quantified over a
period of 2 h. C) Serum insulin levels during the GTT shown in B. D) ITT: mice were injected with insulin (1.4 U/kg body
weight), and glucose levels were determined over a period of 90 min. Values are means $ se, n % 5–6 mice/group. *P & 0.05,
12 wk after HFD.
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also comparable (Supplemental Fig. S1F) suggesting
that ARTD1 does not have a direct role in glucose
homeostasis and insulin signaling under ND, but that
the changes observed with HFD were rather the conse-
quence of dyslipidemia and excessive lipid accumula-
tion in the liver.
Adipocyte size and poly-ADP-ribose (PAR) formation
in ARTD1!/! mice
We have recently reported that ARTD1 regulates adi-
pogenesis in vitro (14), and PPAR! deletion in mouse
adipose tissue was shown to cause increased lipid
deposition in the livers (20). Our results on hepatic
lipid accumulation and the dyslipidemic phenotype in
ARTD1"/" mice fed HFD encouraged us to investigate
the role of ARTD1 on adipocyte and WAT function in
vivo. We therefore analyzed WAT from WT and
ARTD1"/"mice. Surprisingly, neither the expression of
PPAR!2 or its target genes aP2 and CD36 nor the
inflammatory genes IL-1#, IL-13ra, and MCP1 differed
between the WT and ARTD1"/" WAT samples from
mice fed HFD (Fig. 4A and Supplemental Fig. S2).
However, ARTD1"/" WAT tissue from mice fed HFD
expressed less IL-6, which is a main regulator of inflam-
mation. In addition, relative mRNA levels of the inflam-
matory genes IL-10 and IL-12 and of the macrophage
specific genes Pu.1 and MPEG 1 were also reduced,
while SAA3 transcription was elevated. These results
showed that a subset of the inflammatory genes was
affected. Moreover, histological analysis of epididymal
WAT from ARTD1"/" mice revealed a profound
change in adipose tissue morphology, as evidenced by
the significant reduction in adipocyte size (Fig. 4B, C).
These results suggest that altered adipose tissue mor-
phology likely impaired the storage of excess lipids in
ARTD1"/" mice fed HFD and thus caused a patholog-
ical lipid accumulation in the liver. This significant
effect of ARTD1 deficiency on lipid metabolism and on
the size of adipocytes from ARTD1"/" mice fed HFD
suggests a fundamental role for ARTD1 in adipocyte
function. Since we have recently shown that PAR for-
mation is strongly induced in 3T3-L1 cells after 7 d of
adipogenic induction (14), we investigated whether
PAR was also formed in mature adipocytes in vivo. We
could not detect PAR formation in WAT of WT mice
that were fed ND (data not shown), but a distinct PAR
signal was observed in the WAT extracts of WT mice
(but not in the WAT of ARTD1"/" mice) that were
maintained on HFD (Fig. 4D), suggesting that high
energy diet (nutrient availability) induced ADP-ribosy-
lation in WAT in vivo and in an ARTD1-dependent
manner.
Adipogenic gene expression in differentiating aASCs
is dependent on ARTD1
The in vivo results obtained from the studies with
ARTD1"/" mice suggested that ARTD1 and PAR for-
mation are centrally involved in adipose tissue activities.
In addition, ARTD1 and PAR formation have been
implicated in chromatin regulation (21) and were
shown to affect PPAR!2-dependent gene expression
and adipocyte function in differentiating 3T3-L1 cells
(14, 21). We therefore hypothesized that ARTD1 may
also affect the differentiation and development of
functional adipocytes in vivo.
We tested this hypothesis by using ASCs, which can
be easily isolated and expanded and have the ability to
differentiate into several types of mesenchymal tissue.
Differentiating ASCs are an established experimental
system to study adipocyte differentiation (22). To study
the role of ARTD1 and poly-ADP-ribosylation in adipo-
genesis, we compared ASCs from ARTD1"/" and from
WT mice. In uninduced ASCs from WT mice, ARTD1
expression levels were high and increased further at d
10 after the induction of adipogenesis (Fig. 5A). Tran-
scripts of the adipogenesis marker genes PPAR!2, aP2,
and GLUT4 were not detectable prior to the induction
of adipogenesis but increased significantly on adipo-
genic induction in WT mice (Fig. 5B–D). In contrast,
PPAR!2, aP2, and GLUT4 expression remained at sig-
nificantly lower levels in ASCs from ARTD1"/" mice
throughout adipogenesis (Fig. 5B–D). The marked
Figure 4. Adipocyte size and PAR formation in ARTD1"/" mice. A) Real-time RT-PCR analysis in total cell extracts from
epididymal WAT of WT and ARTD1"/" mice that were fed HFD. mRNA levels were normalized with cyclophilin A. Results are
means of 5–6 pooled mice, means $ sd of technical replicates. ns, not significant. *P % 0.05; **P % 0.01; ***P % 0.0001. B)
Whisker plot of adipocyte area from evaluation of 450 adipocytes from 4–5 independent mice. ***P % 0.0001 comparing mean
adipocyte area. C) Representative images of H&E-stained epididymal adipose tissue from WT and ARTD1"/" mice. D) PAR
detection in total cell extracts from epididymal WAT ofWT and ARTD1"/"mice that were fed HFD. All panels: 14 wk after HFD.
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effect of ARTD1 deletion on adipogenic gene expres-
sion suggests that ARTD1 is a major regulator of
normal ASC differentiation.
Functional characterization of adipogenic ASCs
isolated from ARTD1!/! mice
After 10 d of adipogenic differentiation, Oil Red O
staining revealed a significantly higher percentage of
mature adipocytes in ASC cultures isolated from WT
mice as compared to ARTD1!/! mice (Fig. 6A). To
further study the link between ARTD1 and adipogene-
sis, we assessed ASC differentiation in the presence of
the three PARP inhibitors (PJ34, olaparib, and nicotin-
amide) by Oil Red O staining (Fig. 6B–D). All three
compounds significantly reduced the percentage of Oil
Red O-positive cells in a concentration-dependent man-
ner. Interestingly, the detrimental effect of ARTD1 loss
of function on ASC adipogenesis was much less appar-
ent in ASCs undergoing osteogenesis, thus suggestive of
a lineage-specific role for ARTD1 in mesenchymal stem
cell differentiation (Supplemental Fig. S3). These re-
sults are in agreement with the strong and specific
influence of the ARTD1 deletion on PPAR"2-depen-
dent gene expression in adipose tissue and thus further
highlight the importance of ADP-ribosylation in adipo-
genesis.
Taken together, these results demonstrate that
ARTD1!/! deficiency in mice affects adipocyte func-
tion in vivo, and lipid deposition in the liver. This
correlates with the up-regulated expression of hepatic
PPAR"2 and its target genes involved in fatty acid
metabolism in ARTD1!/! mice. The effect of ARTD1
and PAR formation on the adipogenic differentiation
process may represent the underlying cause for the in
vivo effects on WAT function and lipid deposition in
ARTD1!/! mice.
DISCUSSION
In the present study, ARTD1!/! mice of the C57BL/6
background were fed HFD, and adipocyte and WAT
function were analyzed. Several independent groups
have previously reported significant differences in the
body weight of adult WT and ARTD1!/! mice from
various backgrounds (15, 23). While we and others (10)
have observed a decreased body weight in C57BL/6
ARTD1!/! mice fed HFD, ARTD1!/! mice of the
Figure 5. Adipogenesis is impaired in ASCs from ARTD1!/! mice. Expression levels of ARTD1 (A) PPAR"2 (B), aP2 (C), and
GLUT4 (D) were evaluated by qRT-PCR over 0, 5, and 10 d of adipogenic differentiation. Expression value of each gene was
normalized to the amount of ribosomal protein S12 (RPS12) RNA in order to calculate relative amounts of mRNA. *P # 0.05,
**P # 0.01.
Figure 6. Triglyceride accumulation is decreased in adipo-
genic ASCs from ARTD1!/! mice. A) Representative fluores-
cent images of ASCs stained with Oil Red O (red) and
Hoechst 33342 nuclear stain (blue). Scale bars $ 150 %m.
Percentage of cells demonstrating triglyceride accumulation
was quantified in ASCs at d 10. B–D) ASCs fromWTmice were
induced to adipogenic differentiation in the presence of the
ARTD1 inhibitors PJ34 (B), olaparib (C), and nicotin-
amide (D), and the percentage of cells demonstrating triglycer-
ide accumulation was quantified at d 10. All differentiation
studies were carried out using ASCs at passage 3 to 4 and were
performed in triplicate. *P # 0.05, **P # 0.01, ***P # 0.01.
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SV129 background have been shown to be more sus-
ceptible to HFD-induced obesity (11). However, mice
of the C57BL/6 background are readily susceptible to
diet-induced obesity, irrespective of the presence or
absence of ARTD1 (12). Our findings of lower body
weight, increased liver weight, smaller adipocytes, ele-
vated serum cholesterol levels, and impaired glucose
tolerance in ARTD1!/! mice suggest that lipid alloca-
tion is impaired. These results differ from recently
published observations with ARTD1!/! mice of the
same strain background (10), although hepatic lipid
accumulation was not assessed in this study. However, it
should be noted that the two C57BL/6 ARTD1!/!
mouse strains were created independently by targeting
different ARTD1 exons (15, 23), and as such, have given
rise to certain age-related disparities, as evidenced by
alterations in telomere lengths (24, 25). Whether such
differences also account for the contradicting effects of
the ARTD1 deletion on lipid metabolism remains to be
determined. In addition, the metabolic differences
between the two studies using C57BL/6 ARTD1!/!
mice might also be due to the fact that we started HFD
feeding earlier (when the mice were 6–8 wk old),
performed our analysis later (after 12 wk of HFD
feeding) and used an HFD preparation from a different
supplier with slightly different composition (10).
In the present study, PAR formation was only ob-
served inWTmice and on HFD feeding. The absence of
PAR formation in the WAT of ARTD1!/! animals
indicated that PAR formation in WAT was dependent
on nutrient availability and on ARTD1. Alterations in
PAR formation due to ARTD1 deletion could poten-
tially change NAD" metabolism in these animals and
thereby cause the activation of sirtuin 1 (SIRT1; ref.
10). Altered sirtuin activity may, in turn, affect adi-
pocyte gene expression and function, metabolism, or
number of mitochondria, for example, through the
deacetylation of Forkhead box protein O1 (FOXO1;
refs. 10, 26–28). Such indirect effects cannot be ex-
cluded, but our results describing the effects of ARTD1
deletion on ASC adipogenesis also point to a direct
effect of ARTD1 and ADP-ribosylation. These findings
are in agreement with our earlier in vitro observation,
where ARTD1 activity and ADP-ribosylation were in-
duced at d 7 during adipogenesis and crucial for
the sustained expression of PPAR#2 and CCAAT/
enhancer-binding protein $ (C/EBP-$), but not for the
upstream regulator C/EBP-% (14). In the current study,
ASCs from ARTD1!/! mice differentiated less effi-
ciently into mature adipocytes but were capable of
undergoing normal osteogenesis, thus confirming that
ARTD1 plays a lineage-specific role in ASC differentia-
tion. Further studies are needed to confirm the involve-
ment of PAR formation in adipogenesis and also its role
in the regulation of PPAR#2-dependent gene expres-
sion in WAT. The fact that three of the analyzed
inflammatory genes (IL-6, IL-10, and IL-12) were af-
fected by the ARTD1 deletion suggests a limited and
specific effect on only a subset of the genes expressed in
WAT in vivo. Interestingly, two macrophage-specific
genes (Pu.1 and MPEG 1) exhibited reduced mRNA
levels, alluding to a possible involvement of ARTD1 in
macrophage differentiation.
The results presented here point to a direct and
specific involvement of ARTD1 in adipogenesis in vivo.
However, other genes or compensatory mechanisms
seem to assure WAT formation in the absence of
ARTD1. Apart from this, our results suggest that
ARTD1 is required for efficient adipogenesis and that
ARTD1 ablation limits lipid storage in adipocytes, re-
stricts adipocyte size, and causes hepatic lipid deposi-
tion. It therefore appears that ARTD1 may regulate
adipocyte turnover and thereby indirectly affect adi-
pocyte number and the response to different nutri-
tional schemes. It will be interesting to investigate the
metabolism and the long-term effect of HFD on
ARTD1!/! mice. ARTD1 deficient mice may thus be-
come a useful model to study how adipocyte differen-
tiation and function affect pathological responses to
HFD and lead to diet-induced obesity.
Although the storage of excess energy in the form of
triglycerides and the release of FFAs is the principal
function of adipocytes (29), the liver is the organ of fatty
acid uptake, synthesis, and circulation and can therefore
be considered a hub of fatty acid metabolism (30). In
humans, components of the metabolic syndrome, such as
obesity, insulin resistance or dyslipidemia, are associated
with fatty liver syndrome, which is one characteristic of
NAFLD (31, 32). One consequence of NAFLD is an
excessive release of FFAs into the bloodstream, which
exacerbates peripheral insulin resistance. Our findings of
significantly increased hepatic lipid accumulation, ele-
vated serum cholesterol levels, and impaired glucose
tolerance in ARTD1!/! mice, despite the unaffected
insulin response, suggests that other lipid mediators or
related mechanisms, such as inflammation, may be re-
quired for the development insulin resistance. Alterna-
tively, it can be speculated that the hepatic insulin resis-
tance is compensated for during the whole-body insulin
resistance test. To explore insulin sensitivity more specif-
ically at the level of the liver, hyperinsulinemic-euglycemic
clamp studies could be employed, since the majority of
endogenously produced glucose comes from hepatocytes.
Currently, it is also not clear whether elevated cholesterol
levels are only a consequence of the changes in WAT or
whether they are also caused and exacerbated by the
ARTD1 deficiency in liver tissue, which might affect other
metabolic processes. Further studies using conditional
knockout mice with reduced expression of ARTD1 either
in WAT or liver would certainly provide additional in-
sights into this interdependency.
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Suppl. Figure S1. ARTD1 -/- mice on ND exhibit reduced expression of adipogenic 
gene markers in WAT. (A-E) ARTD1 -/- mice display comparable sensitivity with WT mice to 
GTT and ITTs. (A) Body weight (B) Food intake (C) Starving glucose levels of WT and ARTD1 -
/- mice. n=6 mice per group, mean ±SE. (D) Glucose tolerance test (GTT) measured after 14 h 
fasting WT and ARTD1 -/- mice. 6 weeks old mice were injected 0.75 g glucose per kg body 
weight. n = 5 mice per group, mean ±SE. (E) Insulin tolerance test (ITT) measured after 3 hr 
fasting WT and ARTD1 -/- mice. Mice were injected 0.75 U insulin per kg body weight n = 5 
mice per group, mean ±SE. (F) Western blot analysis of phosphorylated Akt (p-Akt) from 
muscle and WAT of insulin (0.75 U/kg, 10 min) injected WT and ARTD1 -/- mice (14 h fast). 
 
Suppl. Figure S2. PPAR! and PPAR! - dependent gene expression in WAT from 
ARTD1 -/- mice on HFD. Real-time RT-PCR analysis in total cell extracts from epididymal 
WAT of WT and ARTD1 -/- mice that were fed with HFD. mRNA levels were normalized with 
Cyclophilin A. Results represent mean ±SD of technical replicates. 
 
Suppl. Figure S3. Osteogenic differentiation of ASCs is not adversely affected by 
ARTD1 deletion. Analysis of osteogenic differentiation in ASCs isolated from wild type (WT) 
and ARTD1-/- mice. (A) The expression level of osteopontin (Spp1) was evaluated by qRT-PCR 
over 0, 3, 7 and 14 days of osteogenic differentiation. The expression value of each gene was 
normalized to the amount of ribosomal protein S12 (RPS12) RNA in order to calculate relative 
amounts of mRNA. (B) Mineral deposition was identified in mouse ASCs by Alizarin red S 
staining (red) at various stages during osteogenic differentiation. (C) The effect of ARTD1 
inhibition on the osteogenic differentiation of ASCs isolated from WT mice was evaluated after 
14 days using Alizarin red S staining. *P < 0.05, **P < 0.01. 
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Supplemental table S1. Primers used for real-time RT-PCR analyses.  
The sequences of forward (F) and reverse (R) primers used for PCR are given in 5`-3`direction. 
Gene  Sequence (F, R; 5`-3`) 
aP2 F: ATGGGTGAAACTCTGGGAGATTCT 
R: CTTGGAGCTTCAGGTCATATTTGTA 
Arginase 1 F: CAGAAGAATGGAAGAGTCAG 
R: CAGATATGCAGGGAGTCACC 
ATGL F: TGTGGCCTCATTCCTCCTAC 
R: TCGTGGATGTTGGTGGAGCT 
CD36 F: ACAACAGGGTTTCAGCAGAAAGAGG 
R: GGTCTCTGACACCTGAGCCAAATG 
Cyclophilin A F: TCACCATTTCCGACTGTGGA 
R: AATGCCCGCAAGTCAAAAGA 
HSL F: GCTGGGCTGTCAAGCACTGT 
R: GTAACTGGGTAGGCTGCCAT 
IL-10 F: GCTCTTACTGACTGGCATGAG 
R: CGCAGCTCTAGGAGCATGTG 
IL-12 F: GAAGTTCAACATCAAGAGCAGTAG 
R: AGGGAGAAGTAGGAATGGGG 
IL-13ra F: TGCTGCTACTGTGGACCGCCA 
R: CCTTCAGGAGGACTCCACGTCCA 
IL-1! F: AAGGAGAACCAAGCAACGACAAAA 
R: TGGGGAACTCTGCAGACTCAAACT 
IL-6 F: CTGCAAGAGACTTCCATCCAGTT 
R: GAAGTAGGGAAGGCCGTGG 
IP-10 F: GCACGAACTTAACCACCATCTTCC 
R: CTACCCATTGATACATACTTGATGACAC 
Lipin F: AGCGCCAAAGAATAACCTGG 
R: TGAAGACTCGCTGTGAATGG 
LPL F: AGGACCCCTGAAGACAC 
R: GGCACCCAACTCTCATA 
MCP-1 F: TTAAAAACCTGGATCGAACCAA 
R: GCATTAGCTTCAGATTTACGGGT 
MPEG-1 F: GTGAAACAAAAGCCAGACAGAGCCT 
R: TCATGGCGCAGATGGTTTTGGC 
PPAR" F: CGGGAAAGACCAGCAACAAC 
R: TGGCAGCAGTGGAAGAATCG 
PPAR#2 F: ATGGGTGAAACTCTGGGAGATTCT 
R: CTTGGAGCTTCAGGTCATATTTGTA 
Pu.1 F: GATCCGCCTTGATCCCCACCG 
R: TCTCCATCGCTGCCCACGAA 
SAA3 F: TGCCATCATTCTTTGCATCTTGA 
R: CCGTGAACTTCTGAACAGCCT 
aP2 Mm00445878_m1 
ARTD1 Mm01321084_m1 
GLUT4 Mm00436615_m1 
PPAR#2 Mm00440940_m1 
RPS12 Mm00488728_m1 
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Mammalian high temperature requirement serine 
protease A1 (HTRA1) belongs to a well-defined 
group of serine proteases originally identified in 
bacteria [1, 2]. They share many common 
features including a highly conserved trypsin-
like serine protease domain and at least one PDZ 
domain at the C-terminus. To date, four HTRA1 
family members have been identified and are 
termed HTRA1, -2, -3, and -4. HTRA2 is the 
best characterized of the four and exists as a 
membrane protein primarily involved in 
mitochondrial quality control [2, 3]. Both 
HTRA1 and -2 are primarily regarded as being 
key regulators of tumor development and 
subsequent malignancies [4-6], although a 
growing body of evidence now exists to suggest 
that HTRA1 may also play a central role in 
musculoskeletal development and disease 
through its proteolytic actions on proteins within 
the extracellular matrix (ECM) [7-10]. 
The skeletal ECM is a structurally dynamic 
scaffold which provides a well organized 
framework for mineralization and orchestrates 
many of the cellular processes required for 
maintaining bone integrity. The bone tissue 
ECM comprises of 70-90% mineral and 10-30% 
protein, the major proportion of which being 
glycoproteins such as collagen, fibronectin, and 
non-collagenous small integrin-binding ligand, 
N-linked glycoproteins (SIBLINGs) >11@. A 
direct interaction between these proteins and 
bone progenitor cells is essential for the 
development of a mineralized matrix [12-14]. 
Furthermore, degradation of specific 
glycoproteins within the ECM by serine 
proteases is also thought to play a central role in 
controlling mineral deposition by osteoblasts 
>15@.
Bone remodeling and regeneration is a strictly 
regulated process, being reliant on the activities 
of resident osteoblasts originating from bone 
marrow-derived mesenchymal stem cells 
(BMSCs) through the process of osteogenic 
differentiation >16@. Osteogenesis is governed by 
a complex series of well orchestrated events 
involving numerous different transcription 
factors, signaling pathways and growth factors 
>17, 18@. The potential involvement of HTRA1 
in osteogenesis and bone development has 
already been alluded to in studies examining the 
expression profile of !"#$% in developing 
mouse embryos and adult mouse bone where it 
was identified in osteocytes and osteoblasts 
within the bone matrix >10, 19@. More recently, it 
was suggested that HTRA1 may actually play a 
negative role in bone and mineral development 
through its ability to inhibit osteoblastic 
differentiation in the mouse 2T3 cell line >20@.
However, no studies have yet sought to 
determine the influence of HTRA1 on the 
osteogenic differentiation potential of MSCs. 
In the present study, we examined the effects of 
recombinant HTRA1 on the osteogenesis of 
human BMSCs (hBMSCs) and matrix 
mineralization by differentiating bone-forming 
cells with an aim to establishing a role for 
HTRA1 in bone formation. Our results 
demonstrate that HTRA1 is an essential 
requirement for osteogenesis and that its effects 
are mediated primarily through its proteolytic 
actions on ECM proteins. 
)*#+$!*,-.*"&.)+#/%&-
)01234056
4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) was from Sigma-
Aldrich. Recombinant IBSP was purchased from 
R & D Systems (Abingdon, UK). Monoclonal 
mouse anti-IBSP, C-terminal region (clone 
ID1.2) and polyclonal donkey anti-collagen type 
1 were from LabForce (Switzerland), polyclonal 
rabbit anti-IBSP, N-terminal region was from 
Enzo Life Sciences (Lausen, Switzerland), and 
polyclonal rabbit anti-HTRA1 was generated as 
previously described >9@. The biotinylated 
polyclonal swine anti-rabbit IgG was from 
DAKO. All anti-IgG horseradish peroxidase 
(HRP)-conjugated and fluorescence-conjugated 
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secondary antibodies were from Jackson 
ImmunoResearch (Suffolk, UK). 
!"#$%&'
Experiments were performed using 5-month-old 
senescence accelerated resistant mice (SAMR1) 
(n = 27) (Harlan, Netherlands). All animal 
research procedures were approved by the 
Animal Experimentation Committee of the 
Veterinary Office of the Canton of Zürich, 
Switzerland (Project License 140/2005 and 
151/2010), and followed the guidelines of the 
Swiss Federal Veterinary Office for the use and 
care of laboratory animals. 
()&&*(+&,+-)*
Mouse ASCs were isolated from the inguinal fat 
pads of SAMR1 mice (n = 4) and purity 
confirmed by fluorescence activated cell sorting 
(Sca1, 98%; CD29, 100%; CD105, 42%; CD34, 
5%; CD45, 0.5%) as previously reported >21@.
Mouse ESCs (E14 129/Ola) are a well-
established cell line and were maintained as 
previously described >22, 23@. Human BMSCs 
were obtained from Lonza Verviers (Belgium) 
and were confirmed as being positive for 
CD105, CD166, CD44 and CD26, and negative 
for CD14, CD34 and CD45 as stated by the 
manufacturer. Cells were maintained in normal 
growth medium consisting of Dulbecco’s 
modified eagle medium (DMEM-low glucose, 
with Glutamax) (Invitrogen AG, Basel, 
Switzerland), supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen AG, Basel, 
Switzerland) and penicillin (50 units/ml) and 
streptomycin (50 ȝg/ml) (Invitrogen AG, Basel). 
Cells were used between passage 2 and 6 unless 
otherwise stated. In some cases, hBMSCs 
undergoing osteogenic differentiation were 
treated with recombinant active or inactive 
HTRA1 (5 Pg/ml) for up to 18 days. For 
protease inhibition studies, AEBSF (20 Pg/ml) 
was also included where indicated. For 3D-
spheroids, mASCs were cultured in 25 Pl
hanging drops in in normal growth medium as 
described above, using Terasaki plates (VWR, 
Switzerland) at 2,500 cells/drop. 
."/+0,#1"*%"/*!"%&2'#'*13*4#33)-)",#%,#1"*
Well established differentiation protocols were 
used to induce and analyze either osteogenesis or 
adipogenesis in mASCs and E14 129/Ola cells 
>21@ and hBMSCs >24@. For differentiation 
assays, a starting density of 5’000 and 10’000 
cells/cm2 was used for human and mouse cells 
respectively. For osteogenic 3D-spheroid 
preparations, mASCs were pre-differentiated in 
2D cultures for 3 days and cultured in hanging 
drops containing osteogenic culture medium for 
a further 2, 4 or 6 days, after which time they 
were harvested and processed for histological 
analysis using previously described techniques 
>25@. Mineralization induced by osteogenic 
differentiation was identified using Alizarin Red 
S (Sigma-Aldrich). Adipocyte formation was 
confirmed by positive staining for oil red O 
(Sigma-Aldrich). Differentiation markers 
specific to either osteogenesis or adipogenesis 
were also quantified by reverse-transcription 
polymerase chain reaction (qRT-PCR) using 
TaqMan Gene Expression Assays (Applied 
Biosystems) (Supplementary Table 1). Total 
RNA was harvested from cells at given time 
points during differentiation and 0.5Pg total 
RNA reverse-transcribed using Superscript II 
(Life Technologies) and an equivalent of 10ng 
total RNA applied as cDNA template in the 
successive qRT-PCR reaction using the 
StepOnePlus (Life Technologies). 
5)01$6#"%",*785!9*:-1/+0,#1"*
Purified recombinant active HTRA1 
(HTRA1'mac) and inactive HTRA1 
(HTRA1'macSA), were produced in 
!"#$%&'#$'() #*+' and purified using metal-
affinity chromatography as previously described 
>26@.
;4;<:!=>*%"/*?)',)-"*@&1,,#"A*
Protein was analyzed by SDS-PAGE using 4-
15% precast Tris-HCl gels (BioRad) under 
reducing conditions and electroblotted onto 
PVDF membranes using the Trans-Blot Turbo 
blotting system (BioRad). IBSP was identified 
using antibodies raised against either the N-
terminal (1:800) or C-terminal (1:500) regions of 
Results 
  84 
 
 
 
 
 
 
Regulation of Osteogenesis by HTRA1 
4
human IBSP and detected using HRP-conjugated 
secondary antibodies (1:10’000) followed by 
incubation in SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) and 
exposure to x-ray film.. 
!""#$%&'#%()*+)$+),
Cells in either 2D or 3D cultures were fixed in 
PBS buffered formaldehyde (4%) or ice cold 
methanol, blocked with normal goat serum 
(1:10) and incubated with polyclonal rabbit anti-
HTRA1 (1:50), polyclonal donkey anti-collagen 
type 1 (1:50) or monoclonal mouse anti-IBSP 
(1:50) in phosphate buffered saline (PBS) 
containing 1% BSA overnight at 4oC. For 
paraffin wax sections, staining reactions were 
performed at 37oC for 1 h. In the case of double 
immunostaining procedures, samples were 
incubated with both polyclonal rabbit anti-
HTRA1 (1:50) and monoclonal mouse anti-IBSP 
(1:50) using the conditions described above. 
Samples were then washed and incubated with 
either goat anti-rabbit-Cy3 (1:400), goat anti-
donkey-Cy3 (1:400), or goat anti-mouse-Cy5 
(1:400) for 1 hour and mounted in DAPI 
containing mounting solution and images 
captured using the Leica DMI6000B automated 
inverted research microscope system (Leica 
Microsystems). 
Immunohistochemistry. Dewaxed paraffin 
sections (8 Pm) were rehydrated and blocked 
with normal swine serum (DAKO) for 30 min. 
Sections were then incubated with polyclonal 
rabbit anti-HTRA1 (1:50) for 1 h at 37oC.
Sections were then washed in PBS and incubated 
with biotinylated swine anti-rabbit IgG (1:500) 
for 1 h at room temperature followed by washing 
and a further incubation for 30 min with 
Vectastain (Vectorlabs). Sections were then 
developed using 3,3' diaminobenzidine 
tetrahydrochloride (DAB), counterstained with 
Harris’ Hematoxylin and mounted in DPX. 
-(%.)%'/.0+,1$2/"),3**4/*,
Degradation of IBSP by HTRA1 was determined 
using methods previously described >9@. Briefly, 
HTRA1 (45 nM) and IBSP (476 nM) were 
incubated in 50 mM Tris-HCl, pH 8.5, 150 mM 
NaCl for up to 24 h at 37 °C. In some reactions, 
active HTRA1 was replaced by proteolytically 
inactive HTRA1. Proteins were separated on a 4-
15% SDS-PAGE gel and analysed by Western 
blot as described above. The proteolytic activity 
of HTRA1 was also investigated in hBMSC 
cultures using immunofluorescence staining. 
Cells were incubated in osteogenic induction 
medium either without or with active or inactive 
HTRA1 (5 Pg/ml), fixed in methanol and IBSP 
or collagen type 1 detected with specific 
antibodies using methods as described above. 
56738,19!:3,
The HTRA1 ELISA was performed using 
HTRA1 specific monoclonal and polyclonal 
antibodies as previously described >9@.
!"#$%,*07;3,
Specific knock down of !"#$% expression was 
performed with Silencer Select siRNA oligos, 
(Ambion, Life Technologies) according to the 
manufacturer’s protocol. Human BMSCs (1x105
cells) were transfected with 100 nM !"#$%-
specific (s11279, s11280) or negative control 
siRNA (Negative Control-1) using the NEON 
Transfection System (Life Technologies). 
Following transfection, cells were seeded in cell 
culture plates with fresh growth medium 
(without antibiotics) and incubated for 24 h at 
37°C, 5% CO2. Medium was then replaced with 
either fresh growth medium or differentiation 
medium and total RNA and supernatants 
harvested at selected time points for further 
analysis. 
<(4+.#(),=%>)',
A rigidly stabilized, unilateral mid diaphyseal 
osteotomy gap was created in the femurs of 
SAMR1 mice (n = 5-6 per time point) using a 
0.22mm gigli saw as previously described >24@.
The immunohistochemical and 
immunofluorescence techniques described above 
were used to detect both HTRA1 and IBSP 
protein in decalcified paraffin wax sections 
(8Pm) from mouse femora at various stages of 
repair (n = 3 per time point). 
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All statistical analyses were carried out using 
SPSS18.0 (SPSS Inc., Chicago, IL). Parametric 
analysis of normally distributed data was 
performed using the two-tailed unpaired 
Student’s !-test for comparison of two groups or 
one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc test for multiple 
group comparisons. The sample size used in 
each study was based upon the observed level of 
variation between individual experiments and the 
need for sufficient sample numbers to allow for 
accurate statistical analyses. In all cases, a "-
value of < 0.05 was considered statistically 
significant, and all data were expressed as mean 
r standard deviation (S.D). 
,-!./0!
10,)2(34567&"$5*($%(.849:7'#"96(;74$*:(
<%"95:9*$&(=*67&"$5*(5>(?!@%(
Differentiation studies conducted using hBMSCs 
demonstrated a small, but significant increase in 
the expression of #$%&' during the early phases 
of osteogenic induction with a greater than 1.5-
fold (" < 0.01) increase in gene expression being 
attained by day 14 (Fig. 1A). However, unlike 
#$%&', expression levels of the closely related 
HTRA family member, #$%&(, decreased 
during osteogenesis and remained significantly 
downregulated throughout the course of the 
study. The early induction of #$%&' gene 
expression was accompanied by significant 
increases in the expression of the well-known 
osteogenic markers runt-related transcription 
factor 2 (%)*+,), alkaline phosphatase (&-.), 
integrin-binding sialoprotein (/01.) and 
Collagen type 1A1 (23-'&) (Fig. 1A). The 
expression level of the late osteogenic marker 
secreted phosphoprotein 1/osteopontin (1..')
was actually downregulated during early 
osteogenesis, but became significantly increased 
during the late phase of osteogenesis at day 21, 
along with noticeable increases in mineralized 
matrix deposition beginning at day 10 as 
determined by alizarin red staining (Fig. 1B). As 
HTRA1 functions primarily as a secreted 
protease, we also investigated the effect of 
osteogenic differentiation on HTRA1 protein 
secretion from hBMSCs using an HTRA1 
specific ELISA and immunofluorescence 
staining. In accordance with increases in its gene 
expression, secreted HTRA1 protein levels were 
also elevated in both the supernatant (Fig. 1C) 
and in the cell matrices (Fig. 1D) of hBMSC 
cultures undergoing osteogenic differentiation. 
Clearly therefore, induction of osteogenesis in 
hBMSCs has a major stimulatory effect on 
HTRA1 production resulting in both enhanced 
gene expression as well as protein secretion. 
In order to investigate whether such effects were 
limited to adult human stem cells only, we 
extended these studies to include both mouse 
embryonic stem cells (mESCs) and mouse 
adipose-derived stromal cells (mASCs). #!4&'
expression was also significantly upregulated in 
a time dependent manner in mESCs (Fig. 2A) 
and mASCs grown in either 2D- (Fig. 2B) or 
3D- (Fig. 2C) culture systems in response to 
osteogenic stimuli. These increases in #!4&'
expression were associated with mineralization 
of differentiating bone-forming cells derived 
from 2D-culutres of either mESCs (Fig. 2D) or 
mASCs (Fig. 2E), as well as 3D-cultures 
composed of osteogenic mASCs (Fig. 2F). 
Furthermore, immunofluorescence staining of 
paraffin wax sections from mASC 3D-spheroids 
identified HtrA1 protein in tissues undergoing 
mineralization, but not in uninduced controls 
(Fig. 2G), thus giving a first hint as to its role in 
stem cell osteogenesis. 
!$'9*&$*:(5>("A9(!"#$%(B9*9(=C8#$4%(
AD?!@(<%"95:9*9%$%(#*6(-*A#*&9%(
)6$85:9*9%$%
In order to investigate the role of #$%&' gene 
expression in the regulation of osteogenesis, we 
next performed loss of function studies by means 
of RNA interference in hBMSC cultures. The 
transfection of hBMSCs with small interfering 
RNA (siRNA) specific for #$%&' prior to 
osteogenic induction, resulted in a significant
downregulation of #$%&' gene expression (Fig. 
3A) and HTRA1 protein secretion (Fig. 3B) 
which was sustained throughout the first 2 weeks 
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of osteogenic differentiation. HTRA1 protein 
levels both within cells and the ECM were also 
markedly reduced (Supplementary Fig. 1). This 
was accompanied by a noticeable reduction in 
alizarin red staining at day 14, indicative of 
reduced mineral deposition in differentiating 
bone-forming cells (Fig. 3C). Biochemical 
analysis using the ALP activity assay revealed 
that these deficits in mineralization were 
accompanied by significant reductions in ALP 
protein activity, which were maintained for up to 
14 days (Fig. 3D). Furthermore, !"# expression 
was also significantly downregulated in these 
cells at an early time point, although expression 
levels of the osteogenic markers $##% and 
&'()* were not significantly affected by 
+,&!% silencing (Fig. 3E). 
Through the course of our studies, it became 
apparent that not only was osteogenesis reduced 
in hBMSCs following +,&!% gene silencing, 
but that adipogenesis appeared to actually be 
increased. Evidence of this was first realized in 
late-stage osteogenic cultures of hBMSC treated 
with +,&!% siRNA, where phase contrast 
microscopy revealed increased numbers of cells 
containing lipid droplets, reminiscent of mature 
adipocytes although control siRNA cultures 
continued to demonstrate matrix mineralization 
(Fig. 3F). In order to confirm this finding, 
hBMSCs transfected with either +,&!% siRNA 
or control siRNA were induced to undergo 
adipogenic differentiation and adipogenic gene 
expression measured by qRT-PCR (Fig. 3G) and 
triglyceride accumulation visualized by oil red O 
staining (Fig. 3H). As anticipated, silencing of 
the +,&!% gene greatly enhanced the number of 
oil red O positive cells present with the hBMSC 
culture and significantly enhanced the expression 
of specific adipogenic gene markers, peroxisome 
proliferator-activated receptor gamma 2
(##!&-*) and fatty acid binding protein 4 
(.!/#0), thereby supporting a differential role 
for HTRA1 in hBMSC lineage commitment. 
!"#$%&'()(*+,-!./+01$*"'(+2(3)(#"4+
35678+94*"$:"("4'4+
As previously mentioned, HTRA1 also exists as 
a secreted protease and thus, may have an 
extracellular role in the osteogenic 
differentiation of hBMSCs. We therefore next 
investigated whether exogenously added 
recombinant human HTRA1 protein could also 
influence osteogenic differentiation. hBMSCs 
undergoing osteogenic differentiation were 
initially treated every three days with either 
active or inactive HTRA1 for up to 14 days and 
mineralization determined by Alizarin red 
staining. Indeed, mineral deposition by 
differentiating bone-forming cells was greatly 
enhanced following stimulation with active, but 
not inactive, HTRA1 (Fig. 4B). Additional 
studies confirmed that these effects could be 
reproduced in late stage (day 10) cultures of 
osteogenic hBMSCs treated for only four days 
with HTRA1 (Fig. 4C). However, short term 
treatment with HTRA1 during the first week of 
osteogenic differentiation only, failed to elicit 
any noticeable increase in mineralization 
(Supplementary Fig. 2), thus implying that the 
stimulatory actions of HTRA1 were dependent 
not only on its protease activity, but also on the 
differentiation status of the cells. Further studies 
using the broad spectrum serine protease 
inhibitor, AEBSF, confirmed the stimulatory 
effects of HTRA1 to be dependent on its 
proteolytic activity (Fig. 4D). Although matrix 
mineralization was clearly enhanced in 
differentiating bone-forming cells treated with 
HTRA1, the expression of several well-known 
osteogenic markers including !"#, &'()* and 
$##% remained unaltered at the time point tested 
(day 10) (Fig. 4E). However, significant 
increases were observed in the expression levels 
of 1/$# and bone morphogenetic protein 5 
(/2#3). Furthermore, a significant decrease in 
the expression level of sclerostin ($4$,) was 
also observed in cells treated with HTRA1. 
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!"#$%&'"()'"*'"%+,'-./0&/#$'"+1!),23+
4$0&$5$"#5+-+6/7$.+894:;+,<=5#&-#$+><&'"%+
?5#$/%$"'@+>'AA$&$"#'-#'/"+/A+B,C5+!"#$!%&'D
In the current study, we demonstrated that 
although !"#$ expression was significantly 
enhanced in hBMSCs following the addition of 
HTRA1, IBSP protein was almost completely 
abolished from the cellular matrix of these 
cultures, an effect not observed with inactive 
HTRA1 (Fig. 5A). This was regarded as being 
specifically due to the HTRA1 protein added due 
to the fact that collagen Type 1, a proteoglycan 
not degraded by HTRA1 >20@, remained 
unaffected within the cell matrices 
(Supplementary Fig. 3). The potential for 
proteolytically active HTRA1 to degrade IBSP 
was further confirmed by %&'(%)*+ enzyme assays, 
where a noticeable reduction in recombinant 
human IBSP (476 nM) was evident after 8 hours 
incubation with HTRA1 (45 nM) as determined 
by Western blot analysis (Fig. 5B). We next 
utilized the mASC spheroid culture system to 
investigate whether endogenous HTRA1 protein 
could be localized to IBSP directly within 
differentiating MSCs. Paraffin wax sections of 
mASCs were stained for HTRA1 and IBSP at 
various stages of osteogenic differentiation, and 
overlays produced to determine whether HTRA1 
could be localized to areas of IBSP protein 
expression. IBSP was detected within mASC 
spheroids during the early phase of osteogenesis 
(day 5), although HTRA1 remained at very low 
levels and mineral deposition was not detected 
using Alizarin red staining (Fig. 5C, ,--.*'-/&.0
and Supplementary Fig. 4A). By day 9, levels of 
HTRA1 had greatly increased and it was 
regularly found co-localized with IBSP in the 
tissue matrix (Fig. 5C, 0+1.*'-/&.0). In addition, 
mineralization of differentiating bone-forming 
cells within 3D-spheroids was also apparent at 
this time point as identified by intense Alizarin 
red staining (Supplementary Fig. 4B). Sections 
incubated with isotype-matched IgG antibodies 
stained negative and served as controls 
(Supplementary Fig. 4C). 
E/@-.'F-#'/"+/A+894:;+-"*+!),2+#/+:&$-5+/A+
6$G+)/"$+H/&I-#'/"+'"+B'@$+
In order to assess the potential involvement of 
HTRA1 in the reparative process of bone tissue, 
we utilized a previously well-established mouse 
femur osteotomy model (Fig. 6A) >24@. HTRA1 
protein was identified in thin paraffin wax bone 
sections taken from mice at various stages of 
fracture repair using immunohistochemical 
staining. At day 7, early osteoid formation was 
observed within the bone marrow at the 
osteotomy site and was associated with intense 
staining for HTRA1 (Fig. 6B). At this time point, 
HTRA1 was also located within the cells and 
tissue of the overlying periosteal layer 
(Supplementary Fig. 5A). By day 14, the non-
mineralized callus had increased greatly in size 
with numerous HTRA1-positive fibroblast-like 
cells present throughout the tissue as well as in 
cells of the newly forming callus (Fig. 6C and 
Supplementary Fig. 5B). Large numbers of 
HTRA1-positive chondrocytes were also evident 
within intact lacunae, and represented the early 
stages of endochondral ossification. By day 28, a 
substantial proportion of the callus had been 
replaced by new bone and HTRA1 was now 
localized to specific areas of active bone 
formation (Fig. 6D) in association with cuboidal 
osteoblasts (Supplementary Fig. 5C). By day 42, 
the osteotomy gap was almost completely healed 
(Fig. 6E) and the bone resembled that of a non-
operative control femur (Fig. 6F). In both cases, 
HTRA1 was almost completely absent, being 
localized to only a small number of osteocytes 
within the bone matrix. 
Having confirmed that HTRA1 protein was 
indeed present within actively forming bone 
tissue, we conducted further investigations to 
determine whether HTRA1 could also be 
localized to IBSP within these bone sections, 
thus providing a potential mode of action for 
HTRA1 in the context of osteogenesis %&' (%(+.
Indeed, co-localization of HTRA1 and IBSP was 
identified in paraffin wax bone sections from 28 
day postoperative mice by double 
immunofluorescence staining, being confined to 
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areas previously identified as undergoing active 
regeneration (Fig. 7 and supplementary Fig. 6). 
!"#$%##"&'
A complex molecular network of signaling 
pathways and regulatory factors govern the 
osteogenesis of multipotent MSCs [17, 18, 27], 
being reliant on the activation and regulation of a 
number of key molecular targets including 
!"#$%&' ()*&' +**,' and' -.+* >28@. Although 
there have been significant advances in our 
understanding of the molecular mechanisms 
involved in controlling osteogenic 
differentiation, the influence of serine proteases 
on such processes remains relatively obscure. In 
the present study, we have shown for the first 
time that the serine protease HTRA1 is a positive 
regulator of MSC osteogenesis and its presence 
is required for the efficient mineralization of 
differentiating bone cells. 
The expression of /0!(, was upregulated in 
hBMSCs upon osteogenic induction and was 
associated with significant increases in the levels 
of its secreted protein product. Furthermore, 
HTRA1 production increased in a time 
dependent manner throughout the course of 
osteogenic differentiation, and was closely 
associated with the appearance of mineralized 
matrix. Interestingly, expression levels of the 
closely related HTRA family member, /0!(1,
were actually downregulated during 
osteogenesis. This was of particular interest as 
HTRA1 and HTRA3 are considered to have 
over-lapping functions due to close structural 
similarities >29@. It may well be therefore, that 
HTRA1 and HTRA3 play differential roles in 
mediating the osteogenesis of hBMSCs. This 
pattern of HTRA1 production during 
osteogenesis of hBMSCs was recapitulated in 
cultures composed of either mASCs or mESCs, 
where significant increases in /23(, expression 
coincided with the appearance of HtrA1 protein 
and mineralized matrix. Although previous 
investigations have alluded to the involvement of 
HTRA1 in mouse osteogenesis >19, 20@, our 
study is the first to report the potential role of 
HTRA1 in human osteogenesis. Based on earlier 
reports of HTRA1 imparting a negative 
influence over mineral deposition by murine 2T3 
osteoblasts >20@, initial expectations were for 
HTRA1 to inhibit osteogenesis of hBMSCs and 
thus prevent mineralization of differentiating 
human bone-forming cells. On the contrary, we 
found that siRNA-induced loss of HTRA1 
function in hBMSCs, effectively suppressed the 
stimulatory effects of osteogenic culture medium 
on ()* expression and intracellular ALP protein 
activity by hBMSCs, as well as the formation of 
a mineralized matrix. Although ()* expression 
levels were compromised in cells lacking 
/0!(,, some of the key regulatory factors 
involved in osteogenesis, including !"#$% and 
+**,, remained intact. It is possible therefore 
that HTRA1 mediates its effects through specific 
pathways, independent of these particular 
elements. In addition to its effects on 
osteogenesis, /0!(, silencing had a profound 
effect on hBMSC adipogenesis as evidenced by 
increases in adipogenic gene expression and oil 
droplet formation. Such observations would 
suggest that HTRA1 may in fact represent a 
decisive factor in determining stem cell lineage 
commitment and that its involvement in stem 
cell differentiation go somewhat beyond it 
simply being a mediator of osteoblast formation. 
Further investigations into the role of HTRA1 in 
other differentiation pathways, such as 
chondrogenesis, myogenesis or even 
tenogenesis, would therefore represent a logical 
progression of these studies and may hold 
particular relevance with regards to the 
involvement of HTRA1 in musculoskeletal 
development as has previously been inferred 
>19@.
Based on the fact that HTRA1 is a secreted 
serine protease, we next directed our attention to 
the possible influence of HTRA1 on hBMSC 
osteogenesis by way of its extracellular effects. 
A specific role for HTRA1 in the osteogenesis of 
hBMSCs and mineralization of differentiating 
bone-forming cells was confirmed in studies 
using both proteolytically active and inactive 
recombinant forms of human HTRA1, as well 
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the broad spectrum serine protease inhibitor 
AEBSF. An increase in mineralized matrix 
formation was observed in cells treated with 
active HTRA1 only, and was dependent on 
HTRA1 being present during the initiation phase 
of mineralization, as short duration treatments 
prior to the onset of mineralization proved 
ineffective. This would therefore infer that the 
stimulatory effects of exogenously added 
HTRA1 protein on hBMSC osteogenesis and 
mineralization of differentiating bone-forming 
cells may be reliant on its ability to regulate 
factors present within the actively mineralizing 
ECM. In addition to its ability to affect ECM 
mineral content, HTRA1 also induced a 
significant upregulation in the expression of 
several positive regulators of mineralization, 
including !"#$ and %!&# >30, 31@' although a 
large proportion of well-known osteogenic genes 
such as ()*+,, -.#, and &##/ remained 
unaffected. In addition, the expression level of a 
potent negative-regulator of mineral formation, 
sclerostin/&0&1 >32, 33@, was markedly 
downregulated in hBMSCs treated with HTRA1 
and may thus represent an additional mechanism 
by which mineral deposition is enhanced in 
differentiating bone-forming cells. It is possible 
therefore, that the effects of HTRA1 protein on 
hBMSC mineralization may be mediated 
indirectly through its ability to modulate the 
production of both activators and inhibitors of 
osteogenic differentiation and/or mineralization. 
These results are in stark contrast to the findings 
presented in a previous report by Hadfield et al 
>20@, where HTRA1 was shown to impart a 
negative influence over mineralized matrix 
formation by mouse 2T3 osteoblasts. One 
possible explanation may lie within the fact that 
2T3 cells are derived from transgenic mice 
overexpressing the simian virus 40 (SV40) T 
antigen and as such, are immortalized >34@. The 
fact that 21(-/ gene expression is known to be 
significantly affected in SV40 transformed cells 
>35@, would imply that modifications of the 
osteogenic status of these cells brought about by 
changes in HTRA1 expression and activity, may 
not be truly representative of non-immortalized, 
primary cells. Further studies aimed at 
determining the effects of 234-/ gene silencing 
or exogenously added recombinant HTRA1 on 
primary mASC osteogenesis, may help to clarify 
this point. 
Of the osteogenic genes that were regulated by 
HTRA1, %!&# held particular relevance to the 
current study due to the fact that its ability to 
regulate mineral deposition has previously been 
reported to be dependent on the actions of serine 
proteases >15@. Attention was therefore focused 
on IBSP and its potential involvement in 
mediating the effects of HTRA1 on both 
osteogenesis of MSCs and mineralization of 
differentiating bone-forming cells. IBSP belongs 
to the family of SIBLING proteins which also 
includes osteopontin, dentin matrix protein 1 
(DMP1), dentin siaolophosphoprotein (DSPP) 
and matrix extracellular phosphoglycoprotein 
(MEPE) >36@. IBSP, along with other SIBLING 
proteins, is found almost exclusively in bone and 
dentin and is a major constituent of the 
mineralizing matrix during new bone formation 
>37-39@. The primary biological function of IBSP 
is unclear, although it has been reported to be 
involved in the initiation of matrix 
mineralization through the nucleation of 
hydroxyapatite crystals >40, 41@. Furthermore, it 
has been proposed that IBSP is required to 
undergo fragmentation, possibly through the 
actions of serine proteases, in order to allow for 
efficient matrix mineralization >15, 42, 43@. In 
the current report, we were able to demonstrate 
co-localization of HTRA1 and IBSP in osteo-
induced mASC spheroid cultures, thus 
confirming the potential for endogenous HTRA1 
to interact with IBSP under osteogenic culture 
conditions. Additional immunofluorescence 
analyses of hBMSCs treated with exogenous 
HTRA1 revealed that this interaction most likely 
resulted in the digestion and subsequent removal 
of IBSP protein from the mineralizing matrix. 
These results would therefore suggest that the 
stimulatory effects of secreted HTRA1 protein 
on matrix mineralization 56785349 are mediated, at 
least in part, through its proteolytic actions on 
IBSP within the ECM. The potential for 
HTRA1-induced IBSP proteolysis was further 
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confirmed by Western bot analysis where 
proteolytically active HTRA1 effectively 
digested recombinant human IBSP protein at 
equivalent concentrations to those used in the 
cell culture studies. However, despite us using 
two different antibodies raised against either the 
N- or C-terminal regions of IBSP, we were 
unable to detect any HTRA1 digest fragments. 
This was somewhat unexpected, as findings from 
previous studies suggest that IBSP fragmentation 
plays an important role in its function as an 
instigator of mineral nodule formation >15@. This 
is based on the assumption that IBSP facilitates 
mineralization predominantly through its ability 
to bind and nucleate hydroxyapatite, although 
evidence exists to suggest that both intact and 
fragmented IBSP can also inhibit hydroxyapatite 
seeded crystal growth >44@. It is possible 
therefore that HTRA1 contributes to 
osteogenesis through the controlled turnover of 
IBSP within the mineralizing ECM. This is 
further supported by the observation that !"#$
gene expression is upregulated by exogenous 
HTRA1 at the expense of its protein product, and 
may thus constitute a novel feedback mechanism 
through which HTRA1 regulates matrix 
mineralization. 
The osteogenic differentiation of BMSCs 
towards mature bone-forming osteoblasts is a 
critical step in the development and repair of 
bone tissue. In the present study, we utilized a 
previously well-established mouse osteotomy 
model to investigate the expression of HTRA1 
protein during bone healing. 
Immunohistochemical analysis identified high 
levels of HTRA1 protein within areas of active 
bone formation at various stages of bone repair 
although no positive staining was observed in 
tissue sections from intact bone, thus confirming 
it to be primarily involved in %&' ()*) bone 
formation. Furthermore, strong positive staining 
for HTRA1 was also evident in callus tissue 
harboring large numbers of chondrocytes, and is 
thus suggestive of its role in both chondrogenesis 
and endochondral ossification. Such findings 
could be of significant importance to fracture 
healing and possibly even cartilage formation, 
and as such, warrant further investigation. 
Immunofluorescence analysis of these sections 
revealed a close association of HTRA1 with 
IBSP in areas considered to be undergoing active 
bone regeneration. This lends support to the 
theory that HTRA1 regulates both osteogenesis 
of MSCs and mineralization of differentiating 
bone-forming cells through its interactions with 
IBSP, although it doesn’t exclude the possibility 
that HTRA1 mediates its actions through the 
proteolytic processing of other SIBLING 
members >45-48@.
!"##$%&
The findings from this study therefore implicate 
HTRA1 as a positive regulator of both 
osteogenesis of MSCs and mineralization of 
differentiating bone-forming cells, possibly at 
the expense of adipogenic differentiation. Based 
on these properties, HTRA1 may be deemed a 
key factor in determining the outcome of 
diseases such as age-related osteoporosis, where 
impaired BMSC osteogenesis and upregulated 
adipogenesis is believed to be a major 
contributor to the underlying pathology >24, 49@.
$'()*+,-./#-)0!
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!"#$%&'() The expression and secretion of HTRA1 is significantly enhanced in hBMSCs undergoing 
osteogenic differentiation. *+,- Quantitative polymerase chain reaction analysis of genes regulated 
during osteogenic differentiation of hBMSCs. Data were normalized to !"#$ and expressed as fold 
change as compared to non-induced controls at day 0 (value 1) using the comparative %T method. Data 
are representative of two independent experiments performed in triplicate r S.D. * & < 0.05, ** & < 
0.01 as determined by 1-way ANOVA. *.,- Representative images of Alizarin red stained hBMSC 
cultures at various time points following osteogenic induction. Scale bar = 2 mm. */,- Secretion of 
HTRA1 by hBMSCs during osteogenic differentiation as determined by HTRA1-specific ELISA (' = 
4). * & < 0.05, ** & < 0.01 as determined by 1-way ANOVA. *0,- Representative fluorescence images 
of anti-HTRA1 (red) and DAPI (blue) stained hBMSCs undergoing osteogenic differentiation. Scale 
bar = 25 Pm. Abbreviations: HTRA1, high temperature requirement protease A1; hBMSCs, human 
bone marrow-derived mesenchymal stem cells; !"#$, beta glucuronidase; ELISA, enzyme-linked 
immunosorbent assay; ECM, extracellular matrix; DAPI, 4,6-diamidino-2-phenylindole. 
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!"#$%&'() !"#$% gene expression is significantly increased in osteogenic mESCs and mASCs. *+,-./
!"#$% gene expression during osteogenic differentiation of mESCs (A), mASCs (B) and mASC 
spheroids (day 7) (C) was determined by quantitative polymerase chain reaction and data normalized 
to &#'(%) and expressed as fold change as compared to non-induced controls (Day 0 and control; 
value 1) using the comparative *T method. Data are representative of at least two independent 
experiments performed in triplicate r S.D. * ' < 0.05, ** ' < 0.01 as determined by 1-way ANOVA. 
*0,1./ Representative images of Alizarin red stained mESCs (D) and mASCs (E) at various time 
points following osteogenic induction. Scale bar = 5 mm. *!./ Representative images of Alizarin red 
and fast green stained paraffin wax sections of mASC spheroids incubated without (control) or with 
osteogenic media (osteogenic) for 7 days. Scale bar = 100 Pm. *2./ Representative 
immunofluorescence images of HTRA1 (red) and DAPI (blue) in paraffin wax sections of osteogenic 
mASC spheroids incubated without (control) or with osteogenic media (osteogenic) for 7 days. Scale 
bar = 25 Pm. Abbreviations: HTRA1, high temperature requirement protease A1; mESCs, mouse 
embryonic stem cells; mASCs, mouse adipose-derived stromal cells; +,-., beta glucuronidase; 
DAPI, 4,6-diamidino-2-phenylindole. 
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!"#$%&' () Repression of !"#$% gene expression alters lineage commitment of differentiating 
hBMSCs. *+,- Quantitative polymerase chain reaction analysis of !"#$% gene expression in hBMSCs 
transfected with !"#$% siRNAs (siRNA (H1) or (H2)) or control siRNA (siRNA (C)) at 3 and 10 
days post-osteogenic induction. Data was normalized to &'() and expressed as fold change (Log10 
scale) as compared to cells transfected with control siRNA using the comparative *T method. * + < 
0.01 as determined by 1-way ANOVA. n = 3 separate experiments, r S.D. *.,- ELISA measurement 
of secreted HTRA1 from hBMSCs transfected with !"#$% siRNAs or control siRNA at various time 
points post-osteogenic induction. * + < 0.01 as determined by 1-way ANOVA. n = 3 separate 
experiments, r S.D. */,-' Representative images of Alizarin red stained hBMSCs transfected with 
!"#$% siRNAs or control siRNA at 14 days post-osteogenic induction. *0,- ALP activity in protein 
lysates from hBMSC transfected with !"#$% siRNA or control siRNA at various time points post-
osteogenic induction. * + < 0.01 as determined by 1-way ANOVA. n = 3 separate experiments, r S.D. 
(E): Quantitative polymerase chain reaction analysis of $,-./ (--%/ 012/#'345 gene expression in 
hBMSCs transfected with !"#$% siRNA or control siRNA at 3 and 10 days post-osteogenic 
induction. Data was normalized to &'() and expressed as fold change as compared to cells 
transfected with a control siRNA (value 1) using the comparative *T method. n = 3 separate 
experiments, r S.D. *!,-' Representative phase contrast micrographs of hBMSCs transfected with 
control siRNA or !"#$% siRNA at 14 days post-osteogenic induction. $66789, mineral deposits. Scale 
bar = 10Pm. *1,- Quantitative polymerase chain reaction analysis of --$#&5 and :$)-; gene 
expression in hBMSCs transfected with !"#$% siRNA or control siRNA at day 6 post-adipogenic 
induction. Data was normalized to &'() and expressed as fold change as compared to cells 
transfected with a control siRNA (value 1) using the comparative *T method. Data is representative of 
two separate experiments, r S.D. * + < 0.01 as determined by 1-way ANOVA. *2,- Microscopic 
images of Oil red O stained hBMSCs transfected with !"#$% siRNA or control siRNA at 7 days post-
adipogenic induction. Scale bar = 20 Pm. Images are representative of two separate experiments. 
Abbreviations: HTRA1, high temperature requirement protease A1; hBMSCs, human bone marrow-
derived mesenchymal stem cells; &'(), beta glucuronidase; ELISA, enzyme-linked immunosorbent 
assay; siRNA, small interfering ribonucleic acid; $,-, alkaline phosphatase; (--%, Secreted 
phosphoprotein 1; #'345, Runt-related transcription factor 2; --$#&5, peroxisome proliferator-
activated receptor gamma 2;/:$)-;, fatty acid binding protein 4. 
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!"#$%&' () Exogenously added HTRA1 protein enhances hBMSC osteogenic differentiation. *+,-./
Representative images of Alizarin red stained day 14 cultures of non-induced hBMSCs (non-induced 
control) and osteogenic induced hBMSCs (A), osteogenic induced hBMSCs previously treated with 
either proteolytically active (HTRA1ǻmac) or inactive (HTRA1ǻmacSA) HTRA1 (5 Pg/ml) for 14 
days (B) or 4 days (C), and osteogenic induced hBMSCs previously treated with proteolytically active 
HTRA1 (5 Pg/ml) for 14 days in the presence or absence of AEBSF (20 Pg/ml) (D). Data is 
representative of 3 independent experiments. Scale bar = 2 mm. *0./ Quantitative polymerase chain 
reaction analysis of osteogenic gene expression in hBMSCs treated at day 7 with active HTRA1 (5 
Pg/ml) and harvested at day 10 post-osteogenic induction. Data was normalized to !"#$ and 
expressed as fold change as compared to untreated cells (value 1) using the comparative %T method. n 
= 3 separate experiments, r S.D. * & < 0.05, ** & < 0.01 as determined by Student’s '-test. 
Abbreviations: HTRA1, high temperature requirement protease A1; hBMSCs, human bone marrow-
derived mesenchymal stem cells; AEBSF, 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride; 
!"#$, beta glucuronidase.
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!"#$%&' () IBSP is an HTRA1 substrate in osteogenic MSC cultures. *+,- Representative 
immunofluorescence micrographs of anti-IBSP (ID1.2) (green) and DAPI (blue) stained day 14 
osteogenic hBMSCs cultures previously treated for 4 days with 5 Pg/ml of either inactive HTRA1 
(HTRA1ǻmacSA) or active HTRA1 (HTRA1ǻmac). Scale bar = 75 Pm. *.,- Western blot analysis of 
an !"#$!%&' enzyme assay using recombinant human IBSP (476 nM) and HTRA1ǻmacSA (45 nM) or 
HTRA1ǻmac (45 nM), incubated together for up to 24 h. Equal sample volumes were loaded onto an 
SDS-PAGE gel and IBSP protein detected using antibodies directed against either the N- or C-terminal 
regions of human IBSP. */,- Representative fluorescence images of anti-IBSP (ID1.2) (green), anti-
HTRA1 (red) and DAPI (blue) stained mASC spheroids at 5 and 9 days post-osteogenic induction.
Scale bar = 25 Pm. Data is representative of 2 independent experiments. Abbreviations: HTRA1, high 
temperature requirement protease A1; hBMSCs, human bone marrow-derived mesenchymal stem 
cells; ()*+, Integrin-binding sialoprotein; DAPI, 4,6-diamidino-2-phenylindole; mASCs, mouse 
adipose-derived stromal cells. 
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!"#$%&' () HTRA1 protein levels are increased during bone regeneration. *+,- Representative 
micrograph of a hematoxylin and eosin stained paraffin wax section of decalcified mouse femur 7 days 
following a 0.22 Pm osteotomy. Scale bar = 250 Pm. *./!,- Representative micrographs of anti-
HTRA1 (brown) stained paraffin wax sections of decalcified mouse femora (representative of n = 3) at 
7 (B), 14 (C), 28 (D) and 42 (E) days following osteotomy. Non-operative femora served as controls 
(F). HTRA1 was visualized using horseradish peroxidase-diaminodenzidine and sections 
counterstained with hematoxylin. HTRA1 positive staining is identified in osteoid (!"#$%&' ())#*'
+%(&$) at day 7 (B), in chondrocyte lacunae (#,%-'())#*'+%(&$) and soft tissue, ./ at day 14 (C) and in 
sites of active bone regeneration (())#*$) at day 28 (D). Scale bar = 100 Pm. Abbreviations: 0, fracture 
gap; 12, bone marrow; !1, cortical bone; HTRA1, high temperature requirement protease A1; DAPI, 
4,6-diamidino-2-phenylindole. 
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!"#$%&' () HTRA1 and IBSP co-localize during bone regeneration. Representative
immunofluorescence micrographs of paraffin wax sections of decalcified mouse femora at 28 days 
following osteotomy stained with DAPI (blue), anti-IBSP (ID1.2) (green), and anti-HTRA1 (red). 
Scale bar = 50 Pm. Abbreviations: !", bone marrow; #!, cortical bone; HTRA1, high temperature 
requirement protease A1; IBSP$ Integrin-binding sialoprotein; DAPI, 4,6-diamidino-2-phenylindole. 
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Supplementary Fig. 1. siRNA HTRA1 reduces HTRA1 protein within the ECM of hBMSCs. Representative 
immunofluorescence images of double staining for HTRA1 (red) and DAPI (blue) in HTRA1 siRNA (HTRA1 
(H1)) or control siRNA (siRNA (C)) transfected hBMSCs after 10 days without (non-induced) or with 
(osteogenic) osteogenic induction. Scale bar = 75 µm. Abbreviations: HTRA1, high temperature requirement 
protease A1; ECM, extracellular matrix; hBMSCs, human bone marrow-derived mesenchymal stem cells; 
DAPI, 4,6-diamidino-2- phenylindole; siRNA, small interfering ribonucleic acid. 
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Supplementary Fig. 2. Exogenously added HTRA1 protein enhances hBMSC mineralization during the later 
stages of osteogenic differentiation only. Representative images of Alizarin red stained day 18 (D18) cultures of 
non-induced hBMSCs (non-induced) and osteogenic induced hBMSCs previously treated either without 
(osteogenic) or with proteolytically active HTRA1 (5 µg/ml) for the various times indicated. Data is 
representative of 3 independent experiments. Scale bar = 2 mm. Abbreviations: HTRA1, high temperature 
requirement protease A1; hBMSCs, human bone marrow-derived mesenchymal stem cells. 
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Supplementary Fig. 3. HTRA1 does not degrade collagen type I within the ECM of hBMSCs. Representative 
immunofluorescence images of COL1A1 (green) and DAPI (blue) in day 14 cultures of non-induced hBMSCs 
and osteogenic induced hBMSCs treated for 4 days without (untreated) or with 5 µg/ml of active (HTRA1Δ
mac) or inactive (HTRA1ΔmacSA) HTRA1. Scale bar = 75 µm. Abbreviations: HTRA1, high temperature 
requirement protease A1; hBMSCs, human bone marrow-derived mesenchymal stem cells; COL1A, collagen 
Type I; DAPI, 4,6- diamidino-2-phenylindole. 
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Supplementary Fig. 4. Osteogenic differentiation of mASC 3D-spheroids. (A-B): Alizarin red staining of 
mASC 3D-spheroids at 5 (A) and 9 (B) days post-osteogenic induction. Scale bar = 100 µm (C): Control 
immunofluorescence staining for HTRA1 and IBSP in mASC spheroids at 5 and 9 days post-osteogenic 
induction. Representative immunofluorescence images of spheroids stained with mouse IgG (M-IgG; green), 
rabbit IgG (R-IgG; red) and DAPI (blue). Data is representative of 2 independent experiments. Scale bar = 25 
µm. Abbreviations: HTRA1, high temperature requirement protease A1; IBSP, Integrin-binding sialoprotein; 
mASC, mouse adipose-derived stromal cells; DAPI, 4,6-diamidino-2-phenylindole. 
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Supplementary Fig. 5. Immunohistochemical staining of HTRA1 in paraffin wax sections of mouse bone. (A-
C): Representative micrographs of anti-HTRA1 (brown) stained paraffin wax sections of decalcified mouse 
femora (representative of n = 3) at 7 (A), 14 (B) and 28 (C) days following osteotomy. HTRA1 was detected in 
the periosteal layer, p, (A), non-mineralized callus tissue (B) and cuboidal cells localized within areas of active 
bone regeneration (white arrows) (C). HTRA1 was visualized using horseradish peroxidase-diaminodenzidine 
and sections counterstained with hematoxylin. Scale bar = 100 µm. Abbreviations: cb, cortical bone; HTRA1, 
high temperature requirement protease A1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
  106
Supplementary Fig. 6. Control immunofluorescence staining for HTRA1 and IBSP in paraffin wax sections of 
mouse bone. Representative immunofluorescence images of paraffin wax sections of decalcified mouse femora 
(representative of n = 3) at 28 days following osteotomy stained with DAPI (blue), mouse IgG (M-IgG; green) 
or rabbit IgG (R-IgG; red). Scale bar = 50 µm. Abbreviations: HTRA1, high temperature requirement protease 
A1; IBSP, Integrin-binding sialoprotein; DAPI, 4,6-diamidino-2-phenylindole. 
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Supplementary Table 1. List of TaqMan Gene Expression Assays used in RT-PCR  
Gene Symbol Protein Product Assay ID a 
Mrps12 Mitochondrial ribosomal protein S12 Mm00488728_m1 
HtrA1 High temperature requirement protease A1 Mm00479887_m1 
GUSB Beta glucuronidase Hs99999908_m1 
HTRA1 High temperature requirement protease A1 Hs01016151_m1 
HTRA3 High temperature requirement protease A3 Hs01099710_m1 
RUNX2 Runt-related transcription factor 2 Hs01047976_m1 
ALP Alkaline phosphatase Hs00758162_m1 
IBSP Integrin-binding sialoprotein Hs00173720_m1 
SPP1 Secreted phosphoprotein 1/osteopontin Hs00960942_m1 
COL1A1 Collagen type 1A1 Hs00164004_m1 
SOST Sclerostin Hs00228830_m1 
BMP5 Bone morphogenetic protein 5 Hs00234930_m1 
PPARG2 Peroxisome proliferator-activated receptor gamma 2 Hs01115513_m1 
FABP4 Fatty acid binding protein 4 Hs01086177_m1 
aTaqMan Expression Assay identity code according to supplier (Applied Biosystems, Rotkreuz, 
Switzerland). 

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Background: HTRA1 has been associated with intervertebral disc (IVD) degeneration although its role is unknown.
Results: HTRA1 up-regulated matrix metalloproteinase (MMP) production by IVD cells via the generation of fibronectin
fragments.
Conclusion: HTRA1 plays a detrimental role in the pathogenesis of IVD degeneration.
Significance: HTRA1 may represent a novel therapeutic target for the treatment of spinal disc degeneration.
HumanHTRA1 is a highly conserved secreted serine protease
that degrades numerous extracellular matrix proteins. We have
previously identified HTRA1 as being up-regulated in osteoar-
thritic patients and as having the potential to regulate matrix
metalloproteinase (MMP) expression in synovial fibroblasts
through the generation of fibronectin fragments. In the present
report, we have extended these studies and investigated the role
of HTRA1 in the pathogenesis of intervertebral disc (IVD)
degeneration. HTRA1 mRNA expression was significantly ele-
vated in degenerated disc tissue and was associated with
increased protein levels. However, these increases did not cor-
relate with the appearance of rs11200638 single nucleotide
polymorphism in the promoter region of the HTRA1 gene, as
has previously been suggested. Recombinant HTRA1 induced
MMP production in IVD cell cultures through a mechanism
critically dependent on MEK but independent of IL-1! signal-
ing. The use of a catalytically inactive mutant confirmed these
effects to be primarily due to HTRA1 serine protease activity.
HTRA1-induced fibronectin proteolysis resulted in the genera-
tion of various sized fragments, which when added to IVD cells
in culture, caused a significant increase in MMP expression.
Furthermore, one of these fragments was identified as being the
amino-terminal fibrin- and heparin-binding domain and was
also found to be increased within HTRA1-treated IVD cell cul-
tures as well as in disc tissue from patients with IVD degenera-
tion. Our results therefore support a scenario in which HTRA1
promotes IVD degeneration through the proteolytic cleavage of
fibronectin and subsequent activation of resident disc cells.
Degeneration of the intervertebral disc (IVD)6 is now
regarded as one of themajor causes of lower back pain, which is
a highly prevalent, debilitating, and costly disorder (1, 2). The
pathogenesis of degeneration is a highly complex and poorly
understood processwithmany different genetic, biological, and
mechanical influences playing key roles in the breakdown of
extracellular matrix (ECM) components (3). The predominant
means by which ECM is degraded is thought to be due to the
proteolytic actions of matrix metalloproteinases (MMPs) and
aggrecanases (ADAMTS). A number of MMPs, including
MMP-1, -3, -7, -9, and -13, as well as ADAMTS-4, have been
shown to increase in the IVD during disc degeneration and are
responsible for the breakdown of several matrix components,
the most notable being aggrecan and collagen (4–7). Both
MMPs and their inhibitors (TIMP-1, -2, and -3) have been
localized to the resident chondrocyte-like cells of the nucleus
pulposus and inner fibrosus compartments of the IVD (4), thus
implicating these cells in disease pathogenesis. The secretion of
MMPs by human IVD cells is mediated in part through the
stimulatory effects of various pro-inflammatory cytokines, the
most prominent of which is IL-1! (8). In addition, fibronectin
peptide fragments of the ECM have also been shown to induce
MMP production by IVD cells (9) and are potent instigators of
experimental disc degeneration (10). Moreover, fibronectin
fragments have been shown to accumulate in the IVD during
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degeneration (11), although the proteases responsible for their
formation remain elusive.
Human HTRA1 (high temperature requirement serine pro-
tease A1) belongs to a well defined family of serine proteases
originally identified in bacteria (12). Although primarily
regarded as a key regulator of tumor development and subse-
quent malignancies (13–15), a growing body of evidence now
exists to suggest that HTRA1 may also play a central role in
determining the outcome of various musculoskeletal disease
pathologies, including Duchenne muscular dystrophy (16),
osteoarthritis (17–19), and rheumatoid arthritis (19, 20). It has
recently been shown in a Japanese population study that a single
nucleotide polymorphism (SNP) located within the HTRA1
promoter is associated with spinal disc degeneration, where
increases in spinal disc narrowing were observed in patients
without the G allele (AA) as compared with those bearing at
least one G allele (GG ! GA) (21). It would therefore appear
that HTRA1may also play a role in disc pathology, although its
influence on disease and its mechanism of action have not yet
been elucidated.
Observations from our own studies examining the role of
HTRA1 in osteoarthritis imply thatHTRA1may actually have a
detrimental effect on the pathogenesis of musculoskeletal dis-
ease. Elevated levels of HTRA1 protein were measured in the
synovial fluid from osteoarthritic patients, and primary syno-
vial fibroblasts isolated from diseased patients were identified
as being amajor source of HTRA1 (19). The addition of proteo-
lytically activeHTRA1 to fibroblast cultures resulted inmarked
up-regulation of various MMPs, including MMP-1 and
MMP-3, both of which have been implicated in cartilage and
joint destruction in arthritic patients. Further experiments con-
firmed that the stimulatory effects of HTRA1 onMMP expres-
sion were protease-dependent and were related to the forma-
tion of fibronectin fragments due to extracellular degradation.
Such observations are therefore strongly suggestive of a central
role for HTRA1 in joint degeneration through its proteolytic
actions on ECMcomponents and thusmay also be indicative of
its role in other disease pathologies, such as disc degeneration.
In the current study, we used IVD tissue and cell samples
from surgical patients in order to further investigate the poten-
tial involvement of HTRA1 in IVD degeneration. Our findings
implicate HTRA1 as a key factor in the underlying pathology
associated with IVD degeneration. HTRA1 may therefore rep-
resent a novel target for the development ofmore effective ther-
apeutic strategies to treat this debilitating condition.
EXPERIMENTAL PROCEDURES
Materials—Human fibronectin and rabbit IgG were pur-
chased from R & D Systems (Abingdon, UK). IL-1 receptor
antagonist (IL-1RA) was obtained from Abcam (Cambridge,
UK), and MEK1/2 inhibitors PD98059 and U0126 were from
Sigma-Aldrich (Buchs, Switzerland). Monoclonal antibodies
against the fibronectin carboxyl-terminal heparin-binding
domain (Mab1935) and the amino-terminal fibrin- and hepa-
rin-binding domain (Mab1936) were from Chemicon Interna-
tional. A polyclonal anti-HTRA1 antibody was generated as
described previously (19). All anti-IgG horseradish peroxidase
(HRP)-conjugated, fluorescence-conjugated secondary anti-
bodies and normal serumwere from Jackson ImmunoResearch
(Suffolk, UK). DAPI was purchased from Sigma-Aldrich. Col-
lagenase NB4 was purchased from Serva/Promega (Dueben-
dorf, Switzerland), and dispase II was from Roche Applied Sci-
ence (Rotkreuz, Switzerland).
Tissue Harvesting—IVD tissue and/or blood was obtained
from a total of 39 patients undergoing spinal surgery for symp-
tomatic degenerative disc disease, disc herniation, or spinal
trauma following informed consent in accordance with the
local ethical guidelines (carried out at the SRHClinic Karlsbad-
Langensteinbach, Karlsbad, Germany). The degree of IVD
degeneration in patients was assessed prior to surgical inter-
vention by magnetic resonance imaging (MRI) using a four-
level grading system based on Pfirrmann’s classification of disc
degeneration (22). Degeneration grades were assigned as fol-
lows: grade 1, non-degenerated (normal disc height); grade 2,
mild degeneration (slight decrease in disc height); grade 3,
moderate degeneration (moderate decrease in disc height);
grade 4, severe degeneration (collapsed disc space).
Isolation and Culture of IVD Cells—Human IVD cells were
isolated from the discs of a total of 14 patients undergoing spi-
nal surgery for disc herniation (carried out at Balgrist Univer-
sity Hospital, Zürich, Switzerland) as described previously (23).
Briefly, IVD tissue was enzymatically digested (0.2% collagen-
ase NB4, 0.3% dispase II) for 4–8 h, and cells were thereafter
cultured in growth medium consisting of DMEM/F-12 supple-
mented with 10% FCS, penicillin (50 units/ml), streptomycin
(50 !g/ml), and amphotericin B (25 !g/ml) and incubated at
37 °C with 5% CO2 and used at passages 2–3.
Recombinant Human HTRA1—Purified recombinant His-
tagged HTRA1 in which the amino-terminal mac25 homology
domain was absent (termed HTRA1"mac) was produced in
Escherichia coli and purified usingNi2!-NTA chromatography
as described previously (19, 24). The enzymatically inactive
mutated form of HTRA1"mac, termed HTRA1"macSA, was
generated through conversion of residue serine 328 to alanine
by mutagenesis.
Stimulation of IVD Cells with Recombinant HTRA1—IVD
cells were cultured in 6-well plates at 3.5# 105 cells/well and
serum starved for 2 h prior to stimulation. Cells were incu-
bated in medium alone or in medium supplemented with
either HTRA1"mac (5 !g/ml) or HTRA1"macSA (5 !g/ml)
for up to 24 h. Concentrations used were based on previous
observations using human synovial fibroblasts (19). After this
time, RNA and culture supernatants were harvested for further
analysis. In the case of inhibition studies, IVD cells were prein-
cubated with either PD98059 (10 !M), U0126 (10 !M), or
IL-1RA (250 ng/ml) for 2 h prior to stimulation.
Quantitative RT-PCR (qRT-PCR)—Total RNA was isolated
from either intact IVD tissue or cells and purified using TRIzol
reagent (Invitrogen AG, Basel, Switzerland) according to the
manufacturer’s instructions. RNA (0.5 !g) was reverse tran-
scribed to cDNA using Superscript II (Invitrogen AG) and ran-
dom hexanucleotide primers (Promega AG, Dübendorf, Swit-
zerland). Quantification of mRNA expression was performed
with TaqMan Gene Expression Assays (Applied Biosystems,
Rotkreuz, Switzerland) (supplemental Table 1) using the
StepOnePlus real-time PCR system (Applied Biosystems), and
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values were normalized toGAPDHmRNA levels and presented
as -fold change according to the 2!""CT method. In cases
where individual patients (n # 36) were compared for expres-
sion levels of HTRA1 and FN mRNA in IVD tissue, data were
normalized to TBP and presented as 2!"CT. Each 10-!l reac-
tion consisted of 1$ TaqMan fast universal PCR master mix
(Applied Biosystems), 1$ TaqMan gene expression assay, and
10 ng of cDNA (based upon initial RNA concentrations). All
reactions were performed in triplicate in fast optical 96-well
reaction plates (Applied Biosystems) at 95 °C for 20 s and 40
cycles of 95 °C for 1 s and 60 °C for 20 s.
SNP Analysis—A total of 35 patients were genotyped using
a TaqMan SNP genotyping assay specific for the SNP,
rs11200638, according to the manufacturer’s instructions
(Applied Biosystems). Patients were grouped according to their
individual genotypes, and association studies were performed
in order to determine the influence of the rs11200638 (A) risk
allele on susceptibility to IVD degeneration. The influence of
rs11200638 on HTRA1 expression in IVD tissue was also
assessed in patients from whom both RNA and DNA samples
were obtained (n# 32).
Western Blot Analysis of Patient IVD Tissue—Patient IVD
samples (n # 12) were selected based on degeneration grade.
Protein was extracted using CelLytic M (Sigma-Aldrich) con-
taining a protease inhibitor mixture (Sigma-Aldrich), and pro-
tein amounts were determined initially by a Bio-Rad protein
assay (Bio-Rad, Reinach, Switzerland). Protein samples were
boiled for 5 min in loading buffer (50 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, 100 mM DTT, 0.002% bromphenol blue),
and equal amounts of protein were loaded onto 12% SDS-poly-
acrylamide gels. Further corrections to the loading volumes
were made following densitometric analysis of Coomassie
Blue-stained gels, thus allowing for accurate comparisons to be
made between individual patient samples. Protein was then
electroblotted onto PVDF membranes using the Trans-Blot
Turbo blotting system (Bio-Rad) and incubated in 5% skim
milk, 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20
(TBST) for 1 h at room temperature. Membranes were then
incubated for 1 h at room temperature with either rabbit anti-
human HTRA1 (1:2000) or mouse anti-fibronectin amino-ter-
minal fibrin- and heparin-binding domain (Mab1936) (1
!g/ml). After washing in TBST three times for 5 min each,
membranes were incubated with a HRP-conjugated anti-
mouse or anti-rabbit IgG (1:10,000) for 1 h at room tempera-
ture. Following a further washing step, peroxidase activity was
detected using SuperSignalWest Pico Chemiluminescent Sub-
strate (Thermo Scientific, Lausanne, Switzerland).
ImmunofluorescenceMicroscopy—Unfixed frozen IVD tissue
sections were air-dried for 20 min, blocked with normal goat
serum (1:10), and incubatedwith polyclonal anti-HTRA1 (1:50)
or control rabbit IgG (2 !g/ml) in phosphate-buffered saline
(PBS), pH 7.3, 1% BSA for 16 h at 4 °C. Tissue samples contain-
ing HTRA1 were then identified using goat anti-rabbit-Cy3
(1:400). Sections were mounted in Mowiol/DABCO (1,4-
diazabicyclo[2.2.2]octane) (Sigma-Aldrich) containing DAPI
(0.5 g/ml), and images were captured using the Leica
DMI6000B automated inverted research microscope system
(Leica Microsystems).
Quantification of SecretedMMP-3—MMP-3 protein levels in
culture supernatants were determined using an MMP-3-spe-
cific ELISA kit according to the manufacturer’s instructions
(R & D Systems).
Proteolytic Enzyme Assays—Degradation of fibronectin by
HTRA1"mac was determined using methods described pre-
viously (19). Briefly, HTRA1"mac and recombinant human
fibronectin, in an equimolar ratio, were incubated together
in Tris-buffered saline (TBS), pH 8.5, for 16 h at 37 °C. In
some reactions, HTRA1"mac was replaced by proteolyti-
cally inactive HTRA1"macSA. Fibronectin, HTRA1"mac,
and HTRA1"macSA were also incubated separately under
the same conditions and served as controls. In order to assess
whether HTRA1"mac could also generate fibronectin frag-
ments in IVD cell cultures, supernatants (20 ml) were har-
vested from cells treated with HTRA1"mac (5 !g/ml) or
HTRA1"macSA (5 !g/ml) for 24 h and concentrated using
Amicon Ultra-15, 10,000 molecular weight cut-off filter units
(Millipore). Fibronectin fragmentswere analyzedon4–15%Mini-
PROTEANTGXPrecast gels (Bio-Rad) by Coomassie Blue stain-
ing and immunoblotting using either mouse anti-fibronectin
carboxyl-terminal heparin-binding domain (Mab1935) (1
!g/ml) or mouse-anti-fibronectin amino-terminal fibrin-
and heparin-binding domain (Mab1936) (1 !g/ml) as
described above. The EnzCheck elastase kit (Molecular
Probes, Basel, Switzerland) was used to confirm the proteo-
lytic activity of recombinant HTRA1 proteins according to
the manufacturer’s protocol.
Effect of Fibronectin Fragments on MMP Expression—
Equimolar concentrations of fibronectin (20 !g) and
HTRA1"mac (5 !g) were incubated under the conditions
described above. Control reactions were also performed and
included TBS, pH 8.5, alone or in combination with either
fibronectin or HTRA1"mac. Samples were then diluted into
equilibration buffer containing TBS, pH 7.6, with 20 mM imid-
azole and incubated with 50 !l of pre-equilibrated HisPur
Ni2%-NTA resin (Qiagen,Hombrechtikon, Switzerland) in spin
columns (Thermo Scientific) for 1 h at 4 °C. Columnswere then
centrifuged for 5 min at 1600 rpm, and the affinity column
flow-through fraction was collected, dialyzed in TBS for 4 h at
4 °C using Slide-A-LyzerMINI dialysis devices (3500molecular
weight cut-off) (Thermo Scientific), and then incubated with
IVD cells for up to 24 h, after which timeMMP expression was
evaluated by qRT-PCR.
Statistical Analysis—All statistical analyses were carried
out using SPSS19.0 (SPSS Inc., Chicago, IL). Parametric
analysis of normally distributed data were performed using
the two-tailed unpaired Student’s t test or one-way analysis
of variance (ANOVA) followed by Tukey’s post hoc tests for
multiple-group comparisons. Pearson’s correlation coeffi-
cient was used to evaluate the relationship between the
expression levels of selected genes in patient tissue samples.
The "2 test was used to compare allele frequencies in
patients with or without IVD degeneration (1 degree of free-
dom). In all cases, a p value of &0.05 was considered statis-
tically significant.
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RESULTS
We have previously demonstrated that HTRA1 plays a cen-
tral role in the regulation of MMP expression in synovial fibro-
blasts from arthritic patients and that its stimulatory effects
may be linked to the generation of fibronectin fragments (19).
In the present report, we further investigated this property of
HTRA1 in IVD cell cultures and aimed to establish its potential
role in IVD degeneration.
Identification of HTRA1 in Patient Tissue—HTRA1 mRNA
levels within IVD tissue samples from patients with varying
degrees of disc degeneration were normalized to TBP and pre-
sented as 2!"CT. Expression levels significantly correlated (r#
0.375; p # 0.024) with patient degeneration grade and were
found to be markedly increased in patients with severity scores
of 3 (4-fold; p# 0.015) and 4 (3-fold; p# 0.2) as compared with
control patients (Fig. 1A). Western blot analysis of IVD protein
samples using a polyclonal antibody against HTRA1 identified
two main species of HTRA1 protein migrating at $50 kDa
(closed arrowhead) and $42 kDa (open arrowhead), which
most likely represented the full-length and processed forms of
HTRA1, respectively (Fig. 1B and supplemental Fig. 1) (25). The
50-kDaHTRA1was found at varying levels in themajority sam-
ples tested, whereas the 42-kDa form of HTRA1 was identified
in degenerated IVD protein samples only and was noticeably
increased in the more severely affected discs. HTRA1 protein
was also identified within both the cells and ECMof frozen IVD
tissue sections, as determined by immunofluorescence stain-
ing, and levels were found to be increased in the more severely
affected patients as compared with the control trauma patients
(Fig. 1C).
Analysis of Patient rs11200638 SNPGenotype—In light of the
recent evidence linking the rs11200638 SNP (G%A) in the
HTRA1 gene promoter and spinal disc degeneration in Japa-
nese women (21), we investigated whether the rs11200638 risk
allele frequency between patient groups used in the current
study was associated with susceptibility to IVD degeneration.
DNA from a total of 35 patients was subjected to SNP genotyp-
ing using the TaqMan SNP genotyping assay specific for
rs11200638 SNP. Contrary to previous expectations, we were
unable to demonstrate any significant differences in SNP allele
frequencies between control patients without disc degenera-
tion (25%) and patients with degeneration grades of 2 (14.3%;
p# 0.4), 3 (15%; p# 0.37), or 4 (15%; p# 0.37) (Table 1). We
also performed a comparative analysis of HTRA1 expression
levels in IVD tissue from 32 patients of known genotype.
However, no significant associations could be made between
FIGURE 1. Detection of HTRA1 in human IVD tissue. A, HTRA1mRNA levels in intact IVD tissue samples from patients (n# 36) with varying degrees of IVD
degeneration were determined by qRT-PCR and presented as 2!"CT. *, p& 0.05, as determined by one-way ANOVA Error bars, S.E. B, protein extracts from
patient IVD tissues (n# 12) were loaded onto a 12% SDS-polyacrylamide gel, and immunoblotting was performed using a polyclonal antibody specific for
HTRA1. Lane 1,HTRA1"mac (4 ng); lanes 2–4, non-degenerated (ND) discs; lanes 5–7,mildly degenerateddiscs; lanes 8–10,moderately degenerateddiscs; lanes
11–13, severely degenerated discs.Closed arrowhead, 50-kDaHTRA1; open arrowhead, 42-kDaHTRA1.C, representative images of HTRA1proteinwithin frozen
IVD tissue sections as identified by immunofluorescence staining. HTRA1was detected using a Cy3-labeled secondary antibody (red), and nuclei were labeled
with DAPI (blue). The specificity of staining was confirmed through the use of a nonspecific rabbit IgG control (IgG). Grade 1 represents a normal, non-
degenerated IVD, whereas grades 3 and 4 signify moderate and severe degeneration, respectively. Scale bar, 50 !m.
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HTRA1 expression levels and the rs11200638 genotype
(Table 1).
Effect of Recombinant HTRA1 on MMP Production by IVD
Cells—In order to investigate how HTRA1 may contribute to
IVD degeneration, we generated both proteolytically active and
inactive recombinant forms of HTRA1 lacking the amino-
terminalmac25 homology domain as described previously (19).
The protease activity of the active protein, termed
HTRA1!mac, was confirmed by its ability to cleave purified
bovine elastin andwas dependent on both incubation time (Fig.
2A) and protein amount (Fig. 2B). No such activity was
observed with the proteolytically inactive form of HTRA1
(HTRA1!macSA) in which serine 328, part of the serine pro-
tease catalytic triad domain, had been substituted for alanine.
The effects of these recombinant proteins onMMP production
by cultured IVD cells were then investigated. Cells were incu-
bated for up to 24 h with either HTRA1!mac (5 !g/ml) or
HTRA1!macSA (5 !g/ml), and the -fold change in mRNA
expression levels of MMP1, MMP3, and MMP13 was deter-
mined by qRT-PCR. HTRA1!mac induced a significant
increase in the expression levels of MMPs tested as com-
pared with untreated cells and cells treated with the proteo-
lytically inactive HTRA1!macSA (Fig. 2, C–E). In addition,
HTRA1!mac also enhanced the expression of ADAMTS4
(aggrecanase-1), although no increase was observed in MMP2
(gelatinase A) expression, and ACAN (aggrecan) expression
was actually reduced (supplemental Fig. 2). MMP expression
was also up-regulated in HTRA1!macSA-treated cells,
FIGURE 2. Regulation of MMP expression in IVD cells by recombinant HTRA1. A and B, recombinant HTRA1 proteolytic activity was determined using soluble
bovine BODIPY FL-labeled DQ-elastin (100!g/ml) as a substrate. Digestion of the DQ-elastin yielded fluorescent fragments detectable at 530 nmby a fluorescence
microplate reader. The amount of DQ-elastin digestionwasmeasured at selected time points (0, 1, 2, 4, and 8 h) using a defined amount of HTRA1 (5!g) (A) or was
determinedafter incubationfor8hwithvaryingamountsofHTRA1(0,0.5,1,3,and5!g) (B).C–E, theeffectsof recombinantHTRA1(5!g/ml)onMMPexpressionlevels
in IVDcells after a24-h incubationperiodweredeterminedbyqRT-PCR, and the -fold changeas comparedwithuntreatedcontrolswasdeterminedusing the2"!!CT
method (n# 4–6patients). F, a specificMMP-3 ELISAwas used to investigate the effects of recombinantHTRA1onMMPprotein secretion in supernatants obtained
from IVD cells. Shown are results of triplicate determinations$ S.D. (error bars). *, p% 0.01, as determined by one-way ANOVA.
TABLE 1
rs11200638 SNP Genotyping of European patients with and without IVD degeneration
Genotype
Degeneration grade
n RelativeHTRA1 expressiona p valueb1 (n! 8) 2 (n! 7) 3 (n! 10) 4 (n! 10)
GG 5 5 7 7 23 204.1$ 35.6
GA 2 2 3 3 8 307$ 87.3 0.20
AA 1 0 0 0 1 14.9
GA& AA 3 2 3 3 9 274.5$ 83.5 0.37
G allele 12 12 17 17
A allelec 4 (25%) 2 (14.3%) 3 (15%) 3 (15%)
p# 0.4d p# 0.37d p# 0.37d
a Comparisons were made between HTRA1 expression levels$ S.E. in IVD tissue and genotype frequency in patients where both RNA and DNA samples were available
(n# 32).
b Student’s t test was used to compare HTRA1 expression levels between patients carrying the risk allele (GA/AA) and those homozygous for the wild type allele (GG).
c Percentages refer to risk allele (A) frequency.
d The "2 test was used to evaluate the significance of differences in risk allele (A) frequency between patients with IVD degeneration (grades 2–4) and control patients with-
out IVD degeneration (grade 1) (n# 35).
Role of HTRA1 in Intervertebral Disc Degeneration
JUNE 15, 2012•VOLUME 287•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 21339
 at Hauptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on April 15, 2014
http://www.jbc.org/
Downloaded from 
Results 
 115 
 
 
 
 
 
although expression levels were over 3–7-fold less than those
observed in cells incubated with HTRA1!mac and were not
deemed statistically significant as compared with untreated
control cells (MMP1, p" 0.19;MMP3, p" 0.41;MMP13, p"
0.41). Clearly, therefore, HTRA1-induced MMP expression in
IVD cells is primarily a protease-dependent phenomenon,
although it would appear that other routes of activation may
also exist. In addition to its stimulatory effects onMMPmRNA
expression,HTRA1!mac also enhancedMMPprotein produc-
tion, as evidenced by results obtained from the MMP-3 ELISA
(Fig. 2F). Low levels of secreted MMP-3 were detected in the
supernatants of untreated cells (0.76 ng/ml# 0.04) but became
significantly elevated following stimulation with HTRA1!mac
(11.33 ng/ml# 0.68; p$ 0.001). As with our previous findings,
these stimulatory effects of HTRA1 were significantly dimin-
ished following inactivation of its protease activity, although
levels remained elevated as compared with untreated cells
(2.23# 0.13 ng/ml; p" 0.089).
Influence of MEK and IL-1! Inhibition on HTRA1-induced
MMP Production—Of the known instigators of MMP expres-
sion by IVDcells, IL-1! is considered to be themost potent and,
as such, is centrally involved in both IVD cell activation and
IVD degeneration (8). Furthermore, IL-1! has previously been
shown to play a central role in mediating MMP production by
fibronectin fragments in cultures of bovine articular cartilage
(26).We therefore investigated if the expression of IL-1!, along
with several other cytokines, including IL-6 and IL-8, was up-
regulated in IVD cells by HTRA1!mac and whether this had
any influence on the induction of MMP expression by
HTRA1!mac. Indeed, expression levels of the cytokines tested
were up-regulated in IVDcells stimulatedwithHTRA1!mac (5
"g/ml) in a time-dependent manner (Fig. 3A). However, addi-
tional studies focusing on the inhibition of IL-1! signaling
using the IL-1RA (250 ng/ml) failed to demonstrate any signif-
icant alterations in the ability of HTRA1 to induce MMP
expression in IVD cells (Fig. 3B and supplemental Fig. 3). This
would suggest that HTRA1 does not mediate its stimulatory
effects through IL-1! production, although we cannot exclude
the possibility that other cytokines may be involved.
We have previously demonstrated that MMP expression by
human synovial fibroblasts is up-regulated in response to
HTRA1 stimulation and that this was at least partly dependent
on the generation of fibronectin fragments (19). Furthermore,
fibronectin fragments were recently confirmed as being potent
inducers of MMP expression in IVD cells, mediating their
effects through activation of the MEK pathway (27). We there-
fore investigated whether inhibition of MEK could influence
the actions of HTRA1 on IVDMMP expression. Indeed, inclu-
sion of either of the specific MEK inhibitors PD98059 (10 "M)
or U0126 (10 "M) 2 h prior to treatment with HTRA1!mac (5
"g/ml) significantly abrogated its stimulatory effects on the
expression ofMMP1 andMMP3 (Fig. 3C), thereby supporting
the theory that fibronectin fragments may represent one possi-
ble route through which HTRA1 mediates its stimulatory
effects on IVD cells.
Effect of Fibronectin Fragments on MMP Expression by IVD
Cells—Based on the above results, we further investigated the
potential involvement of fibronectin fragments in mediating
the actions of HTRA1 on IVD cells. We observed a noticeable
increase in the level of a 27–29-kDa fibronectin fragment
containing the amino-terminal fibrin- and heparin-binding
domain in the supernatants from IVD cell cultures previ-
ously treated with HTRA1!mac (5 "g/ml) as compared with
cells incubated in medium alone or with the inactive
FIGURE 3.Down-regulationofHTRA1-inducedMMPexpression in IVDcells byMEK inhibition.A, IL1B, IL6, and IL8mRNAexpression levelsweremeasured
in IVD cell cultures byqRT-PCR in response toHTRA1!mac (5"g/ml) stimulationover the course of 24h, and the -fold change as comparedwith untreated cells
was determined using the 2%!!CT method. B, the influence of IL-1! inhibition on HTRA1-inducedMMP1 andMMP3 expression by IVD cells was evaluated by
qRT-PCR after a 24-h incubation with HTRA1!mac (5 "g/ml) in combination with the IL-1RA (250 ng/ml), and the -fold change as compared with untreated
controls was determined using the 2%!!CT method. C, the effects of MEK inhibitors PD98059 (10"M) and U0126 (10"M) on HTRA1-inducedMMP1 andMMP3
expression by IVD cells were evaluated by qRT-PCR after a 24-h incubation, and the -fold change as compared with untreated controls was determined using
the 2%!!CTmethod. In each case, data are representative of at least two separate experiments performedusing IVD cells isolated froma total of n" 5 patients.
Shown are results of triplicate determinations# S.D. (error bars). *, p$ 0.01, as determined by one-way ANOVA.
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HTRA1!macSA (5 !g/ml) (Fig. 4A and supplemental Fig.
4A). Interestingly, increases in fibronectin fragments con-
taining the carboxyl-terminal heparin-binding domain were
evident in both HTRA1!mac- and HTRA1!macSA-treated
cell cultures as compared with untreated controls. Fur-
ther analyses confirmed that HTRA1!mac, but not
HTRA1!macSA, could digest equimolar concentrations of
human plasma-derived fibronectin after a 16-h incubation
period, resulting in various sized fragments being generated,
as determined by SDS-PAGE (Fig. 4B). The appearance of
HTRA1!mac as several bands is due to its autoproteolytic
activity, as described previously (19), an effect not observed
with HTRA1!macSA. Western blot analysis of the products
generated from HTRA1!mac-induced fibronectin proteolysis
revealed the presence of numerous fragments containing the
carboxyl-terminal heparin-binding domain as well as the
27–29-kDa fragment containing the amino-terminal fibrin-
and heparin-binding domain previously identified in the super-
natants fromHTRA1!mac-treated IVDcells (Fig. 4C).Wenext
investigated whether the fibronectin fragments generated by
HTRA1 were also capable of activating IVD cells. Following an
overnight incubation of human plasma-derived fibronectin
with HTRA1!mac (equimolar concentration), digested and
undigested fibronectinwas purified by affinity chromatography
using Ni2"-NTA to remove the majority of His-tagged
HTRA1!mac (supplemental Fig. 4B) and then incubated for up
to 24 h with IVD cells. The expression levels ofMMP1,MMP3,
and MMP13 (Fig. 4D) were all significantly increased in IVD
cells incubated with the purified mixture of fibronectin frag-
ments. By comparison, MMP expression in control cultures
stimulated with the affinity column flow-through fraction from
HTRA1!mac samples in the absence of fibronectin was 6–9-
fold less (p# 0.01), thus confirming that fibronectin fragments
were the predominant cause of IVD cell activation.
FIGURE 4. Stimulation of IVD cells with HTRA1-generated fibronectin fragments. A, concentrated protein supernatants (15 !g) from IVD cells treated for
24 h without or with HTRA1!mac (5 !g/ml) or HTRA1!macSA (5 !g/ml) were subjected to immunoblotting using antibody Mab1935 specific for the
fibronectin carboxyl-terminal heparin-bindingdomain (C terminus) orMab1936 specific for the fibronectin amino-terminal fibrin- andheparin-bindingdomain
(N terminus). Fibronectin fragments containing the amino-terminal fibrin- and heparin-binding domain are identified by the closed arrowhead. B, purified
human plasma-derived fibronectin (Fn) was incubated with HTRA1!mac or HTRA1!macSA at equimolar concentrations in TBS, pH 8.5, for 16 h at 37 °C, and
samples were loaded onto a 4–15%gradient gel and stainedwith Coomassie Blue. Fibronectin and recombinant HTRA1 alonewere also loaded and served as
controls. C, an equimolar concentration of human plasma-derived fibronectin and HTRA1!mac were incubated for 16 h, and fibronectin fragments were
visualized by Western blot analysis using the antibodies described in A. D, equimolar concentrations of fibronectin (20 !g) and HTRA1!mac (5 !g) were
incubated for 16 h, and fibronectin fragments were purified by affinity chromatography. IVD cells were incubated with purified HTRA1-digested fibronectin
(Fn"HTRA1!mac) for 24 h, and expression levels of MMP1,MMP3, and MMP13mRNA were determined by qRT-PCR and the -fold change as compared with
untreated controlswasdeterminedusing the2$!!CTmethod.Additional cultureswere incubatedwith either affinity-purified Tris-buffered saline, pH7.6 (TBS),
fibronectin (Fn), or HTRA1 (HTRA1!mac) or left untreated (Control). Data are representative of two separate experiments performed using IVD cells from two
patients. Shown are results of triplicate determinations% S.D. *, p# 0.01, as determined by one-way ANOVA.
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Association of Fibronectin Fragments with Disc Degeneration—
Both fibronectin and fibronectin fragments are known to
increase with increasing disc degeneration and are thus consid-
ered to be an integral part of the underlying pathology (11). In
the present study, fibronectin mRNA levels within IVD tissue
samples from patients with varying degrees of disc degenera-
tion were normalized to TBP and presented as 2!"CT.
Fibronectin expression levels within patient disc tissue samples
were indeed elevated in response to increases in degeneration
grade (Fig. 5A) and correlated significantly withHTRA1mRNA
expression levels (r # 0.856; p $ 0.01) (Fig. 5B). Furthermore,
Western blot analysis of IVD protein samples revealed an
increase in fibronectin fragments containing the amino-termi-
nal fibrin- and heparin-binding domain (Fig. 5C) in degener-
ated discs. Moreover, the majority of amino-terminal frag-
ments identified were found to be of a similar size (27–29 kDa)
to the fragment identified within samples of HTRA1-digested
human fibronectin (lane 1). Membranes were counterstained
withCoomassie Blue to confirmequal protein loading (Fig. 5D).
DISCUSSION
In the current study, we have identified HTRA1 mRNA and
protein in the IVDs of human subjects and demonstrated an
association between expression levels and severity of IVD
degeneration. HTRA1 has previously been linked with disc
degeneration following the association of a single nucleotide
polymorphism, rs11200638, in theHTRA1 gene and loss of disc
height in postmenopausal Japanese women (21). In the present
study, we were unable to show any significant association
between the frequency of the risk allele (A) of SNP rs11200638
and IVDdegeneration in a small European surgical patient pop-
ulation (n# 35). Furthermore, we found no evidence to suggest
that the A allele of SNP rs11200638 has any significant influ-
ence on HTRA1 expression levels in IVD tissue. This is sup-
ported by findings from studies investigating the role ofHTRA1
in age-related macular degeneration, where, although closely
associated with disease risk, rs11200638 alone was unable to
significantly alter HTRA1 expression (28, 29). It was subse-
quently reported that the additional disruption of the adjacent
gene, LOC387715, was necessary in order for rs11200638 to
have a positive influence on HTRA1 expression (28).
We have previously shown that HTRA1 has the potential to
stimulateMMPproduction by human synovial fibroblasts, thus
implicating it in the pathogenesis of arthritis (19). As in the
joints of arthritic patients, MMPs play a central role in orches-
trating ECM breakdown in discs of patients with IVD degener-
ation (4–7). Therefore, we next investigated whether HTRA1
could also influence MMP production in human IVD cells.
Consistent with our earlier findings with human synovial
fibroblasts, recombinant HTRA1 was able to induce the
expression ofMMP1,MMP3, andMMP13mRNA, as well as
MMP-3 protein, in short term IVD cell cultures. In addition,
we also observed a significant increase in ADAMTS4 expres-
sion in IVD cells stimulated with HTRA1. As with MMP-1,
-3, and -13, ADAMTS-4 is also up-regulated in degenerated
discs (4) and may therefore represent an additional route
through which HTRA1 could influence ECM breakdown.
These stimulatory effects were found to be primarily reliant on
HTRA1 protease activity as evidenced by the fact that the pro-
teolytically inactive form of HTRA1 (HTRA1"macSA) was
unable to significantly enhance MMP production. Neverthe-
FIGURE 5.Detection of fibronectin fragments in degenerated IVD tissue.A, fibronectin (FN)mRNA levels in intact IVD tissue samples frompatients (n# 36)
with varying degrees of IVD degenerationwere determined by qRT-PCR and presented as 2!"CT% S.E. (error bars). B, correlation study between FN andHTRA1
mRNA levels (2!"CT) in patient IVD tissue samples (n# 36). R
2, square of correlation coefficient; p$ 0.01 as determined from Pearson’s correlation coefficient.
C, protein extracts frompatient IVD tissues (n# 12)were loaded onto a 12%SDS-polyacrylamide gel, and immunoblottingwas performedusing amonoclonal
antibody (Mab1936) specific for the amino-terminal fibrin- and heparin-binding domain.D, the PVDFmembrane used in Cwas stainedwith Coomassie Blue in
order to confirm equal protein loading. Lane 1, HTRA1-digested human plasma-derived fibronectin; lanes 2–4, non-degenerated (ND) discs; lanes 5–7, mildly
degenerated discs; lanes 8–10, moderately degenerated discs; lanes 11–13, severely degenerated discs.
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less, increases in MMP production were apparent in cultures
treated with HTRA1!macSA andmay be indicative of an addi-
tional, and as yet unidentified, protease-independent mecha-
nism through which HTRA1mediates its stimulatory effects. It
is possible that further studies utilizing other mutant forms of
HTRA1may further assist in trying to decipher the exact cause
of these stimulatory effects.
Degradation of the ECM within degenerated IVDs can give
rise to fibronectin fragments of various sizes, which themselves
are capable of activating resident disc cells to produce matrix-
degrading proteases in a MEK-dependent manner (9, 27). Fur-
thermore, the stimulatory properties of certain fibronectin
fragment species on cellular MMP production are known to be
mediated through the actions of IL-1! (26). In the current
report, we demonstrated that the stimulatory effects of HTRA1
on MMP production by IVD cells were indeed MEK-depen-
dent. Moreover, despite the fact HTRA1 induced the expres-
sion of IL1B, along with several other cytokines, inhibition of
IL-1! signaling through the use of the IL-1RA failed to have any
significant impact onHTRA1-inducedMMPexpression in IVD
cells. On closer examination, it was revealed that IVD cell cul-
tures and purified human plasma-derived fibronectin incu-
bated with HTRA1!mac both consisted of increased levels of a
fibronectin fragment containing the 27–29-kDa amino-termi-
nal fibrin- and heparin-binding domain. Furthermore, MMP
expression was enhanced in IVD cells following stimulation
with the proteolytic products of HTRA1-digested human
plasma-derived fibronectin. Considering this, togetherwith the
additional observation that HTRA1-induced MMP expression
was also dependent onMEKactivity, we conclude that the stim-
ulatory effects of HTRA1 onMMP production by IVD cells are
mediated, at least in part, through the generation of fibronectin
fragments. Interestingly, increases in fibronectin fragments
containing the carboxyl-terminal heparin-binding domain,
were also evident in the culture supernatants of cells treated
with the HTRA1!macSA. The fact that HTRA1!macSA was
proteolytically inactive and only able to generate fibronectin
fragments in the presence of cells would suggest that these
effects weremost likelymediated through the stimulated secre-
tion of other active proteases. This may therefore offer some
explanation as to why MMP production by IVD cells was
enhanced with HTRA1!macSA, although the mechanism of
action still remains to be determined. Furthermore, the obser-
vation that levels of the 27–29-kDa fibronectin fragment con-
taining the amino-terminal fibrin- and heparin-binding
domain were elevated predominantly in cell cultures treated
with HTRA1!mac would further imply that these fragment
species are of particular relevance with regard to IVD cell
activation.
Increased production of fibronectin by resident IVD cells has
been observed within degenerated disc tissue samples and is
considered to be central to the ongoing reparative and remod-
eling processes associated with IVD degeneration (30, 31). In
the present study, we observed amarked increase in fibronectin
expression in IVD tissue from patients with moderate to severe
disc degeneration, which correlated significantly with changes
inHTRA1 expression levels. At present, it is not knownwhether
fibronectin and HTRA1 share common regulatory pathways,
although it would appear that both of their expression patterns
are dependent on factors intrinsic to the degenerative process.
Given the fact that HTRA1-generated fibronectin fragments
serve as potent inducers ofMMPproduction, overexpression of
fibronectin and HTRA1 within IVDs is likely to have a signifi-
cant influence on the development of disc degeneration. This is
supported by our finding that small molecular mass fragments
(27–29 kDa) containing the amino-terminal fibrin- and hepa-
rin-binding domain of fibronectin could also be identified
within degenerated disc samples. The involvement of such frag-
ments in disc degeneration has already been alluded to in a
recent report by Anderson et al. (32), where a single fibronectin
fragment with an estimated size of 25 kDa was detected in
degenerated discs by immunoblotting with the same monoclo-
nal antibody as used in the current study. It is possible, there-
fore, that HTRA1 protease activity may in fact be one of the
main causative agents responsible for generating such fibronec-
tin fragments within degenerated discs.
Taken together, these findings led us to propose a working
model for the biological role of HTRA1 in IVD degeneration
(Fig. 6). In addition to its already well characterized ability to
directly degrade ECM proteins known to be present within
IVDs (19, 20, 33–35), HTRA1 may also further modulate ECM
breakdown indirectly through fibronectin fragment production
and subsequent up-regulation of MMPs by resident disc cells.
Clearly, further investigations are required in order to identify
which particular fragments are responsible for the activation of
FIGURE 6.A theoreticalmodel for the role of HTRA1 in IVDdegeneration.
Based on our findings, we propose that HTRA1 accumulates in IVD tissue
undergoing degeneration and stimulates MMP production by resident cells
in a predominantly protease-dependent manner, via activation of the MEK
pathway. Furthermore, we suggest that the stimulatory effects of HTRA1 on
IVD cells are mediated indirectly through its ability to generate fibronectin
fragments, although other routes of cellular activation cannot be ruled out.
IDD, intervertebral disc degeneration.
Role of HTRA1 in Intervertebral Disc Degeneration
JUNE 15, 2012•VOLUME 287•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 21343
 at Hauptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on April 15, 2014
http://www.jbc.org/
Downloaded from 
Results 
 119 
 
 
 
 
 
IVD cells in vitro and to clarify the involvement of fibronectin
fragments in IVD degeneration. Furthermore, additional stud-
ies are needed to fully evaluate the potential stimulatory effects
of other soluble mediators (e.g. cytokines) released by IVD cells
following incubation with HTRA1. Moreover, examination of
the possible interplay between inflammatory mediators and
fibronectin fragments in the regulation of Toll-like receptor
signaling pathways in IVD cells may also lend further insight
into how HTRA1 contributes to the catabolic response in IVD
degeneration (36). These results therefore encourage the
design of specific HTRA1 inhibitors for the treatment of
patients with disc degeneration, an endeavor that will no doubt
be facilitated by information gleaned from the recently solved
crystal structure of HTRA1 (37).
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Supplementary Figure Legends 
 
Supplementary Figure 1. Protein loading control for patient IVD samples. The PVDF 
membrane used in the Western blot analysis of HTRA1 protein within normal and degenerated 
discs was counter stained with Coomassie blue in order to visualize total protein and thus confirm 
equal sample loading. Lane 1, HTRA1!mac (4 ng) ; lanes 2 to 4, non-degenerated (ND) disc; lanes 
5 to 7, mildly degenerated discs; lanes 8 to 10, moderately degenerated discs; lanes 11 to 13, 
severely degenerated discs.  
 
Supplementary Figure 2. Regulation of aggrecanase-1 (ADAMTS4), gelatinase A (MMP2) and 
aggrecan (ACAN) expression in IVD cells by recombinant HTRA1. A–C, the effects of 
HTRA1!mac on ADAMTS4, MMP2 and ACAN mRNA expression in IVD cells after a 24 h 
incubation period were determined by qRT-PCR and the fold change as compared to untreated 
controls determined using the 2-!!CT method. Data is representative of two independent experiments 
(±S.D. triplicates). * p < 0.05, ** p < 0.01,  as determined by Student’s t-test. 
 
Supplementary Figure 3. Downregulation of IL-1"-induced MMP expression in IVD cells by 
IL-1RA. The inhibitory effects of IL-1RA (250 ng/ml) on IL-1" (5 ng/ml)-induced MMP 
expression in IVD cells after a 24 h incubation period were determined by qRT-PCR and the fold 
change as compared to untreated controls determined using the 2-!!CT method. * p < 0.01 as 
determined by Student’s t-test (±S.D. triplicates). 
 
Supplementary Figure 4. Generation of fibronectin fragments.  A, The PVDF membrane used 
in the Western blot analysis of fibronectin fragments within concentrated IVD cell culture 
supernatants was counter stained with Coomassie blue in order to visualize total protein and thus 
confirm equal sample loading. B, Fibronectin (20 µg) (Fn), recombinant HTRA1 (5 µg) 
(HTRA1!mac) or a combination of fibronectin and HTRA1 (Fn+ HTRA1!mac) were incubated for 
16 h at 37oC and then subjected to Ni2+-NTA affinity chromatography in spin columns. The 
columns were initially centrifuged at 1600 rpm for 5 min and the flow through fraction (FT) 
containing unbound protein collected. Columns were then washed with TBS, pH 7.6, and the wash 
fraction (W) collected. Remaining protein bound to the column was then removed with TBS, pH 
7.6, 300 mM imidazole and the elution fraction (E) collected. All samples were then loaded onto a 
4-15% gradient gel and stained with Coomassie Blue. The closed arrow indicates the eluted his-
tagged HTRA1!mac (37 kDa). M, Protein marker. 
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Supplementary Table 1. List of TaqMan Gene Expression Assays used in RT-PCR analysis 
Gene Symbol Protein Product Assay ID a  
ADAMTS4 Disintegrin and metalloproteinase with thrombospondin motifs 4 Hs00943031_g1 
ACAN Aggrecan Hs00202971_m1 
FN Fibronectin Hs01549976_m1 
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase Hs02758991_g1 
HTRA1 High Temperature Requirement Protease A1 Hs01016151_m1 
IL1B Interleukin-1 beta Hs00174097_m1 
IL6 Interleukin-6 Hs00174131_m1 
IL8 Interleukin-8 Hs00174103_m1 
MMP1 Matrix Metalloproteinase-1 Hs00233958_m1 
MMP2 Matrix Metalloproteinase-2 Hs01548724_m1 
MMP3 Matrix Metalloproteinase-3 Hs00968308_m1 
MMP13 Matrix Metalloproteinase-13 Hs00233992_m1 
TBP TATA-box binding protein Hs00427620_m1 
aTaqMan Expression Assay identity code according to supplier (Applied Biosystems, Rotkreuz, 
Switzerland). !
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4 General discussion and perspectives 
The number of patients experiencing bone fractures is expected to steadily rise due to 
changes in life style, increases in population growth and life expectancy [186]. The majority 
of patients who are eligible for bone replacement procedures are elderly, and their bones 
display poor mechanical properties and, most importantly, exhibit limited regeneration 
potential. Therefore, bone quality is an essential factor to prevent bone from fracture and 
reflects the incorporation of bone density and mechanical strength as well as architecture and 
mineralization [13, 77, 78], and is affected during aging by alterations in bone turnover 
through the process of bone remodeling. As such, fracture repair in aged and osteoporotic 
bone presents a major challenge to the orthopaedic surgery due to inferior properties of the 
cancellous bone [79-81]. Although bone has an intrinsic ability to regenerate itself, this 
capacity is limited to small fractures, and therapeutic alternatives are still necessary to 
improve bone healing as well as to treat bone deficiencies associated with degenerative 
disorders, such as osteoporosis. 
The incidence and management of osteoporotic fractures is adversely affected by low bone 
mass and poor healing potential and thus results in higher complication rates. The importance 
of developing new therapies to counteract the effects of aging bone is highlighted by the fact 
that on average, 20% of the patients sustaining an osteoporotic-related fracture die within the 
first year due to complications caused by immobility. This figure is expected to rise due to 
shifts in the age pyramid. It is envisaged that the concept of local treatment of age-related 
osteoporosis by stem cells, harvested from autologous tissue samples addressed in this thesis, 
could be directly translated into clinical applications and has enormous potential for 
enhancing osteoporotic bone regeneration thereby reducing morbidity and health costs 
associated with this disorder. 
Stem cells, and in particular MSCs, represent a promising tool for the development of clinical 
strategies for the repair of site specific bone defects, and could help reduce the prevalence of 
various bone disorders like osteoporosis [164]. To date a number of studies exist which 
support the role of BMSCs in the development and progression of age-related osteoporosis 
and subsequent alterations in the levels of bone quality [14, 15, 88]. BMSCs are considered 
as being key elements of the BMU due to their osteogenic potential, and therefore play an 
important role in the overall maintenance of bone quality. However, their general fitness 
appears to reduce with age and passage number in vitro, as demonstrated by increases in 
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cellular aging markers and an inability to maintain their osteogenic potential under normal 
conditions or following exposure to stress [187-189]. Additionally, alteration in the 
differentiation capacity of resident BMSCs in osteoporotic patients and animal models has 
led to the hypothesis that impaired BMSC osteogenesis may be involved in the development 
of age-related osteoporotic phenotypes, due inadequate numbers of active osteoblasts. 
The idea of dysfunctional BMSCs as being a basic cause of age-related osteoporosis and 
impaired bone quality is supported by several reports for both human osteoporotic patients [3, 
15], and also in experimental mouse models [88, 190, 191]. It has been shown that BMSCs 
isolated from Sca-1−/− mice have a reduced tendency to differentiate towards osteogenesis 
and that these mice displayed many of the phenotypes associated with age-related 
osteoporosis [192]. In a similar study, a low turnover osteoporosis was observed in the klotho 
mouse strain, where bone marrow osteogenesis was also significantly reduced [83]. 
Moreover, results from several investigations utilizing the senile osteoporotic SAMP6 model 
have revealed that the osteogenic differentiation potential of resident BMSCs is remarkably 
reduced as compared to BMSCs isolated from the age-matched SAMR1 control strain [88, 
190, 191]. These observations therefore highlight the fact that age-related inadequacies in 
cellular differentiation must be taken into account when considering the potential impact of 
therapeutic strategies aimed at restoring bone quality in osteoporotic patients.  
There are certain aspects apart from BMSC functionality that need to be taken into account 
when considering the use of BMSCs for therapeutic purposes. These include limitations in 
the amount of cells that can be harvested at any one time, plus the fact that collection of bone 
marrow is a painful and sometimes risky procedure [116, 149, 176]. As such, efforts have 
been made to identify other potential sources of multipotent bone progenitor cells. In this 
thesis, I studied the role of adipose tissue as an alternative autologous cell source from which 
a sufficient number of osteo-progenitor cells may be easily accessed. ASCs have a similar 
differentiation potential, morphology, phenotype and gene expression pattern as BMSCs, and 
may therefore represent a promising autologous cell source of osteoprogenitor cells for the 
treatment of age-related osteoporosis [193, 194].  
In the first part of this thesis, I investigated the possibility of using the SAMP6 mouse as a 
model for senile osteoporosis. The results presented in this part confirmed that bone quality 
was significantly compromised in SAMP6 mice as compared to their age-matched non-
osteoporotic counterparts, SAMR1 mice. Furthermore, the observation that SAMP6 mice 
have shorter telomere lengths is suggestive of an age-related osteoporotic phenotype. I was 
also able to harvest and purify ASCs from the subcutaneous inguinal fat pads of SAM mice 
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and could expand these cells in culture over several passages. They displayed similar 
characteristics to BMSCs, as they consistently expressed mesenchymal cell surface markers 
and readily differentiated into adipocyte, chondrocytes, and osteoblast cell lineages, thus 
confirming their multipotency. Additionally, in the same study, I also analyzed ASCs for 
various biological markers of premature aging, due to the premature aging-like features 
associated with the SAMP6 model. Although isolated from aged, osteoporotic mice, ASCs 
displayed no signs of cellular senescence or impaired osteogenic differentiation. Moreover, 
unlike BMSCs isolated from these mice, ASCs were not prone to excessive adipogenic 
differentiation [88]. 
Despite the intense excitement surrounding stem cells and their potential to revolutionize 
modern regenerative medicine, translation of stem cell research from bench to bedside has 
proceeded more slowly than expected. One possible reason for this may involve the culture 
conditions used. Classically, 2D culture systems have been used to grow, maintain and 
differentiate MSCs. However, the incorporation of cells within a 3D microstructure 
configuration is believed to be more representative of their natural physiological condition, 
where cells are surrounded by neighbouring cells and are embedded in an ECM which helps 
contribute to cellular communication pathways [195]. Therefore, in the second part of this 
thesis, I established a methodology for preparing ASCs in a 3D culture system, and 
investigated their potential for osteogenesis. I used the hanging drop method to culture ASCs 
in a scaffold-free 3D culture system, which allowed for gravity-enforced ASC microtissue 
spheroid formation (ASC-MTs). This method of culturing ASCs allowed me to investigate 
ASC osteogenesis in a more native cellular environment, and also offered me the possibility 
of an alternative means by which to deliver osteoprogenitor cells directly to sites of interest in 
vivo.  
The concept of culturing ASCs in a 3D system was investigated further in the third part of 
this thesis. In the first approach, SAMP6-derived ASCs were cultured in a scaffold-free 3D 
culture system, ASC-MT, as introduced in the second part of this thesis. ASCs cultured in 
ASC-MTs were confirmed as being able to retain both their proliferative capacity as well as 
their osteogenic potential. This was considered to be of crucial importance if microtissues 
were to be used for the purpose of delivering ASCs to osteoporotic bone. In the second 
approach, SAMP6-derived ASCs were seeded on silk fibroin scaffolds and allowed to 
differentiate for up to 6 weeks. Not only did this enable further analysis of ASC behaviour 
under 3D culture conditions, but also better mimicked the environmental conditions found in 
trabecular bone. A steady increase in mineralized tissue formation was observed in ASC-
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seeded scaffolds upon osteogenesis as determined by micro-CT. Taken together, these 
findings confirmed that SAMP6-derived ASCs were capable of maintaining their functional 
capacity for osteogenesis when cultured in 3D environments and thus encouraged me to 
further investigate their capacity to influence bone formation in vivo. 
In order to evaluate the potential beneficial effects of SAMP6-derived ASCs on bone quality 
in the same mouse strain, I opted for a local delivery regime, whereby single cell suspensions 
of ASCs or ASC-MTs were injected directly into the tibia, and bone parameters compared 
with untreated contralateral tibia. Bones injected with PBS/EDTA served as controls. I 
observed a significant improvement in the trabecular bone quality of SAMP6 mice after 42 
days following a single intratibial injection of either undifferentiated ASCs or pre-
differentiated osteogenic ASC-MT in comparison to untreated contralateral bones. 
Furthermore, CM-Dil labeled ASCs could still be detected within the bone marrow of treated 
tibia even at this late time point. However, I unexpectedly encountered adverse effects of a 
single intratibial injection of pre-differentiated osteogenic ASCs when delivered as a cell 
suspension, which caused high mortality rates as a result of pulmonary embolism. It remains 
unclear as to why such adverse events should have occurred following the use of these cells, 
especially as other studies using pre-differentiated mouse ASCs reported no untoward effects 
[196]. This could in fact represent an important point of concern when considering such an 
approach in humans and may therefore required further investigation. However, it would 
appear that implementing ASC-MTs might represent one possible means by which to 
overcome this potentially detrimental effect of pre-differentiated osteogenic ASCs when 
injected directly into the bone marrow cavity. 
In addition to improvements being made in trabecular bone, the elevation of gene expression 
profiles of several bone turnover markers in the tibia of ASC-treated mice was also observed 
as compared to PBS/EDTA-treated mice. This is in agreement with previous studies in which 
the positive effects of locally administered ASCs on mouse bone quality have been associated 
with alterations in genetic markers of osteogenesis [196]. However, it should be mentioned 
that in the experimental setup used in this thesis, the majority of genes tested were 
upregulated in both ASC- and PBS/EDTA-treated mice when compared to untreated 
contralateral bones, thus indicating that the mere act of intratibial injection alone was 
sufficient to upregulate gene expression, possibly due to the stimulation of bone formation 
caused by accessing the bone cavity during operation procedure. 
It is interesting to note, that the capacity of pre-differentiated osteogenic ASC-MT to enhance 
trabecular bone quality was comparable to undifferentiated ASCs, despite them having 
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already been induced along the osteogenic lineage. This observation would therefore imply 
that the transplanted ASCs might have mediated their effects through the stimulation of 
resident cells, rather than instigating new bone formation directly by differentiating to 
osteoblasts. This concept of a paracrine effect was further tested in vitro utilizing ASCs and 
BMSCs isolated from human osteoporotic patients in collaboration with my colleagues in 
Innsbruck University Hospital. Initial results presented in this thesis confirmed that the 
osteogenic potential of osteoporotic BMSCs was significantly impaired as compared to 
normal, age-matched non-osteoporotic control samples. We could also demonstrate that 
conditioned media harvested from ASCs isolated from osteoporotic patients was able to 
better support mineralization of osteoporotic BMSCs as compared to cell cultures 
supplemented with media obtained from osteoporotic BMSCs. Although similar findings 
were reported in studies utilizing human ASCs with either human BMSCs or mouse 
osteoblastic cell lines [194, 197], as far as I‘m aware, this is the first direct evidence that 
human osteoporotic ASCs have the capacity to impart a pro-osteogenic paracrine effect on 
human osteoporotic BMSCs in vitro. It is possible therefore, that the increases in SAMP6 
trabecular bone quality following ASC treatment were partially due to the paracrine actions 
of injected ASCs on resident BMSC populations. These findings therefore support the use of 
isogeneic and possibly even autologous ASCs for the treatment of age-related bone loss. 
Currently, several systemic-based pharmacotherapies are available to treat osteoporosis (e.g. 
bisphosphonates), although local therapeutic modalities may also be useful to treat bone loss. 
One possible alternative could be to treat bone loss with a local application of ASCs 
harvested from autologous tissue samples.  
The isolation of human ASCs is now a well-established procedure worldwide, and as such, 
could easily be incorporated into the working practices of standard patient care in many 
different countries. In fact, a number of clinical studies are currently on-going, or have 
already been completed, in which ASCs are or have been augmented in a composite graft for 
the purposes of treating proximal humeral fractures (http://clinicaltrials.gov: NCT01532076). 
With this in mind, supplementation of osteoporotic bone with competent osteoprogenitor 
cells may therefore represent a viable means by which to re-establish normal bone 
homeostasis and enhance bone quality. Indeed, this concept has already been tested by 
several independent research groups and has been shown to have significant benefits in terms 
of preventing bone loss in various experimental OVX mouse models. Human ASCs 
demonstrated a protective effect on OVX-induced bone loss in nude mice when intravenously 
injected at the time of surgical intervention [197]. These effects were hypothesized as being 
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mediated mainly through paracrine effects of the transplanted ASCs based on the fact that no 
cells could be visualized within bone after 48 h post injection. Similarly, the systemic 
administration of genetically modified mouse ASCs restored normal bone parameters in 
immunocompetent mice after 28 days, although no data was presented to indicate whether 
ASCs could be detected within the bones of treated animals [198]. More recently, it was 
shown that a single intrafemoral injection of ASCs into OVX senescence-accelerated mouse 
prone 8 mice (SAMP8) resulted in significant increases in BMD as compared to control 
groups, which was evident at 4 months following the initial treatment [196]. However, these 
effects appeared to require the in vitro osteogenic differentiation of ASCs prior to 
implantation.  
It was previously shown that in SAMP6 mice, BMSCs displayed a higher tendency for 
adipogenic differentiation [88], which is supposed to be one underlying reason for the 
deficiency of bone quality in human osteoporotic patients. This phenomenon may lead to 
increased fat deposition within the bone marrow of osteoporotic patients, which is undesired 
for normal physiological condition of bone. However, it should be noted that not all types of 
fat tissue within bone marrow may have a detrimental effect on bone homeostasis. In humans, 
it is known that the amount of adipose tissue in the bone marrow increases around the time of 
peak bone mass and may therefore play an important role in bone acquisition during this time 
of increased bone formation. Moreover, studies in some mouse strains with high bone mass 
have revealed the presence of BAT has the capacity to burn calories and decrease lipid stores 
[199]. As such, it would be interesting to assess the types of fat marrow found in osteoporotic 
versus healthy bones, and the putative involvement of BMSCs in this process. Additionally, 
stimulation of BMSCs towards brown adipocytes rather than white adipocytes may possibly 
provide another novel approach to positively affect bone metabolism. 
In summary, results demonstrated in my thesis show that SAMP6-derived ASCs retain a high 
capacity for osteogenesis, display no alterations in adipogenic differentiation potential, 
maintain telomere length, and show no signs of premature cellular senescence. In addition, in 
vivo studies demonstrated that a single intrabone injection of isogenic undifferentiated ASCs 
or pre-differentiated ASC-MTs, significantly enhanced bone quality parameters in SAMP6 
mice. Furthermore, in vitro data utilizing human osteoporotic BMSCs and ASCs is provided, 
which supports the concept that transplanted osteoporotic ASCs may influence bone 
formation in a paracrine manner. These observations therefore support the idea of using 
adipose tissue as a promising source for cell-based therapeutic strategy to treat age-related 
osteoporosis. 
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